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Abstract
Accumulating epidemiological evidence correlates indices of poor growth in utero
with increased risk of disease in later life, particularly hyperglycaemia, insulin
resistance, hypertension, and ischaemic heart disease. This concept of early life
events having permanent effects upon health has been termed "programming". The
mechanisms linking these effects are not understood, but over-exposure of the foetus
to glucocorticoids has been proposed as a potential mediator. Treatment ofpregnant
rats with dexamethasone (dex) results in offspring of low birth weight, which
become hypertensive, glucose intolerant and insulin resistant in adulthood.
Permanent tissue-specific changes in the expression ofkey genes, particularly the
glucocorticoid receptor (GR), have been observed in the offspring of dex-treated
mothers. In the liver, increased GR is associated with elevated expression of
phosphoenolpyruvate carboxykinase, the rate-limiting enzyme of gluconeogenesis,
and therefore, increased hepatic glucose output. This thesis addresses the question of
whether programming of insulin resistance extends to skeletal muscle and adipose
tissue, and whether altered expression of GR in insulin target tissues is important in
determining the programmed insulin resistance.
GR was elevated by prenatal treatment with dex in retroperitoneal (RP) fat, and
reduced in soleus muscle, while its expression was unchanged in two other muscles
and subcutaneous fat. In RP fat, this was accompanied a reduction in lipoprotein
lipase mRNA and a shift from PPARyl to PPARy2 expression, while leptin and
resistin mRNA levels were unchanged. In quadriceps muscle, glycogen storage was
reduced, associated with a downward trend in expression of the insulin-regulated
glucose transporter. In summary, tissue-specific programming ofGR in muscle and
fat is associated with impaired lipolytic activity and a shift in PPARy expression in
visceral fat, and evidence of attenuated glucose uptake into skeletal muscle. These
findings are consistent with the presence of insulin resistance in muscle and visceral
adipose tissue as a result ofprenatal dex.
18
To test whether changes in GR expression were secondary to
hypercorticosteronaemia or insulin resistance, the [corticosterone] (cort) was varied
in adult offspring, or rats were treated with insulin-sensitising drugs. No effect of
varying [cort] was found in muscles or fat depots, while liver GR was increased by
both adrenalectomy and supraphysiological cort. Metformin reduced GR, especially
in the liver and muscle of dex-treated rats, but rosiglitazone reduced GR only in the
liver and independently of prenatal treatment. The implications are that programming
of GR in insulin target tissues is independent of circulating hypercorticosteronaemia
and insulin resistanceper se. Moreover, it seems that the mechanism of action of
metformin may be in part glucocorticoid-mediated.
Finally, exposure ofpregnant rats to noise pollution perinatally resulted in vehicle-
treated offspring developing similar hypertension and features of the insulin
resistance syndrome as seen in dex-treated offspring, despite normal birth weight.
This demonstrates that perinatal stress can induce a similar phenotype to
glucocorticoid over-exposure.
These findings add weight to the hypothesis that in utero over-exposure to
glucocorticoids can programme insulin resistance in later life, and support a role for
both skeletal muscle and adipose tissue metabolism in mediating this. Furthermore, it
seems that programmed dysregulation of GR in insulin target tissues plays a
significant role in determining the offspring phenotype.
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1 Chapter One - Introduction
1.1 Background
My thesis is concerned with a possible mechanism for the "Foetal origins of disease"
hypothesis, proposed by Professor David Barker as a result of epidemiological
studies undertaken in the late 1980s and early 1990s (Barker 1995).
Barker et al obtained collections of detailed records concerning term births made by
midwives early in the 20th century, and followed up the individuals concerned in
middle age. Strong correlations were discovered between indices of poor growth in
utero and increased incidence of disease and factors predisposing towards disease in
adulthood (Barker et al. 1990; Barker et al. 1989; Hales et al. 1991). Barker's
resulting hypothesis stated that "Foetal undernutrition in middle to late gestation,
which leads to disproportionate foetal growth, programmes later.. .disease" (Barker
1995).
There has been much interest in the likely physiological and molecular mechanisms
involved in the "programming" ofmetabolism by early life environment. In our
laboratory, we are utilising a rodent model of in utero over-exposure of the foetus to
glucocorticoids to attempt to explain this phenomenon. The phenotype of the model
recapitulates many of the features associated with low birth-weight in humans,
including poor glucose tolerance and insulin resistance (Lindsay et al. 1996b). In my
investigations I have been attempting to determine whether gene expression and
metabolism of peripheral insulin-responsive tissues are "programmed" by prenatal
treatment, as part of this syndrome.
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In this introduction, I describe the pertinent biology associated with these
investigations, as well as the epidemiology of, and the progress made towards the
understanding of, the "programming" effect.
1.2 Glucose and Lipid Metabolism
In this section I will present a summary of the physiology and biochemistry of the
principal insulin-responsive tissues: liver, muscle and fat. Derangement of some or
more of these processes may underlie the observed programming effect.
1.2.1 Metabolic substrates in the fed and fasted state
Energy is required by all living tissues in order to carry out their functions. This is
provided in animals by the oxidation of complex organic molecules, principally
carbohydrates, lipids and proteins, which are ultimately provided by ingestion in
food.
Glucose derived from ingested carbohydrates provides the bulk of the body's short-
term energy requirements in the fed state. Excess glucose is stored as glycogen in the
liver and skeletal muscle (Radziuk & Pye 2001), or used along with lactate, pyruvate
and amino acids in lipogenesis (Wakil et al. 1983). The resulting lipid, along with the
bulk of ingested lipid, is stored in adipose tissue. Proteins not required for other uses
are degraded, and the resulting amino acids deaminated and excreted.
In conditions of relative starvation, fatty acids are liberated from adipose tissue and
oxidised to provide the bulk of the body's energy requirement. Ketone bodies are
also generated by fatty acid oxidation, and are preferentially oxidised (McGarry &
Foster 1980). Gluconeogenesis takes place in the liver principally, and produces
glucose from other substrate molecules (Radziuk & Pye 2001). Gluconeogenesis and
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glycogenolysis in the liver are necessary to provide the CNS and red blood cells with
glucose, as these tissues are obligate glucose consumers (Smith 1997).
The energy liberated by the catabolism of any of these compounds is stored in the
high-energy phosphoanhydride bonds of ATP molecules, which are generated in
these reactions. This chemical energy (7.3 kcal / mole) is released when required by
the hydrolysis ofATP, a reaction which is linked to most energy-utilising processes
(Olson 1997).
1.2.2 Uptake and storage of glucose
Ingested carbohydrates are digested by enzymes in the alimentary tract to yield
glucose and other monosaccharides, which are absorbed in the small intestine.
Glucose reaches the liver via the hepatic portal vein, and then passes into the
systemic circulation for distribution throughout the body.
When plasma glucose is in excess, glycogenesis occurs in the liver and skeletal
muscle, producing a non-osmotically active carbohydrate, which can be stored.
Glucokinase in liver, and hexokinase in muscle, catalyse the phosphorylation of
glucose, and the glucose 6-phosphate generated is further "activated" by glucose 1-
phosphate uridylyltransferase. Glycogen synthase then catalyses the transfer of the
activated glucosyl moiety of UDP-glucose to a glycogen molecule. This enzyme,
along with 1,4-a-glucan branching enzyme, is responsible for creating the chains of
glucose units that comprise glycogen (Harris 1997).
The disposal of glucose into muscle as glycogen is quantitatively the most important
means of lowering blood glucose levels after a meal. However, excess pyruvate
produced from glucose in glycolysis can be used to synthesise fatty acids in the liver,
via the production of acetyl CoA, and hence lipids for deposition in adipose tissue
(Wakil etal. 1983).
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1.2.3 Release and use of glucose
Glucose yields energy as ATP when it is metabolised by the glycolytic pathway and
by aerobic oxidation.
Glycolysis occurs in the cytoplasm of all cells, and yields two moles of ATP per
mole of glucose metabolised (Harris 1997). Glucose is first phosphorylated by
hexokinase, in common with the first step of glycogen synthesis. 6-Phosphofructo-l-
kinase is a "rate-limiting" enzyme of the pathway, catalysing the unidirectional ATP-
dependent phosphorylation of fructose 6-phosphate. Pyruvate kinase catalyses
another irreversible reaction: the conversion of PEP into pyruvate. In the presence of
oxygen, pyruvate is final product of the glycolytic pathway, whereas lactate is
produced in an anaerobic environment. Tissues containing relatively few
mitochondria, including white muscle, are dependent on glycolysis to fulfil their
ATP requirements. White (type II, fast twitch) muscle fibres have a much higher
capacity for glycogenolysis and glycolysis than red (type I, slow twitch) muscle
fibres, permitting short bursts of intense anaerobic activity. Red muscle fibres are
rich in mitochondria, and tend aerobically to oxidise glycogen in a slower and more
sustained fashion (Gaster et al. 2000; Rivero et al. 1998).
Glucose can be readily released from stored glycogen. The action of glycogen
phosphorylase and a-amylase produces glucose 1-phosphate units, from which
glucose 6-phosphate is regenerated by phosphoglucomutase. In the liver, glucose 6-
phosphatase hydrolyses the glucose 6-phosphate, releasing glucose for use around
the body (Harris 1997). In muscle, however, this enzyme is present in only trace
amounts (Lackner et al. 1984), so the majority of the glucose 6-phosphate is
consumed within the muscle, generating ATP locally as required by activity levels.
Gluconeogenesis is the net synthesis of glucose in the liver and kidney from other
substrates; amino acids, lactate, pyruvate, glycerol, and other monosaccharides are
used for this purpose. Alanine and lactate generated by skeletal muscle activity are
used for gluconeogenesis, as is the glycerol released from fat after lipid hydrolysis
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(Harris 1997). The gluconeogenic pathway utilises many of the glycolytic enzymes,
catalysing the reverse reactions to those of glycolysis. Additional enzymes are
required to bypass the irreversible steps: mitochondrial pyruvate carboxylase
catalyses the synthesis of oxaloacetate from pyruvate, and PEPCK catalyses the
production ofPEP from oxaloacetate (Hanson & Reshef 1997). Fructose 1,6-
bisphosphatase and glucose-6-phosphatase are also required to yield glucose as an
end product, and all of these enzymes provide critical points for regulation of the
process.
1.2.4 Mitochondrial oxidation and uncoupling
Pyruvate undergoes oxidative decarboxylation in mitochondria to form acetyl CoA,
catalysed by the pyruvate dehydrogenase complex. This enzyme is a key point for
regulation, as the reaction product can be used for oxidation, ketone body production,
or fatty acid synthesis (Hultman 1995; Mandarino et al. 1987).
Acetyl CoA is completely oxidised via the tricarboxylic acid cycle in mitochondria.
The cycle consists of a series of reactions which generate reducing equivalents,
which are then utilised to generate ATP by electron transport / oxidative
phosphorylation along the inner mitochondrial membrane. Three molecules of
NADH and one of FADH2 are generated per molecule of acetyl CoA entering the
cycle. A total of twelve ATPs are produced as a result of these two processes, and
during the complete oxidation of glucose, the net yield is 38 ATPs (Olson 1997).
Electron transport occurs through a series of oxidation-reduction reactions, utilising a
sequence of electron donating and accepting proteins, with oxygen as the final
acceptor. According to Mitchell's chemi-osmotic hypothesis, this process creates an
electrochemical gradient across the mitochondrial membrane by the outward
pumping of protons. The subsequent dissipation of the gradient is "coupled" to the
synthesis ofATP by mitochondrial FiFo ATPase (Mitchell 1979).
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"Uncoupling" of respiration and phosphorylation occurs in response to the
destruction of this proton gradient, allows the consumption of oxygen without ATP
production, and the consequent dissipation of the energy generated as heat.
Chemicals such as 2,4-dinitrophenol can achieve this effect, but endogenous
uncoupling proteins also trigger it (Olson 1997). See Figure 1-1 for a summary. The
first uncoupling protein discovered (designated UCP-1) is expressed in brown
adipose tissue, which occurs principally in small mammals, and is the site for non-
shivering thermogenesis. In rodents exposed to the cold, newborns, or animals
emerging from hibernation, activation of the sympathetic innervation to brown
adipocytes initiates the protonophoric effect of UCP-1 in the numerous mitochondria
present therein (Ricquier & Bouillaud 2000). In these scenarios, additional body heat
is the useful product.
Figure 1-1 Diagrammatic summary of the coupling and uncoupling of
oxidative phosphorylation in mitochondria (after Ricquier & Bouillaud 2000)
An electrochemical gradient is established across the mitochondrial membrane by the outward
pumping of protons. Dissipation of this gradient is coupled to ATP synthesis. "Uncoupling" of
respiration and phosphorylation occurs in response to the destruction of this proton gradient by
chemicals or endogenous uncoupling proteins (UCPs). This allows the consumption of oxygen











A further three homologous UCPs have now been discovered: UCP2 is widely
distributed throughout the body (Fleury et al. 1997), while UCP3 is expressed
specifically in skeletal muscle and the brown fat of rodents (Vidal-Puig et al. 1997a).
These proteins have been shown to be involved in the metabolic adaptation to
fasting, (Millet et al. 1997) weight control and thermogenesis (Fleury et al. 1997),
through their influence on metabolic rate and glucose homeostasis of the whole
animal (Clapham et al. 2000).
1.2.5 Uptake, synthesis and storage of lipids
Ingested lipids are hydolysed to varying extents by digestive enzymes and absorbed
through the small intestinal mucosa. Chylomicrons are assembled in the intestine to
transport dietary TAG, cholesterol, and fat-soluble vitamins along lacteals, and pass
via the lymphatic system into the blood. Useful fatty acids are also derived from the
catabolism of sugars, some amino acids, and other fatty acids, via acetyl CoA, which
is the source of all carbon atoms for their cytoplasmic de novo synthesis (McGarry
1997). Acetyl CoA produced in mitochondria is transported out as citrate, and re-
derived in the cytoplasm by ATP-citrate lyase. Carboxylation of acetyl CoA by
acetyl CoA carboxylase to form Malonyl CoA is the key initial step in the synthesis
(Kim & Tye 1994), then two-carbon units are added progressively by the enzyme
fatty acid synthase, yielding palmitoyl CoA. This can then be modified by
elongation, desaturation, or hydroxylation in the endoplasmic reticulum to produce
the majority of fatty acids required by the body (Cinti et al. 1992).
Fatty acids can be converted to triacylglycerol for storage in many tissues of the
body, but the liver and adipose tissue largely carry out this process. The liver either
utilises the TAG it produces, or incorporates it in VLDL for transport to adipose
tissue predominantly, but also to muscle (Ferraro et al. 1993; Tan et al. 1977), and
elsewhere. Lipoprotein lipase is expressed by capillary endothelial cells, especially
those within adipose tissue, and is responsible for the hydrolysis of TAG within
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chylomicrons and VLDL, allowing the uptake of fatty acids by adjacent cells. (Eckel
1989)
TAG synthesis from fatty acids requires glycerol 3-phosphate or dihydroxyacetone
phosphate produced during carbohydrate metabolism. Each hydroxyl group on these
molecules is sequentially esterified by acyltransferase to produce TAG, which
accumulates as cytoplasmic lipid droplets (McGarry 1997).
1.2.6 Release and use of lipids
Hydrolysis of TAG to form mono- and diacylglycerols by hormone-sensitive lipase
is the first step in the recovery of stored fatty acids, and is a key point for control of
this pathway (Osterlund et al. 1996; Sztalryd & Kraemer 1995). Fatty acids and
glycerol are generated by further hydrolysis, and re-circulate from adipose tissue for
oxidation elsewhere, and use in carbohydrate metabolism respectively. NEFAs are
transported bound to plasma albumin when liberated into the circulation after
lipolysis by adipose HSL or LPL (McGarry 1997).
Fatty acids are utilised for energy production by many tissues, principally by the
process of P-oxidation, but they are an especially important energy source for the
heart, while the appropriate metabolic pathways are absent from the CNS (McGarry
& Foster 1980). Fatty acyl CoAs are synthesised and carried into mitochondria as
acyl carnitine, produced and de-acylated by carnitine palmitoyltransferases I and II,
respectively. P-oxidation by acyl CoA dehydrogenases within the mitochondria
produces acetyl CoA, NADH and FADH2 molecules, which are oxidised in the same
way as those generated from carbohydrate metabolism, producing up to 129 ATPs
per mole ofpalmitate entering the cell (McGarry 1997).
Ketone bodies are synthesised in the mitochondria of the liver and kidney using
acetyl CoA produced by P-oxidation. Acetoacetate and P-Hydroxybutyrate are the
final products of a series of reactions, one ofwhich is catalysed by HMG CoA
synthase, which is expressed at high levels in liver mitochondria. Ketone bodies are
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water-soluble, and hence can circulate around the body dissolved in plasma, to
tissues where they are used as fuel alongside fatty acids. They form a significant
source of energy in states of starvation, and can also be utilised by the CNS
(McGarry & Foster 1980).
1.3 Control of glucose and lipid metabolism
1.3.1 Mechanisms of control of substrate flux through metabolic
pathways
Flux through the various interconnected metabolic pathways described above is
controlled at several levels, the most basic level being that of substrate availability
for each enzyme. For anabolic processes this relies ultimately upon dietary intake,
and the quantitative significance of each pathway in the generation ofATPs or the
storage of energy depends upon nutritional state. For example, in the well-fed state,
oxidation of glucose predominates, while the oxidation of fatty acids becomes a
major source of energy when the supply of carbohydrate is reduced, sparing glucose
for use in the CNS. This is the basis of the glucose-fatty acid cycle (Randle et al.
1963).
Since many reactions, for example in the glycolytic / gluconeogenic pathway, are
reversible, the predominant direction of the reaction is determined additionally by
product inhibition. Flux of substrates through the pathway in that direction relies on
swift removal of the product by further reactions or transport. Additionally, binding
of allosteric factors away from the substrate-binding site alters the enzyme
conformation such that its affinity for substrate is altered (Harris & Crabb 1997). For
example, fructose 2,6-bisphosphate stimulates 6-phosphofructo-l-kinase and inhibits
fructose 1,6-bisphosphatase, thereby stimulating glycolysis and inhibiting
gluconeogenesis (Pilkis et al. 1995).
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Covalent modification is frequently used to activate or deactivate enzymes through
conformational changes, and is under the control of hormones. Phosphorylation by
protein kinases and dephosphorylation by protein phosphatases is a common form of
this, and is utilised for the control of glycogen synthase activity. Various kinases
deactivate the enzyme by phosphorylation, while the active form is regenerated
through dephosphorylation by phosphoprotein phosphatase (Hunter 1995).
Changes in the expression of enzymes provide a mechanism for longer term
regulation of activity, through induction or repression by hormones or nutritional
factors. When over-fed, for example, an individual's liver will show reduced levels
of enzymes favouring glucose synthesis, such as PEPCK, while showing increased
levels of enzymes concerned with fat synthesis, such as acetyl CoA carboxylase
(Gurney et al. 1994).
1.3.2 Insulin
Insulin is the hormone secreted by the P cells of the pancreas, responsible for the
lowering of blood glucose and triglycerides in situations of plenty- its action is
predominant after a meal. It is also significant in the longer term in protein synthesis
and growth (Newsholme & Dimitriadis 2001). Control of its secretion is mediated by
amino acids and gastro-intestinal hormones, but the main signal is hyperglycaemia,
believed to be detected through the activity of pancreatic glucokinase, in a "glucose
sensor" mechanism (Matschinsky et al. 1993). It is synthesised as an 86 amino acid
precursor, proinsulin, which undergoes proteolytic cleavage to form the active
peptide prior to secretion.
Insulin achieves its activity through binding to insulin receptor, situated in the
plasma membrane of target cells. Binding to the external a-subunit activates the
tyrosine kinase activity of the internal P-subunit, which is responsible for the
initiation of intracellular second messenger systems. Phosphorylation of insulin-
receptor substrates (IRSs) and other proteins can lead to activation of the MAP
kinase or inositol triphosphate (IP3) pathways, resulting in cell division /
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differentiation and metabolic effects respectively (Combettes-Souverain & Issad
1998).
Through these mechanisms, insulin exerts control at many points in the pathways of
carbohydrate and lipid metabolism. Please see Figure 1-2 for a summary. Within
seconds, translocation of the insulin-regulated glucose transporter (GLUT-4) from
intracellular vesicles to the plasma membrane occurs (Gibbs et al. 1988), increasing
the rate of glucose uptake, especially in skeletal muscle and adipose tissue. Shortly
afterwards, phosphorylation-dephosphorylation cascades are responsible for
activation or de-activation of rate-limiting enzymes, for example the activation of
glycogen synthase (Shulman et al. 1995). Longer term effects are exerted through
altered transcription rate of genes, for example glucokinase gene transcription is up-
regulated (Vaulont & Kahn 1994), and altered translation rate ofmRNA species. The
net effects of insulin on carbohydrate metabolism are to increase glucose uptake into
cells, to increase the rate of glycolysis and glycogenesis, and to reduce the rate of
glycogenolysis and gluconeogenesis.
Insulin also increases the rate of lipolysis of chylomicrons and VLDL through
increased LPL expression and activation (Eckel 1989), and the subsequent uptake of
triglycerides into cells. Conversely, the rate of intracellular lipolysis in adipocytes by
HSL (Holm et al. 1997) is reduced, and hence the release of fatty acids into the
circulation from fat. Most energy is derived from carbohydrates under the action of
insulin, while triglyceride synthesis predominates over |3-oxidation.
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Figure 1-2 Post-prandial effects of insulin on glucose disposal and metabolism.
Increased plasma glucose resulting from intestinal absorption of digested carbohydrates causes insulin
secretion by the pancreatic islets. Insulin acts to return plasma glucose to the normal range by
discouraging hepatic glycogenolysis and gluconeogenesis, and increasing glucose uptake and
synthesis of glycogen and triglycerides by liver, muscle and adipose tissue.
Key: + up-regulation; - down-regulation.
1.3.3 Glucagon
Glucagon is a polypeptide hormone secreted by the a cells of the pancreatic islets in
response to falling concentrations of blood glucose, occurring some time after a
meal, or during exercise. Its effects on metabolism are broadly antagonistic to those
of insulin: liver glycogenolysis and gluconeogenesis are potently induced, resulting
in release of glucose into the blood (Exton 1987), and HSL is activated, such that
fatty acids are released into the circulation from adipose tissue for oxidation
elsewhere. Its activity is mediated through binding of glucagon to cell membrane
receptors, which enhances the conversion ofATP to cAMP by adenylate cyclase.





deactivation of glycogen synthase, for example (Exton 1987), and also exerts
transcriptional effects, e.g. enhancing expression of PEPCK (Hanson & Reshef
1997).
1.3.4 Sympatho-adrenal
Catecholamines (mainly adrenaline) are secreted by chromaffin cells of the adrenal
medulla as a result of stress-induced neural activation and glucocorticoid secretion.
These hormones prepare the body for activity by increasing blood glucose, amongst
other activities. Binding of adrenaline to P-adrenergic receptors on the plasma
membrane of hepatocytes results in cAMP production, and hence achieves the same
effects as glucagon (Exton 1987). P-adrenergic effects are also exerted on muscle,
where glycogenolysis is stimulated. Binding to a-adrenergic receptors on
hepatocytes additionally results in glycogen synthase inactivation through the IP3
signalling system.
P receptors on adipocytes permit catecholamine- and autonomic-induced lipolysis in
white adipose tissue, releasing fatty acids for oxidation in other tissues, and
uncoupling ofmitochondrial oxidation and phosphorylation in brown adipose tissue
(Silva & Rabelo 1997).
1.3.5 Hormones secreted by adipose tissue
Several substances have now been identified that are secreted from adipocytes and
have an impact on lipid metabolism and energy balance through paracrine or
endocrine mechanisms. Adipsin / acylation stimulating protein is a serine protease
homologue secreted by adipocytes (Cook et al. 1987), which is believed to regulate
triglyceride synthesis in a paracrine fashion. It achieves this by increasing adipocyte
glucose uptake and the activity of diacylglycerol acyltransferase within (Sniderman
& Cianflone 1994). Resistin is a recently-identified signalling molecule secreted by
adipose tissue of rodents (Steppan et al. 2001), but perhaps not significantly in man
(Nagaev & Smith 2001). Its function has not yet been characterised, but its
significance will be discussed further later.
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Leptin is the hormone which has attracted by far the most attention. It has been
identified as the secreted protein produced by the "ob" gene, which is mutated in the
obese ob/ob mouse strain. Administration of recombinant leptin reversed the
phenotype of this model (Pelleymounter et al. 1995), implying a role for this
hormone in reducing fat mass: it acts as a fat mass sensor. It is secreted in proportion
to adipose mass in many species, including man (Lonnqvist et al. 1995), and acts
upon specific receptors in the hypothalamus to exert negative neuronal control over
appetite (Campfield et al. 1995). The gene encoding the leptin receptor protein was
identified as the site ofmutation in the obese db/db mouse, which could not be
rescued by administration of recombinant leptin (Maffei et al. 1995). More recently,
peripheral direct effects of leptin on white adipose tissue mass have been identified,
involving UCP1 (Commins et al. 2001), presumably tying-in with the effect of cold
in reducing leptin expression (Hardie et al. 1996). Additionally, leptin has been
shown to induce LPL, UCP1, 2 and 3 expression in adipose tissue (Scarpace et al.
1998; Zhou et al. 1997), presumably encouraging weight loss. Furthermore, leptin
modulates the hypothalamic-pituitary-adrenal (HPA) axis, through inhibition of
corticotrophin releasing hormone (CRH) (Heiman et al. 1997) and Cortisol
(Bornstein et al. 1997) secretion.
1.3.6 Transcription Factors
A series of orphan nuclear receptors also have an influence on carbohydrate and lipid
metabolism, including the Hepatocyte Nuclear Factors (HNFs), the CCAAT-
enhancer binding proteins (C/EBPs), and the peroxisome proliferator-activated
receptors (PPARs). These transcription factors bind to response elements on target
genes, and exert effects at the level of transcription. C/EBPs are highly expressed in
lipid-metabolising tissues, especially liver and fat (Birkenmeier et al. 1989), and are
important in development (Darlington et al. 1995) and metabolic gene regulation in
these tissues (Park et al. 1990; Kaestner et al. 1990). The HNFs are primarily
expressed in the liver, and similarly mediate lipid and carbohydrate metabolism
(Kaestner 2000; Sladek 1993).
33
PPARa is predominantly expressed in liver, and PPARy in adipose tissue, and the
putative ligands for each are fatty acids and lipid derivatives, such as prostaglandins
(Braissant et al. 1996). PPARy is thought to be important in adipocyte differentiation
and metabolism (Chawla et al. 1994; Tontonoz et al. 1994), and exists in two
isoforms, PPARyl and 2, which differ by 28 amino acids at the amino terminus (Zhu
et al. 1995; Yanase et al. 1997). PPARy has been shown to exert transcriptional
control over leptin, antagonising the effect of C/EBPa (Hollenberg et al. 1997), and
over adipogenic genes, such as PEPCK (Tontonoz et al. 1995), while PPARa has
equivalent functions in the liver (Marcus et al. 1993; Keller et al. 1993).
1.4 Glucocorticoids
1.4.1 Synthesis, transport and metabolism
Glucocorticoids are steroid hormones, which are synthesised in the mitochondria and
endoplasmic reticulum of cells of the zona fasciculata and the zona reticularis in the
adrenal cortex. The molecular structures of the principal active hormones, Cortisol in
man, and corticosterone in rodents, are depicted in Figure 1-3. They are synthesised
from cholesterol using a common pathway, shown in Figure 1-4. Hormonal control
over this process is exerted through elevation of intracellular cAMP and calcium
ions, which induce the transfer of cholesterol to the mitochondrial inner membrane,
where it can be metabolised to form pregnenolone by the cytochrome p450
cholesterol side chain cleavage enzyme, and which affect the transcription of other
enzymes of the cascade. The formation of Cortisol requires the presence of
endoplasmic reticulum cytochrome p450-linked 17a-hydroxylase (17aH) and 21-
hydroxylase (21H), and mitochondrial 11 P-hydroxylase (11PH), enzymes which are
only present in the zona fasciculata and the zona reticularis of the adrenal, hence
glucocorticoids cannot be synthesised in other steroidogenic tissues, such as the
gonads (Litwack & Schmidt 1997).
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Figure 1-3 Molecular structure of the principal active glucocorticoid in man
(Cortisol) and rodents (corticosterone)
Corticosterone Cortisol
Figure 1-4 Summary of the steroid synthetic pathway of the adrenal cortex.
Cortisol and corticosterone are synthesised from cholesterol in the endoplasmic reticulum and
mitochondria of cells in the zona reticularis and zona fasciculata of the adrenal cortex. Aldosterone
production occurs exclusively in the zona glomerulosa.
Abbreviations used: 17aH: cytochrome p450-linked 17a-hydroxylase, 21H: 21-hydroxylase, lipH:
11 P-hydroxylase, 3pHSD: 3P-Hydroxysteroid dehydrogenase.
Cholesterol
Side chain cleavage enzyme
17aH 17aH
















Once secreted, glucocorticoids are mostly transported bound either to albumin, or
with high affinity to transcortin / corticosteroid-binding globulin (CBG), synthesised
by the liver (Rosner 1991). The unbound glucocorticoid (8% of Cortisol in humans)
is the form that can diffuse through cellular membranes to achieve an effect. Secreted
molecules become bound to receptor or degraded, with a half-life of 90 minutes,
within the liver or elsewhere. This metabolism is undertaken by a variety of
enzymes, including 5a- and 5|3-reductases and 11 P-Hydroxysteroid dehydrogenase
(11P-HSD) type II (Finken et al. 1999), which is discussed further below.
Conjugation ofproducts in the liver by glucuronidation or sulphatation precedes
excretion through the bile or kidney. This occurs in a 1:3 ratio in humans, while
biliary excretion predominates in rodents.
1.4.2 The Hypothalamic-Pituitary-Adrenal (HPA) axis
Glucocorticoids are secreted by the adrenal cortices in response to activation of
adenyl cyclase to produce cAMP by adrenocorticotrophic hormone (ACTH), a
polypeptide secreted by the anterior pituitary. It is derived by cleavage of the
preprohormone pro-opiomelanocortin (POMC), which also yields melanocyte-
stimulating hormone, beta-lipotrophin and beta-endorphin. ACTH is released under
stimulation from corticotrophin releasing hormone (CRH) and / or arginine
vasopressin (AVP), arriving through the hypophyseal portal system from the
hypothalamus. These components comprise the HPA axis (Guyton & Hall 1996), and
are pictured in Figure 1-5. CRH and AVP are also polypeptides, synthesised within
the cell bodies of specific neurones in the paraventricular nucleus (PVN), and subject
to regulation through numerous neuronal connections from other brain regions,
mainly the limbic system and lower brain stem. Through these connections, stress
induces CRH secretion, and hence glucocorticoid production. Particular attention has
been paid to inputs from the hippocampus, which down-regulate CRH production
(Sapolsky et al. 1985). Glucocorticoids have a negative feedback effect upon their
own secretion through binding to receptors in the hippocampus, hypothalamus, and
the pituitary.
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Figure 1-5 The Hypothalamic-Pituitary-Adrenal Axis of the Rat.
Corticosterone is secreted by the adrenal cortex in response to the secretion of ACTH by the anterior
pituitary, secretion of which is in turn triggered by CRH and AVP release by the paraventricular
nucleus of the hypothalamus. Corticosterone has a negative feedback effect upon its own secretion at
the hypothalamus and pituitary, and also influences the activity of neuronal projections to the
hypothalamus from higher brain centres.
Key: + up-regulation, - down-regulation
In the absence of other stimuli, CRH, ACTH, and glucocorticoid secretion oscillate
through the day, but conform to a circadian rhythm overall. In man and other diurnal
animals, peak secretion occurs in the early morning, while the nadir is usually around
midnight, while in rodents, the cycle is reversed, reflecting their nocturnal activity
(Dallman et al. 1993).
1.4.3 Physiological Effects
Glucocorticoids have wide-ranging effects on metabolism and immunity, which
typify the changes seen in the body during periods of "stress". These effects are
exerted primarily through altered transcription rate of target genes. A list of
metabolic genes regulated by glucocorticoids is displayed in Table 1-1.
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Table 1-1 Relevant metabolic targets for glucocorticoid action in skeletal
muscle and white adipose tissue
Effects of glucocorticoids on transcription from target genes and the activity of their products in
skeletal muscle (M) and white adipose tissue (A) are shown, as detailed in the literature. T signifies a
resulting increase, and 4 a decrease in transcription or activity.




4 mRNA / binding M (Korn et al. 1998; McKay et
al. 1997)
11 (3-HSD type I T mRNA / activity A (Bujalska et al. 1999)
GLUT-4 No effect on expression
4 recruitment to plasma
membrane
AM (Haber & Weinstein 1992;
Dimitriadis et al. 1997)
(Weinstein et al. 1998;




•I sensitivity to insulin-
induced activation
M (Koerts-de Lang et al. 1999)
(Dimitriadis et al. 1997;
Coderre et al. 1991)
Fructose 2,6-
bisphosphatase
T mRNA / activity M (Marker et al. 1989)
PEPCK I mRNA / activity A (Franckhauser-Vogel et al.
1997; Glorian et al. 1998)
Hormone-
sensitive lipase
4 activity A (Samra et al. 1998)
Lipoprotein
lipase
-4 or T mRNA / activity A (Fried et al. 1993; Ottosson
et al. 1994; Ong et al. 1992)
UCPs i mRNA AM (Scarpace et al. 2000;
Zakrzewska et al. 1999)
PPARy t mRNA (synergism
with insulin)
A (Vidal-Puig et al. 1997b)
Leptin t mRNA A (De Vos et al. 1995)
Resistin t mRNA A (Haugen et al. 2001)
The effects of glucocorticoids on metabolism are broadly antagonistic to those of
insulin. Moreover, they inhibit insulin signalling in target tissues (de Pirro et al.
1980; Kahn et al. 1978), and reduce insulin secretion (Novelli et al. 1999; Delaunay
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et al. 1997). Whereas they do not affect overall levels ofGLUT-4 (Haber &
Weinstein 1992), insulin-stimulated translocation ofGLUT-4-containing vesicles to
the plasma membrane of both muscle and fat is inhibited (Weinstein et al. 1998;
Dimitriadis et al. 1997; Carter-Su & Okamoto 1987), hence peripheral glucose
uptake is reduced. Increased plasma glucocorticoid and NEFAs cause increased
hepatic VLDL secretion (Brindley 1995) and fatty acid oxidation in muscle and fat
(Bitar 2001; Guillaume-Gentil et al. 1993), which may also inhibit glucose uptake
through the Randle cycle (Randle et al. 1963). Furthermore, glycogen synthesis and
glucose oxidation are reduced (Dimitriadis et al. 1997). Glucose utilisation is
reduced in the liver by glucocorticoids (Rooney et al. 1993), while hepatic glucose
output is increased as a result of induction of PEPCK, and therefore gluconeogenesis
(Hanson & Reshef 1997). The net result of all these changes is increased blood
glucose.
Glucocorticoids antagonise the effects of insulin by mobilising fatty acids and
promoting (3-oxidation, hence their secretion results in an increase in plasma
triglycerides. They also promote the mobilisation of amino acids from muscle and
reduce amino acid transport into non-hepatic cells and protein synthesis throughout
much of the body. Glucocorticoid excess hence results in muscle wasting, occurring
preferentially in fast twitch fibres (Polla et al. 1994). Effects are also exerted upon
other hormones directly: glucocorticoids induce leptin expression, for example (De
Vos et al. 1995).
In addition to their metabolic effects, glucocorticoids also prevent the development
of inflammation and speed its resolution, through effects on lysosomes, capillary
endothelia, white blood cells, and cytokine secretion.
1.4.4 Pre-receptor Modulation
The effects of glucocorticoids are mediated in a tissue-specific manner by expression
of the glucocorticoid receptor, but also by expression of the two isoforms of the
enzyme 1 ip-HSD. 11 P-HSD type I is NADPH-dependent and is a predominant
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reductase, converting cortisone to Cortisol in man, and 11- dehydrocorticosterone to
corticosterone in rodents. Conversely, 11 (3-HSD type II is NAD-dependent, and
converts Cortisol to cortisone in man, and corticosterone to 11- dehydrocorticosterone
in the rodents. I.e. the type II enzyme is responsible for the de-activation, and the
type I enzyme the re-activation of glucocorticoids (Seckl & Chapman 1997).
11 |3-HSD type I is widely expressed in tissues which also express the glucocorticoid
receptor, and is especially abundant in liver and adipose tissue, where it locally
amplifies the effect of glucocorticoids (Chapman et al. 1997). Its expression is under
the regulation of glucocorticoids (Jamieson et al. 1999) and other hormones (Moore
et al. 1999; Napolitano et al. 1998), and its absence results in attenuated
glucocorticoid-inducible responses (Kotelevtsev et al. 1997).
11 p-HSD type II is expressed in tissues also expressing the mineralocorticoid
receptor (MR), including the kidney, and also in the placenta (Edwards et al. 1996).
This enzyme prevents exposure ofMR to active glucocorticoids, which act as a
ligand for MR, and circulate in higher concentrations than aldosterone. Absence,
mutation, or pharmacological inhibition of this isoform results in hypertension due to
excessive salt retention (Stewart et al. 1994; Kotelevtsev et al. 1999). Protection of
the foetal HPA axis from the higher concentrations of glucocorticoids in the maternal
circulation is similarly engendered by the type two isoform in its placental location
(Benediktsson et al. 1997). The enzyme is expressed at the materno-foetal junction,
until towards the end ofpregnancy in the rat (Waddell et al. 1998). The implications
of this will be discussed further in the section on programming.
1.4.5 The Glucocorticoid Receptor
The receptor for glucocorticoids is a member of the steroid-thyroid-retinoid receptor
super-family, and it is typically expressed in its unbound form in the cytoplasm of
cells, although membrane receptor has been reported in the CNS (Orchinik et al.
1991). The members of the super-family have a common functional domain
structure. This includes a variable N-terminal domain, often important for trans-
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activation of transcription; a well conserved DNA-binding domain, crucial for
recognition of specific DNA sequences and protein: protein interactions; and at the
C-terminal end, a ligand-binding domain, important for hormone binding, protein:
protein interactions, and additional trans-activation activity (Kumar & Thompson
1999). Members of this family are active only as dimers, and GR homodimerises to
yield a 94 kDa protein (Chalepakis et al. 1990; Tsai et al. 1988). The GR gene
consists of 9 exons, the untranslated first containing the promoter region, and the
remaining structural exons 2-9 (Encio & Detera-Wadleigh 1991).
In addition to the widely-expressed GRa, a GRP has been identified, derived from an
alternate splice transcript, and differing in the addition of 15 amino acids at the
carboxyl terminus, which has been reported to exert a dominant negative effect upon
GRa trans-activation in man (Brogan et al. 1999; Oakley et al. 1999), perhaps
modulating tissue GR sensitivity (Bamberger et al. 1995). However, the importance
of this receptor isoform is still controversial (Carlstedt-Duke 1999), especially in
view of its absence in rodents (Otto et al. 1997). Recently, a 91kDa alternately
translated form of the receptor has also been identified in human cell lines, leading to
subdivision of human GRa into types A and B. The latter form is reported to be
twice as efficient at trans-activation, and probably arises from a leaky ribosomal
scanning mechanism (Yudt & Cidlowski 2001).
1.4.6 Transcriptional activation by GR
As glucocorticoids are fat-soluble, they enter cells by simple diffusion and activate
cytoplasmic receptor via the ligand-binding domain. This process involves
dissociation from the heat-shock proteins (HSPs) that form a complex with unbound
receptor (Gustafsson et al. 1989; Pratt et al. 1993), and translocation of the hormone-
ligand complex across the nuclear membrane (Hache et al. 1999). Once its nuclear
effect has been achieved, receptor is recycled to the cytoplasm, where it re-associates
with HSPs (Yang & DeFranco 1996). A summary of the events involved in the
activity of GR is depicted in Figure 1-6. Recent work implies that the
phosphorylation status of the receptor is key in its degree of activation (Orti et al.
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1992), and also in determining its half life (Webster et al. 1997), according to the
degree of activation of a proteasomal degradation mechanism (Wallace & Cidlowski
2001).
Figure 1-6 Model of Glucocorticoid Receptor activity (after Litwack
&Schmidt, in "Textbook ofBiochemistry", Ed. Devlin, 1997)
Free hormone dissociates from the circulating transport protein (CBG), diffuses into the cytosol, and
binds to inactive GR. This activates the receptor by causing dissociation of the heat-shock protein
complex (HSP), and the receptor dimerises and is translocated into the nucleus. Here, the activated
receptor binds to glucocorticoid-response elements in the promoter region of target genes, and recruits
other elements of the transcriptional apparatus of the cell. Transcribed mRNA is translated into
protein products by ribosomes in the cytosol.
Liganded receptor classically exerts an effect through attachment of the DNA-
binding domain to specific sequences ofDNA in the promoter regions of target
genes, known as glucocorticoid response elements (GREs) (Payvar et al. 1983;
Scheidereit et al. 1983; Becker et al. 1986). It can also achieve an effect by protein:
protein interactions with other transcription factors, which bind DNA (Gottlicher et
42
al. 1998; Reik et al. 1994). Complexes are also believed to be formed with various
co-aetivators or co-repressors, which modulate the induced transcriptional activity of
target gene promoters (Jenkins et al. 2001; Sheppard et al. 1998). Binding of GR and
other transcription factors initiates chromatin remodelling and modulates the
assembly of the transcriptional machinery, such that target gene transcription in
activated or repressed (de Lange et al. 1997). Appropriate response elements have
now been identified in multiple genes involved in carbohydrate and lipid metabolism
(Lange et al. 1989; Hanson & Reshef 1997).
1.4.7 Regulation of GR expression
In addition to its role in regulating transcription from other genes, the expression of
GR itself is regulated, because its abundance determines tissue sensitivity to
glucocorticoids (Schmidt & Meyer 1994). Control of expression is exerted through
binding of transcription factors to response elements within its promoter region, and
also through post-translational mechanisms (Dong et al. 1988), including enhanced
proteasomal degradation rate (Wallace & Cidlowski 2001). The most frequently
studied mechanism is the induction or repression of GR transcription or activity by
glucocorticoids. This can be achieved through binding of liganded receptor to GREs
in the promoter region of the GR gene (Okret et al. 1986; Burnstein et al. 1991), and
permits feedback control on glucocorticoid-regulated events at multiple levels.
A further mechanism of GR regulation could be through usage of alternate promoter
regions of the gene (McCormick et al. 2000; Gearing et al. 1993). Multiple
transcription initiation sites have now been identified within exon 1 of rats
(McCormick et al. 2000), mice (Strahle et al. 1992) and man (Breslin et al. 2001)
that yield transcripts with different 5' untranslated regions, permitting transcriptional
control through different specific response elements on each promoter region. These
numerous facets of control ofGR permit very specific expression of the receptor
according to developmental stage (Kalinyak et al. 1989; Cole et al. 1995), age
(Tohgi et al. 1995; Djordjevic-Markovic et al. 1999), tissue (Kalinyak et al. 1987;
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McCormick et al. 1998), sex (Liu et al. 2001; DuBois & Almon 1984), and hormonal
and metabolic milieu (Bumstein et al. 1991; Okret et al. 1986).
1.5 The Metabolic Syndrome
1.5.1 Definition and epidemiological significance
Having discussed normal carbohydrate and lipid metabolism, and its control,
especially by glucocorticoids, I will now discuss relevant associated
pathophysiology.
The "metabolic syndrome" or "syndrome X" is a cluster of abnormalities that are risk
factors for the development of ischaemic cardiovascular disease. These include
insulin resistance and compensatory hyperinsulinaemia, glucose intolerance,
increased plasma triglycerides, decreased high-density lipoprotein cholesterol,
smaller denser low-density lipoprotein particles, and hypertension (Reaven 1995).
Obesity is an additional risk factor that usually co-exists (Bjorntorp & Rosmond
1999), the effects ofwhich are often very difficult to disentangle from those of
insulin resistance (Steppan et al. 2001). In fact, there exists a "chicken and egg"
question between these two syndromes. Aberrant lipid deposition in muscle as a
result of obesity is important in determining local insulin resistance (Simoneau et al.
1999; Kelley et al. 1999), but muscle insulin resistance can lead to increased adipose
deposition (Kim et al. 2000b).
Occurrence of this syndrome is traditionally associated with lifestyle factors such as
poor diet, lack of exercise, and consumption of alcohol and cigarettes (Barker et al.
1989). The significance of this group of disease entities is emphasised by examining
the World Health Organisation report of 1998, which rated cardiovascular disease as
the number one cause ofmortality in the developed world for the preceding year, at
46% (World Health Organisation 1998).
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1.5.2 Insulin Resistance, Diabetes Mellitus and Cardiovascular Risk
Diabetes mellitus is a series of diseases characterised by lack of control over
glycaemia. Type I diabetes refers to the early onset disease caused by an inability of
the pancreatic P-cells to secrete sufficient insulin. Type II or non insulin-dependent
diabetes (NIDDM), however, has a typical onset in middle-age, and is related to poor
glucose tolerance. Resistance to insulin-stimulated glucose uptake is present in the
majority of human patients with impaired glucose tolerance or type two diabetes, and
in approximately 25% of non-obese individuals with normal oral glucose tolerance.
In these conditions, deterioration of glucose tolerance can only be prevented if the P-
cell is able to increase its insulin secretory response and maintain a state of chronic
hyperinsulinemia (Reaven 1988). There is still debate on the relative contribution of
pancreatic insufficiency (Kulkarni et al. 1999; Novelli et al. 1999) and resistance of
tissues to insulin in the development ofNIDDM, but it seems most likely that insulin
resistance comes first (Bjorntorp et al. 1999; Reaven 1995).
The insulin resistance syndrome reflects as a reduced capacity for many tissues to
respond to insulin. Gluconeogenesis proceeds at an increased rate in the liver (Boden
et al. 2001), but reduced glucose uptake and glycogen synthesis in liver, adipose
tissue, and especially skeletal muscle are quantitatively more significant (Abel et al.
2001; Bonadonna et al. 1996; Cline et al. 1999; Kelley et al. 1996). As one would
also expect, there is also reduced fatty acid synthesis in adipocytes (Richardson &
Czech 1978), and impaired uptake of fatty acids by adipose tissue (Maheux et al.
1997; Reynisdottir et al. 1997), explaining the elevated plasma triglycerides and
LDL observed.
The link between insulin resistance and hypertension, and subsequent cardiovascular
disease is as yet not fully explained. However, insulin has been shown to be
responsible for peripheral vasodilatation, which may partially determine glucose
uptake (Baron 1994), and it is also implicated in salt sensitivity (Sechi 1999), and
linked with the sympatho-vagal balance of cardiac innervation (Flanagan et al.
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1999). Since salt retention, tachycardia and peripheral vasoconstriction all contribute
to hypertension, cardiovascular or renal insulin resistance could be implicated. These
links are being further explored in models such as the spontaneously hypertensive
rat, in which glucose uptake is impaired (Reaven 1991; Collison et al. 2000).
1.5.3 Mediators of insulin resistance
There have been many factors implicated in the mechanism of development of
insulin resistance, reflected in a vast literature. This thesis is concerned with the
importance of glucocorticoids in insulin resistance, which will be discussed further
below, but I will review here a selection of other proposed mechanisms.
Impairment in insulin-signalling mechanisms have been identified, which would
reduce the effect of circulating insulin on metabolism. The IP3 cascade (Cusi et al.
2000) and early post-receptor phosphorylation steps (Paez-Espinosa et al. 1999) have
both been implicated. There has been much attention paid to involvement of aberrant
lipid metabolism, since the observation that accelerated release of fatty acids
impaired glucose uptake (Randle et al. 1963). It has further been shown that elevated
fatty acids are associated with reduced glucose oxidation and glycogen synthesis
elsewhere (Ebeling & Koivisto 1994; Boden et al. 1994). Redistribution of lipid from
adipose tissue to muscle (Dobbins et al. 2001; Turcotte et al. 2001) and liver (Mori et
al. 1997; Kim et al. 2001a) occurs, and is associated with insulin resistance in these
tissues (Pan et al. 1997; Kim et al. 2001a). Adverse lipoprotein profile (high LDL,
low HDL) is a key part of the syndrome which may be implicated in this re¬
distribution, and apolipoprotein abnormalities have been shown to cause insulin
resistance (Castellani et al. 2001).
Altered secretion of hormones or cytokines from adipose tissue has been implicated
in the development of insulin resistance, and in the linkage of insulin resistance and
obesity. Tumour necrosis factor a is over-secreted from adipose tissue and muscle of
obese, insulin resistant individuals (Hotamisligil et al. 1993; Saghizadeh et al. 1996),
and has a negative effect on insulin signalling (Kroder et al. 1996). Subnormal leptin
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secretory responses (Liu et al. 1999) and the associated over-expression ofmelanin-
concentrating hormone (Ludwig et al. 2001) are also associated with both related
syndromes. Secretion of adiponectin has been shown to correlate inversely with fat
mass, and reduced secretion is associated with obesity, insulin resistance, and
endothelial inflammation (Ouchi et al. 1999; Yamauchi et al. 2001). Finally, the
recently described product, resistin, secreted in larger amounts in obese rodents, has
been claimed to reduce peripheral glucose uptake through reduction in insulin
sensitivity (Steppan et al. 2001). Reduced levels of the hormone also have been
noted in several models of obesity (Masuzaki et al. 2001; Way et al. 2001a), so its
expression may additionally be secondarily influenced by insulin resistance.
1.5.4 Importance of glucocorticoids in insulin resistance and obesity
As has been discussed earlier, the effects of glucocorticoids upon lipid and glucose
metabolism are broadly antagonistic to those of insulin. The potential importance of
glucocorticoids in these two related syndromes can be readily appreciated, therefore,
by considering the features of the syndrome associated with chronic over-secretion of
glucocorticoids: Cushing's Syndrome. This condition is associated with increased
truncal adiposity, which may be a result of specific up-regulation of GR (Bronnegard
et al. 1990), 1 lp-HSD type I, and LPL in this fat depot (Bujalska et al. 1997;
Rebuffe-Scrive et al. 1988). Several features of the metabolic syndrome are also seen
in Cushing's: patients have impaired glucose uptake, hyperlipidaemia, and
hypertension (Friedman et al. 1996) associated with peripheral insulin resistance
(Heaney et al. 1997).
Evidence for the importance of glucocorticoids in insulin resistance comes both from
evidence of increased glucocorticoids in tissues, and increased glucocorticoid-
mediated metabolism. Epidemiological associations have been identified between
increased HPA axis activity and the presence of cardiovascular risk factors
(Reynolds et al. 2001), and obesity especially (Rask et al. 2001; Pasquali et al.
1993). This may be mediated through increased circulating NEFAs, as the feeding of
a high fat diet causes E1PA hyperactivity (Tannenbaum et al. 1997). At the receptor
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level, improved insulin sensitivity results from lower GR in muscle (Vestergaard et
al. 2001), while receptor polymorphisms have been associated with both insulin
resistance and obesity (Weaver et al. 1992; Rosmond et al. 2000). Finally, up-
regulation of adipose 11(3-HSD I is present in obese rats and humans, which would
increase local glucocorticoid concentrations (Rask et al. 2001; Livingstone et al.
2000a). Hyperglycaemia would be predicted as a result of the magnification of the
metabolic effects of glucocorticoids on carbohydrate metabolism in tissues described
above.
1.6 Foetal Origins of Adult Disease
1.6.1 Determinants of foetal development
Growth is an ongoing process between fertilisation and adulthood, consisting of
hypertrophy, hyperplasia, and differentiation of cells. It is, however, not a uniformly
continuous process, as different cells and tissues are occupied in each or these
processes, or are quiescent, during different periods of normal development. In utero,
growth is determined by the genetic composition of the foetus, maternal physiology,
and the placenta, which is responsible for selective exchange ofmaterials between
the two, and is an endocrine organ. Placental function is crucial to permit the supply
of the foetus with sufficient metabolic substrates and oxygen, and for the removal of
waste. Periods ofmore rapid growth of placenta and foetus do not necessarily
coincide, hence potential demands on the placenta also vary throughout gestation
(Robinson et al. 1995). Placental secretion of luteinising hormone, progesterone, and
oestrogen is important in maintaining pregnancy, but other endocrine products of the
placenta have also been identified, including CRH (Goland et al. 1993).
After the glands have fonned, foetal endocrine control of development becomes very
significant. Whereas growth hormone assumes more importance after birth, thyroid
honnones, glucocorticoids and insulin all have crucial effects prenatally. Insulin
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promotes tissue accretion by stimulating cell proliferation, and has anabolic effects
on foetal metabolism (Fowden 1989). Thyroid hormones affect differentiation and
proliferation of different tissues at different times during gestation, and hence have
an asymmetric effect on growth (Fowden 1995). In contrast, glucocorticoids are
mainly concerned with differentiation, especially in preparing the foetus for birth
(Liggins 1994). For example, they promote the production of surfactant, which is
required for lung inflation (Liley et al. 1989), and induce PEPCK transcription,
allowing perinatal gluconeogenesis (Girard 1986). In most species, glucocorticoid
levels rise towards the end of pregnancy, and are involved in the initiation of
parturition (Karalis et al. 1996). Hormones and glucose concentration affect the
production of IGFs, through which many of their effects are probably achieved. In
utero, IGF-II predominates, while IGF-I increases after birth (Sara & Hall 1990), but
both stimulate growth, and it seems that foetal IGF-I may be more significant in
modulating cell proliferation in response to the specific endocrine and hormonal
conditions prevailing in utero (Fowden 1995; Oliver et al. 1999).
1.6.2 Epidemiological associations between birth weight and adult
disease
Barker's original observations were based upon the re-examination of adults for
whom rigorous birth records had been retained in hospitals in Preston and
Hertfordshire, UK. Strong inverse and continuous correlations between birth weight
and the incidence of hypertension, insulin resistance and cardiovascular disease in
middle age were identified (Barker et al. 1989; Barker et al. 1990; Hales et al. 1991).
The basic association between low birth weight and adult disease has been made now
in numerous studies in populations on four continents (Fall et al. 1995b; Curhan et
al. 1996; Hofman et al. 1997). In most studies, findings were independent of adult
lifestyle factors, such as alcohol intake, and adult body mass (Gale et al. 2001;
Curhan et al. 1996; Barker et al. 1990).
Birth weight is used as a surrogate for growth of the foetus in utero in these studies,
but this measurement is crude at best. Separate associations have also been made,
however, between thinness at birth (measured as ponderal index) and insulin
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resistance and cardiovascular disease in later life (Phillips et al. 1994; Barker et al.
1993). This may implicate reduced resources during gestation for the liver and
pancreas specifically in the development of insulin resistance. Placental weight has
also been considered as a risk factor for later disease, since the placenta controls the
access of nutrients to the foetus. One study found a clear beneficial effect of a large
placenta (Thame et al. 2000), but the combination of a large placenta and a small
foetus has been found to be most detrimental (Barker et al. 1990; Barker et al. 1993).
Some workers have further attempted to control for confounders, including genetic
composition, by examining homozygotic twins. Although birth weight has not
correlated with later disease in all studies of this sort, many have recapitulated the
original associations in identical twins (Dwyer et al. 1999; Poulter et al. 1999;
Levine et al. 1994; Poulsen et al. 1997), implying that the effect of small variations
in the maternal environment to which the twins are exposed, can outweigh that of
genetic factors.
Much work has also addressed the timing of development of differences between
high and low birth weight cohorts, and the effect of catch-up growth in modifying
associations between birth data and later disease. It seems that individuals born
small, who go on during childhood to reach equivalent size to their peers, are at still
greater risk of cardiovascular disease (Mortaz et al. 2001; Ong et al. 2000; Fall et al.
1995b). Although risk factors for cardiovascular disease have been looked for most
frequently, altered foetal growth has additionally been associated with changes in
immunity (Beasley et al. 1999; McDade et al. 2001a; McDade et al. 2001b),
osteoporosis (Dennison et al. 2001), intelligence (Haddow et al. 1999) and renal
impairment (Hinchliffe et al. 1992).
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1.6.3 Potential mechanisms for the foetal origin of adult disease
During periods of rapid growth or differentiation, tissues are more susceptible to the
effects of external stimuli, i.e. specific "windows" exist for the environment to have
an effect on development (Widdowson & McCance 1975). Research in the 1970s
showed that very discrete interventions, such as a single dose of androgen, could
have permanent effects on physiology, through altered development, if they occurred
during one of these "windows" (Arai & Gorski 1968; Gustafsson & Stenberg 1974b).
This phenomenon was termed "programming".
Investigation into the mechanisms of the programming of adult disease by in utero
growth retardation is lagging some way behind the accumulation of epidemiological
associations. However, a number of changes in maternal physiology have now been
demonstrated to be associated with, or to cause, IUGR and subsequent deranged
metabolism and disease. The earliest hypothesis, and the one that still receives the
majority of attention, is that maternal malnutrition is responsible (Godfrey et al.
1994; Roseboom et al. 2001b). This is discussed further in the next section.
Alternative hypotheses implicate secreted factors in the maternal circulation.
Administration of cytokines to rats during pregnancy causes reduced insulin
sensitivity, increased adipose mass, and increased stress responsiveness in the
offspring (Dahlgren et al. 2001). The HPA axis has also been programmed by
postnatal endotoxin treatment (Shanks et al. 1995), and handling of pups (Liu et al.
2001; O'Donnell et al. 1994), with effects on stress-responsiveness.
In view of the significance of endocrine control of foetal metabolism and
development, perturbations in hormone levels in utero could potentially have long
term effects. And, indeed, this is the case, as altered androgen (Goldman et al. 1976;
Gustafsson & Stenberg 1974a), oestrogen (Vom Saal et al. 1997), and thyroid
hormone status (Castello et al. 1994; Haddow et al. 1999) have been associated with
permanent effects on reproduction and brain function respectively. Prenatal over¬
exposure to glucocorticoids has marked effects (Seckl et al. 2000; Edwards et al.
1993), and is discussed further below.
A contrasting alternative hypothesis has been put forward by Hattersley, the "Foetal
insulin hypothesis" (Hattersley & Tooke 1999). This proposes that genetically
determined insulin resistance results in impaired insulin-mediated growth in the
foetus, as well as insulin resistance in adult life. It is quite likely that this mechanism
operates in tandem with environmental effects.
1.6.4 Programming by nutrition
Many investigators propose that maternal malnutrition during pregnancy is
responsible for low birth weight and subsequent cardiovascular disease in their
offspring, however there are few prospective studies in human populations yet
published that support this contention. An exhaustive survey of the literature
produced three papers that correlated combinations of poor maternal weight gain,
low skin-fold thickness, and low maternal haemoglobin during pregnancy, with
offspring hypertension (Clark et al. 1998; Adair et al. 2001; Godfrey et al. 1994). A
further paper inversely correlates, retrospectively, protein / carbohydrate intake ratio
and blood pressure (Roseboom et al. 2001b). Other surveys have examined
populations affected by historical famines, but have not produced consistent
associations (Stanner et al. 1997; Stein et al. 1995). Finally, the one genuine
prospective study examining maternal food intake showed no association between
birth or placental weight, and any macro-nutrient (Mathews et al. 1999).
The evidence for this hypothesis, therefore, is mostly restricted to the results of
animal studies, which have been conducted mainly in the rat or the sheep, and
typically involve either restriction of food availability (Woodall et al. 1996) or
protein intake (Hales 1997) in the former species, and timed restriction of availability
in the latter (Gallaher et al. 1998; Whorwood et al. 2001). The phenotype of each
model shows a degree of variation, but in general, tends to re-capitulate that of
human in utero growth retardation. One commonly used model involves the feeding
of a 6-9% protein diet (versus an 18-20% protein diet) to pregnant mothers, which
reduces the amino acid supply to the offspring; amino acid supply has been shown to
be subnormal in growth-retarded babies (Cetin et al. 1988).
52
In the low protein rat model, offspring have reduced birth weight, undergo catch-up
growth (Vehaskari et al. 2001; Ozanne 1999) and develop insulin resistance (Ozanne
& Hales 1999; Holness et al. 2000) and hypertension (Langley-Evans et al. 1996c;
Vehaskari et al. 2001; Kwong et al. 2000) in adulthood. Defects in the kidney have
been reported at birth in two models (Vehaskari et al. 2001; Merlet-Benichou et al.
1994), and the reduced availability model (30-50% normal intake of food) shows
delayed puberty (Engelbregt et al. 2000), and hyperphagia and obesity in adulthood
(Vickers et al. 2000; Jones et al. 1984). Clearly under-nutrition, when severe, and in
various guises, can have a marked effect on development and long-term health.
Whether there is a genuine variation in offspring health as a direct result of the more
subtle variation in the nutrition of First World mothers, is still a matter for debate.
1.7 Prenatal Programming by Glucocorticoids
W m
1.7.1 Rationale and Proposed Mechanism
An alternative hypothesis has been proposed to explain the programming effect,
based upon the over-exposure of the foetus to glucocorticoids (Edwards et al. 1993).
This hypothesis is reasonable, given that these hormones are important in the
development of various organ systems before birth (Liggins 1994; Fowden 1995),
and high dose administration in utero has teratogenic effects (Mosier et al. 1982;
LaBorde et al. 1992). Additionally, foetal Cortisol is known to be elevated in
naturally-occurring IUGR (Goland et al. 1993), while exogenous glucocorticoids
have been shown to reduce birth weight in humans and animals (Reinisch et al. 1978;
Mosier et al. 1982). Furthermore, glucocorticoids are directly associated in adulthood
with both hypertension and insulin resistance (Walker et al. 1998), as described
above.
As discussed earlier, placental 11 |3-HSD type II is responsible for maintaining the
lower foetal level of circulating glucocorticoid, by inactivating endogenous hormone
53
(Benediktsson et al. 1997). However, administration of dexamethasone, which is a
poor substrate for the enzyme, to pregnant rats, results in over-exposure of the foetus
to glucocorticoid, and resulting offspring have low birth weight and develop
subsequent hypertension (Benediktsson et al. 1997). If the enzyme is inhibited by
liquorice derivatives, such as carbenoxolone, the effects are similar (Lindsay et al.
1996a; Lindsay et al. 1996b). A summary diagram of this proposed mechanism can
be seen in Figure 1-7.
Activity of placental 11 {3-HSD type II has been found to correlate positively with
term weight (Benediktsson et al. 1997; Stewart et al. 1995), while feeding of a
restricted diet causes a reduction in placental enzyme activity (Bertram et al. 2001;
Lesage et al. 2001; Langley-Evans et al. 1996b), an observation which may provide
the mechanistic link between dietary and endocrine models. The basic similarity
between the models is further underlined through the observations that maternal
weight gain is interrupted as a result of prenatal dex (Nyirenda et al. 2001), while
administration ofmetyrapone to protein malnourished mothers prevents the
programming of offspring hypertension (Gardner et al. 1997). Glucocorticoids have
also been shown to down-regulate placental glucose transporters, which could restrict
nutrient supply to the foetus (Hahn et al. 1999).
The window for the programming effect has been elucidated to some degree in the
rat model. Glucocorticoid over-exposure throughout pregnancy (Benediktsson et al.
1993), or during the third week alone (Levitt et al. 1996), creates low birth weight
offspring, which later become hypertensive, but treatment during the third week
alone is required to cause insulin resistance in adulthood (Nyirenda et al. 1998)
(Lindsay, unpublished observations). Hence, the most striking effects are specifically
exerted during the period that is the rough equivalent of the human third trimester.
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Figure 1-7 The placental barrier, and the proposed mechanism of
programming by in utero over-exposure to glucocorticoids
Corticosterone concentration is maintained at a lower level in the foetus than in the maternal
circulation by the enzyme 11 P-Hydroxysteroid dehydrogenase type II, which inactivates the majority
of maternal glucocorticoid diffusing across the placenta. However, over-exposure of the foetus to
glucocorticoid occurs if dexamethasone is administered to the mother, which is a poor substrate for
the enzyme, or if carbenoxolone is administered during pregnancy, which inhibits the enzyme.
Legend: rectangles: 11P-HSD type II molecules; black squares: corticosterone molecules; white
squares: 11-dehydrocorticosterone molecules (inactive); black triangles: dexamethasone molecules;
circles: carbenoxolone molecules.
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1.7.2 Adult Phenotype of Glucocorticoid Over-exposure Model
A number of groups have now examined the effect of excess glucocorticoid on long-
term health and metabolism, considering a number of systems. As mentioned, dex-
treated rats are born with an 11-16% reduction in their body mass, versus controls
(Nyirenda et al. 1998; Welberg et al. 2001; Levitt et al. 1996; Sugden et al. 2001),
and develop relative hypertension (Benediktsson et al. 1993; Levitt et al. 1996;
Sugden et al. 2001) from 2-3 months of age. Administration of dexamethasone or
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carbenoxolone in utero also results in glucose intolerance and insulin resistance from
around six months (Nyirenda et al. 1998; Saegusa et al. 1999), i.e. some major
components of the metabolic syndrome are present. Adverse effects of the treatment
have also been noted in the kidney (Celsi et al. 1998), heart (Langdown et al. 2001),
lung (Price et al. 1992), immune system (Bakker et al. 2000), and brain (Carlos et al.
1992; Welberg et al. 2000; Welberg et al. 2001), the latter affecting behaviour.
Effects of prenatal glucocorticoid have also been noted in guinea pigs (Liu et al.
2001) and sheep. Repeated injection with dex during early pregnancy programmes
hypertension (Dodic et al. 1998) and reduced lipolytic capacity (Gatford et al. 2000),
but glucose intolerance is only induced by treatment spanning mid to later gestation
(Moss et al. 2001). Additionally, one study showed that pre-term treatment with
glucocorticoids results in relative hypertension in adolescent humans (Doyle et al.
2000). Hence, not only are differing long term effects achieved through different
windows of susceptibility, there is also inter-species variation in the timing of these.
1.7.3 Programming of Insulin-Glucose Metabolism
Much work is currently addressing potential underlying molecular mechanisms for
the programming of insulin resistance. It has been shown that in utero dex and
perinatal dietary manipulations reduce glucose-induced insulin secretion long term
(Holness & Sugden 2001b; Aalinkeel et al. 2001; Petrik et al. 1999), probably due to
impaired pancreatic development resulting in a programmed reduction in P-cell mass
(Berney et al. 1997; Garofano et al. 1999; Petrik et al. 1999). Insulin target tissues
are also affected by prenatal manipulations, however. Permanent up-regulation of
PEPCK has been reported in both models (Desai et al. 1997b; Nyirenda et al. 1998a),
while glucokinase is down-regulated in the low protein model (Desai et al. 1997b).
The net result of reduced glycolytic flux and increased gluconeogenesis is likely to
be increased hepatic glucose output.
Insulin-stimulated glucose clearance is impaired in dex offspring (Holness & Sugden
2001b), but molecular changes explaining this have not yet been documented in
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muscle and fat. In young offspring of protein-malnourished dams, glucose uptake
into muscle (Ozanne et al. 1996) and adipocytes (Ozanne et al. 1999) is actually
improved, and this is associated with increased membrane insulin receptor and
GLUT-4 in muscle (Ozanne et al. 1996). Increased presence of insulin-signalling
components in fat further explains these observations (Ozanne et al. 1997), but belies
a reduced effect of insulin on lipolysis (Ozanne et al. 1999; Holness et al. 1998).
Low protein rats have reduced blood triglycerides, as a result of this, and probably
reduced synthetic activity (Ozanne et al. 1998a), and resist ketosis (Ozanne et al.
1998b).
Reduced food intake during pregnancy has also been shown to programme
hyperphagia and obesity, a phenotype which is exacerbated by subsequent feeding of
a hypercaloric diet (Vickers et al. 2000). The co-existent paradoxical
hyperleptinaemia is hypothesised to dysregulate the adipo-insular axis, leading to
adipogenic diabetes (Vickers et al. 2001). Additionally, a low protein diet in utero
exacerbates the loss of insulin sensitivity induced by high fat feeding in later life
(Holness & Sugden 1999). The added effects of obesity upon those of in utero
malnutrition have also been recognised in humans (Stanner et al. 1997), but are
difficult to separate from the increased prevalence of obesity in low birth weight
groups (Curhan et al. 1996; Ong et al. 2000).
1.7.4 Programming of Glucocorticoid Action
In addition to the programming effects of in utero glucocorticoids, the HPA axis and
GR are both targets for programming. Epidemiological data show that low birth
weight babies develop hyper-activity of the HPA axis later in life (Reynolds et al.
2001; Clark et al. 1996) associated with elevated adrenal androgens (Clark et al.
1996; Dahlgren et al. 1998), and that elevated Cortisol is associated with glucose
intolerance and hypertension (Phillips et al. 1998). Hyperactivity of the HPA axis
was proposed as a factor linking low birth weight with later insulin resistance as a
result of this. Elevated corticosterone has been reported in the adult offspring of dex-
treated models (Levitt et al. 1996; Welberg et al. 2000), although reduced adrenal
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size has been recorded in pups more aggressively dex-treated or malnourished in
utero (Hristic et al. 1997; Lesage et al. 2001). Reduced GR in the hippocampus has
been found several times in different prenatal programming models (Lesage et al.
2001; Langley-Evans et al. 1996a; Levitt et al. 1996; Welberg et al. 2000; Welberg
et al. 2001), while GR up-regulation is programmed by postnatal handling ofpups
(Meaney et al. 1989; O'Donnell et al. 1994). Since, as previously discussed, the
hippocampus has an important feedback input into the HPA axis, these findings are
probably responsible for HPA hyper- and hypo-activity respectively in these animal
models.
Altered GR expression and / or binding capacity has additionally been observed in
other tissues. Increased GR is found in the liver of the dexamethasone and low
protein models (Nyirenda et al. 1998; Bertram et al. 2001), localised in the former
case to the periportal zones. It is likely that this leads to the elevation of PEPCK in
these models. A preliminary report also suggests GR is increased in the pancreas of
the dexamethasone model (Sugden & Bulmer 2001), and this change has also been
reported in the kidney, whole brain, and lung of low protein rats (Bertram et al.
2001) and nutrient-restricted sheep (Whorwood et al. 2001). Increased GR implies
increased tissue sensitivity to glucocorticoids, and this is exacerbated in the kidney
and adrenal of low protein rats and sheep by reduced activity of 11 (3-HSD type II
(Whorwood et al. 2001; Bertram et al. 2001).
The level of GR expression is not known as yet in tissues mediating peripheral
disposal of glucose. Furthermore, it has not been investigated whether changes in GR
expression are important in determining the adult phenotype of dex-programmed
offspring, or whether they are merely a part of it. Dysregulation ofGR could be
secondary to insulin resistance, in view of the associations observed between the two
(Vestergaard et al. 2001), or secondary to hypercorticosteronaemia, since tissue-
specific effects of plasma glucocorticoid concentration on GR expression have been
observed previously (Kalinyak et al. 1987). The resolution of this conundrum could
be a significant step forward in the understanding of the molecular basis of the
programming of insulin resistance by prenatal glucocorticoids.
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1.7.5 Stress and programming
Maternal stress during late gestation has also been shown to exert long term
programming effects on rat offspring (Meaney et al. 1996), particularly on stress-
responsiveness and glucocorticoid sensitivity of brain regions (McCormick et al.
1995; Koehl et al. 1999; Takahashi et al. 1992). These findings are similar to those
in the offspring of rats given dex in the last week ofpregnancy (Welberg et al. 2001).
Glucocorticoids are responsible for the mobilisation, production and distribution of
energy substrates during stress, and hence it is not surprising that stressors cause
hyper-activation of the maternal HPA axis (Williams et al. 1999). An increase in
exposure of the foetuses to endogenous glucocorticoids is the likely consequence of
this, which may explain the similarity between offspring phenotypes generated by
prenatal dex and by stress. Programming effects are not restricted to prenatal
manipulations, however, as neonatal handling (Meaney et al. 1989; O'Donnell et al.
1994) and stress (Meaney et al. 1996) have also been shown to exert long-term
effects on stress susceptibility and brain GR expression. However, the long term
metabolic consequences ofperinatal stress have not been investigated.
1.8 Aims
Against this background, my thesis addresses the key questions listed below:
1) Is skeletal muscle and white adipose tissue metabolism programmed by
prenatal over-exposure to glucocorticoids?
2) Is GR expression altered in these tissues?
3) Is programming of GR expression a primary determinant of the phenotype of
the model, or is its level of expression set secondary to circulating glucocorticoid
excess or insulin resistance?
4) What is the effect of perinatal stress upon the phenotype of in utero dex-
treated and control rats?
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2 Chapter Two - Materials and Methods
2.1 Materials
Materials were obtained from the following sources:
2.1.1 General Laboratory Chemicals
Bactotryptone
Yeast extract
Agar Becton Dickinson, Cowley, Oxon, UK.
Liquid Nitrogen British Oxygen Company Gases,
Guildford, Surrey, UK.




Formaldehyde (38%) BDH-Merck, Poole, Dorset, UK.
Malate Dehydrogenase Roche Diagnostics Ltd, Lewes, East
Sussex, UK.










HB101 and JM109 cells
p-GEM 3 and p-Gem-T Easy Vector cloning kit
Taq DNA polymerase and buffer
Wizard Plus Miniprep DNA purification
System Promega Ltd, Southampton, Hants, UK.
Agarose BioWhittakerMolecular Applications,




Low Melting Point Agarose
TRIzo1r Invitrogen Life Technologies / Gibco
Wokingham, Surrey, UK.
BRL, Paisley, UK.
Qiagen PCR purification kit Qiagen Ltd, Crawley, West Sussex, UK.
Oligonucleotides TAGN, Newcastle-Upon-Tyne, UK.
ThermoSequenase Radiolabeled






PVL167: pGEM-T Easy vector,
Containing 186bp GR exon 2.
Derived by 5'-RACE PCR from rat
Thymus RNA
Kodak Biomax MR film
Tris-saturated phenol
Phenol / Chloroform / Iso-amyl alcohol
(25:24:1 ratio)
Electrophoresis Power Pac 300
Model 583 Gel Dryer
2.1.3 Antibodies
Anti-Corticosterone antibody
GR (M-20) anti-GR polyclonal antibody
RalRGT anti-GLUT 4 polyclonal Ab
Phillip Harris Scientific, Ashby-de-la-
Zouch, Leicestershire, UK.
Ambion Inc, Austin, Texas, USA.





Raised in rabbits by Dr. Chris Kenyon,
then ofGlasgow University.
Santa Cruz Biotechnology Inc, (Autogen
Bioclear UK Ltd, Calne, Wiltshire, UK).
Biogenesis Ltd, Poole, Dorset, UK.
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Anti-rabbit horseradish peroxidase-linked








55.5TBq/mmol Amersham Pharmacia Biotech
2-[3H(G)]-Deoxy-D-Glucose,
222GBq/mmol NENLife Science Products Inc, Boston,
Massachusetts, USA.
2.1.5 Animals
Wistar rats were supplied by Charles River UK Ltd, Margate, Kent, UK, or Harlan
Orlac, Bicester, Oxon, UK. Females were purchased for mating at 200-250g, along
with males of an equivalent age.
Feed (Standard rat chow) was supplied by Special Diet Services, Witham, Essex, UK,




Metformin (1,1 Dimethylbiguanide) Sigma
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Rosiglitazone (BRL 49653C) GlaxoSmithKline, Welwyn Garden City,
Hertfordshire, UK.
2.1.7 Materials for Protein Work
Glass microfibre filters
Meltilex melt-on scintillator sheets Wallac Oy, Turku, Finland /Perkin-




Colour Protein Markers Sigma
ECL Western Blotting Detection Reagents
Hybond ECL nitrocellulose membrane Amersham Pharmacia Biotech
Non-Fat Dry Milk Blocker
Mini-Protean 2 vertical electrophoresis
System
Bradford Protein assay reagent Bio-Rad Laboratories, Ltd
2.1.8 Materials for Cell Glucose Uptake Assay
Type 1 Collagenase Worthington Biochemical Corporation,
Lakewood, New Jersey, USA.
Adenosine





Human Actrapid Insulin 600pM lOOiu/ml Novo Nordisk, Crawley, West Sussex,
UK.
Dow Corning 200/1OOcS fluid BDH-Merck.
2.1.9 Materials for Ribonuclease Protection Assay (RPA)
Nick sephadex G-50 DNA column Amersham Pharmacia Biotech
Picofluor-40 scintillation fluid Canberra-Packard, Pangbourne,
Berkshire, UK.
Aquasafe 300 Plus scintillation fluid Zinsser Analytic, Maidenhead,
Berkshire, UK.
Hybspeed RPA kit
(Containing 5mg/ml Torulla Yeast RNA, 5M Ammonium acetate, Hybspeed
hybridisation buffer, Hybspeed RNase digestion buffer, Hybspeed inactivation /
precipitation mix, Gel loading buffer 2, RNase A/Tj solution).
Century RNA size markers Ambion Inc.
RNase A
RNase T i Roche Diagnostics Ltd
Kodak D19 developer
Amfix high speed fixer H.A. West, Edinburgh, UK.
2.1.10 Materials for plasma assays
Anti-rabbit scintillation proximity assay
Reagent Amersham Pharmacia Biotech
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Mouse Leptin ELISA Kit
(Containing Antibody-coated microplates, 2.56ng lyophilised leptin standard, sample
diluent, guinea pig anti-mouse leptin serum, anti-guinea pig IgG enzyme conjugate
stock solution, enzyme conjugate diluent, enzyme substrate solution, enzyme
reaction stopping solution, 20x washing buffer stock solution.)
Rat Insulin ELISA Kit
(Containing Antibody-coated microplates, 2ng lyophilised rat insulin standard,
lyophilised sample diluents 1 and 2, guinea pig anti-insulin lyophilised serum, anti-
guinea pig lyophilised antibody enzyme conjugate, o-phenylenediamine tablet,
enzyme substrate diluent, phosphate-buffered saline powder, enzyme reaction
stopping solution, 20% Tween-20.) Crystal Chem Inc, Chicago, Illinois, USA.
Infinity Glucose Reagent
(Containing 2.1 mM ATP, 2.5 mM NAD, >1500U/1 yeast hexokinase, >3200 U/l
Glucose-6-phosphate dehydrogenase.)
p-Hydroxybutyrate Assay kit
(Containing P-HBA reagent (4.6 mM NAD, oxamic acid and buffer, pH 7.6), 50
units/ml P-Hydroxybutyrate dehydrogenase, pH 7.6, 50 mg/dl D-P- Hydroxybutyrate
Calibrator.)
10, 25 and 75 mg/dl D-p-











(RTs and RNA denaturation)
Hybaid Ltd.
1450 Microbeta Plus Liquid Scintillation
Counter
(used for standard cpm counting)
Wallac Oy.
Minaxi |3 Tricarb 4000 Liquid





(used for <2ml volume Eppendorf tubes)
EppendorfAG, Hamburg, Germany.
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competent cells and cytosol preps.) Beckman Instruments, High Wycombe,
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Leicestershire, UK.
Jouan EB115 Incubator
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Autotrap 24
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Q-biogene, Harefield, Middlesex, UK.
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dEhO, UV-treated and autoclaved.
0.5ml DEPC was added to 500ml
deionised water, agitated and left to
stand for 1 -24 hours prior to
autoclaving.
5M sodium chloride solution, treated




20 x GTB (glycerol tolerant buffer)
10 x MOPS buffer




Ambion gel loading buffer 2
RNase A/T i mixture
8.25g Boric acid and 2.7g sodium
hydroxide were dissolved in 11 dFFO
and set to pH 7.4 with hydrochloric
acid.
150ml formamide was mixed with 15g
mixed bed ion-exchange resin for >1
hour, filtered twice and stored away
from light.
216g tris, 72g taurine and 4g EDTA
dissolved in 11 dH20.
42g MOPS, 16.6ml 3M sodium acetate
and 20ml 0.5M EDTA were dissolved
in 11 deionised water, adjusted to pH 7,
and treated with DEPC as above.
104.9g Tris, 55.7g boric acid and 4.7g
sodium EDTA dissolved in 11 deionised
water and autoclaved.
lOmM tris, 2mM DTT, 1.5mM EDTA,
0.1M sodium molybdate, 10% glycerol,
set to pH 7.2.
0.25% (w/v) bromophenol blue, 0.25%
(w/v) xylene cyanol, 30% glycerol in
water.
0.35% (w/v) orange G, 40% glycerol in
water.
95% formamide, 0.025% xylene cyanol,
0.025% bromophenol blue, 18mM
EDTA, 0.025% SDS.
25mg (1250 Kunitz units) RNase A
powder dissolved in 2.3ml lOmM Tris
15mM sodium chloride pH 7.5. 0.2ml
RNase Ti (20000 units) in 3.2M
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20 x TBS buffer
2 x Laemmli buffer
Western Blot Running Buffer







ammonium sulphate pH 6 added.
Mixed, aliquoted and frozen at minus
80°C.
24.2g tris and 80g sodium chloride
dissolved in 500ml dH20, pH 7.6.
4% w/v SDS, 20% glycerol, 2mM DTT,
125mM tris, 10% P-mercaptoethanol in
water, pH 6.8, with bromophenol blue
added to effect.
3.03g tris, 14.4g glycine and lg SDS
made up to 1 litre with dH20.
3.03g tris, 14.4g glycine and 200ml
methanol made up to 1 litre with dH20
and chilled to 4°C.
lOg bactotryptone, 5g bacto yeast
extract, 5g sodium chloride in 11
deionised water, autoclaved
immediately.
LB broth plus 15g agar per litre added
prior to autoclaving.
50mM glucose, 25mM tris, lOmM
EDTA in deionised water, adjusted to
pH8 with hydrochloric acid, (used
fresh)
245.6g potassium acetate was dissolved
in 300ml water, and the volume made to
500ml with 57.5ml glacial acetic acid
and 142.5ml water.
0.2M sodium hydroxide, 1% w/v SDS.
lOmM tris, ImM EDTA, adjusted to
pH8 with conc. hydrochloric acid.
Autoclaved before use.
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Caesium chloride / TE buffer 100g CsCl dissolved in 100ml TE
buffer.
Anthrone Reagent 38ml of freshly opened concentrated
sulphuric acid added to 15ml dH20 on
ice. 150mg of anthrone mixed in. (70%
H2SO4 4mM anthrone).
2.2 Methods
2.2.1 Maintenance of Animals
All animal procedures were carried out under the terms of the Animals (Scientific
Procedures) Act 1986 and Project Licence number 60/2466. Keith Chalmers ,Vince
Ranaldi and Donald Hay were responsible for the maintenance of and prenatal
injections given to the rats.
Animals were under the primary care of the animal technicians of the Biomedical
Research Facility, or the Medical Faculty Animal Area throughout the experiments.
All rats were maintained under controlled lighting (0700h - 1900h daily) and
temperature (22°C) conditions, with ad lib access to food and water. Adult and post-
weaning rats were kept four to a cage or two to a cage when their size required, and
cleaned out weekly.
2.2.2 Production and care of offspring
Bought-in rats were allowed to acclimatise to their environment in home cages in the
animal unit for a period of at least a week prior to mating. Single virgin females were
placed in breeding cages with a male to permit mating, and recorded as such when an
expelled vaginal plug was noticed. This was designated day zero of pregnancy.
Males were used to impregnate an average of three females each. Females were
72
housed singly during pregnancy, and littered down on day 22. Litters were weighed
individually at birth and culled to eight, retaining as many males as possible. Pups
were weaned at three weeks of age and males retained for experiments in the
company of litter-mates. Offspring were weighed at days 25, 40, 60, 80, 100 etc.
In all cases, experimental cohorts comprised male offspring selected randomly from
as many litters as possible (usually a maximum of two offspring per litter were used
per experiment). Males alone were used to complement the results from previous
studies using this model (Nyirenda et al 1998; Nyirenda et al 2001; Welberg et al
2001), and to avoid the confounding influence of varying progesterone levels on
glucocorticoid-mediated metabolism (Xu et al 1990; Hirota et al 1985).
2.2.3 Prenatal administration of dexamethasone
Pregnant mothers were injected subcutaneously with a solution of100pg per kg
dexamethasone in 0.9% saline containing 4% ethanol (Dex mothers) or with an
equivalent volume of vehicle (1ml per kg) (Saline mothers) each morning between
days 15 and 21 ofpregnancy inclusive.
2.2.4 Killing and harvesting of tissues
After mating or weaning was completed, bought-in rats were killed by cervical
dislocation. Subject offspring were killed similarly or by decapitation at between six
and nine months of age, between 9am and 12pm, without prior withdrawal of food.
Unless indicated otherwise, relevant tissues were removed by dissection, weighed
where appropriate, and quickly frozen on dry ice or in liquid nitrogen. Trunk blood
was collected into a plastic tube containing 1ml lOOmM EDTA through an EDTA-
coated funnel, and removed to ice. As soon as possible thereafter, the tubes were
centrifuged at 2000g for 7 minutes, and the supernatant plasma removed to
Eppendorf tubes. Plasma and tissues were stored thereafter at minus 80°C.
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2.2.5 Oral Glucose Tolerance Test
Rats were starved for 17 hours prior to oral glucose tolerance testing. Commencing
between 9 and 9:30am, rats were weighed, and then the distal 5mm of their tails
removed with a scalpel. Each tail was then massaged distally and the basal (time=0)
blood sample collected into a 1.5ml Eppendorf tube pre-coated with 5000iu/ml
heparin. The rats were then given 2g/kg glucose solution (0.2g/ml, lOml/kg) by
gavage and replaced in their cages. After 20 or 30, and 120 minutes, a further blood
sample was collected by "milking" the tail, as before. In each instance,
approximately 300-400pl ofwhole blood was collected, and centrifuged as above for
collection ofplasma, which was frozen at minus 80°C.
2.2.6 Measurement of Plasma [Insulin] and [Leptin] by ELISA
The concentration of insulin in plasma samples obtained during oral glucose
tolerance testing was measured using Crystal ChemR ELISA kits, according to the
manufacturer's instructions (see Materials). The kits measure [insulin] in the range
156 to 10000 pg/ml; intra- and inter-assay CVs are reported as 3.5 and 6.3%. Leptin
concentration was measured in stored trunk plasma using the Crystal ChemR mouse
leptin ELISA kit. The manufacturer reports that the anti-mouse leptin antibody
supplied shows 90% cross-reactivity with rat leptin. The assay is designed for
[leptin] between 200 and 12800 pg/ml, and intra- and inter-assay CVs of 5.4 and
6.9% respectively are quoted.
2.2.7 Measurement of Plasma [Glucose] by Hexokinase Assay
This assay was undertaken on starved plasma samples collected during oral glucose
tolerance testing, using the Sigma Infinity™ glucose reagent. Hexokinase catalyses
the phosphorylation of glucose, and the glucose-6-phosphate produced is oxidised to
6-phosphogluconate, with the generation ofNADH. The amount ofNADH formed is
proportional to the glucose present, and was measured by the increase in UV
absorbance of the reaction mixture.
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1 ml of dH20 was added to 1Opl of each plasma sample and the non-specific
absorbance at 340nm measured on the spectrophotometer, zeroed with water. The
UV absorbances of duplicate or triplicate lOpl plasma aliquots or glucose standards
in dH20 (0, 2, 4, 6, 8, 10, 15 and 20mM) were then measured in a single assay after
the addition of 1ml reagent and 5-60 minutes' incubation at RTP. Standard curves of
Glucose / mM versus UV absorbance units were constructed and sample glucose
concentrations calculated after the deduction of non-specific absorbance.
2.2.8 Measurement of Plasma [p-Hydroxybutyrate]
P-Hydroxybutyrate was measured in trunk plasma of rats. The assay relies on the
equimolar generation ofNADH during the oxidation of P-hydroxybutyrate to
acetoacetate by P-hydroxybutyrate dehydrogenase, with detection as for the glucose
assay.
Sigma calibrators were diluted with water to obtain standards of 0, 2, 4, 6, 8, 10, 15,
25, and 35 mg/dl. UV absorbances of samples and standards in duplicate were
measured in a single assay on the spectrophotometer at 340nm, zeroed with dH20.
To 17pl ofwater, standard or sample, 1.02ml of P-HBA reagent was added, and the
mixture was warmed in a hot-block to 37°C. 17pl of P-Hydroxybutyrate
dehydrogenase was mixed in and the UV absorbance of the incubate measured
swiftly after 10-15 minutes at 37°C. Where possible, sample blanks in dH20 were
measured and deducted from measured absorbances. Standard curves of [P-
Hydroxybutyrate] / mg/dl versus absorbance units were used to calculate sample
concentrations.
2.2.9 Measurement of Plasma lipid parameters
These measurements were made by Dr. Philip Wenham, Department ofMedical
Biochemistry, Western General Hospital, Edinburgh.
75
Automated assays based upon a colourimetric end-point were used, utilising kits
obtained from Wako Pure Chemical Industries Ltd, Osaka, Japan (Non-Esterified
Fatty Acids) or Roche Diagnostics Ltd (Total and High Density Lipoprotein
Cholesterol, Triglycerides).
2.2.10 Measurement of Plasma [Corticosterone] by Radioimmunoassay
Plasma cort concentration was measured in aliquots of thawed plasma by
radioimmunoassay. The assay was developed by Dr. Chris Kenyon, who found intra
and inter-assay variations of 9.4 and 9.2% respectively, and cross-reactivities for
progesterone, deoxycorticosterone and Cortisol of 7.7, 6.5 and 5.3% respectively,
compared to cort (100%) (MacPhee et al. 1989).
25pl of plasma was mixed with 225pl of borate buffer containing 0.5% BSA, 1%
methanol and 0.1% ethylene glycol, and heated to 75°C for 30 minutes to destroy
corticosterone-binding globulin.
The solvent was evaporated from an aliquot of H cort in a glass vial, and the steroid
was suspended in borate buffer to give between 8000 and 13000 cpm per 50pl
solution on the P-counter. 20pl aliquots of diluted plasma or cort standard (320, 160,
80, 40, 20, 10, 5, 2.5, 1,25, 0.625 and OnM cort in ethanol) were incubated in
duplicate with 25pl rabbit anti-cort Ab (final dilution 1:40000) and 25pl diluted 3H
cort for one hour in 96 well plates.
50pl anti-rabbit scintillation proximity assay reagent diluted with borate buffer was
then added to each well, the plates sealed, shaken, and left at RTP for 24 hours to
equilibrate. Plates were counted on the P-counter and [cort] in each sample
calculated from a graph of cpm versus [cort] generated using the Multicalc
programme.
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2.2.11 Systolic Blood Pressure Measurement
Systolic BP was measured in rats using a tail cuff plethysmography method, first
outlined by (Evans et al. 1994), and utilising an identical set of apparatus. This
provides a quick, non-invasive measurement ofBP, based upon the detection of a
pulse in the tail of a rat, while the pressure in a more proximal occluding cuff is
varied. Its accuracy is limited by movement artefacts and the effect of stress in
raising the BP of the subjects. Other workers have published comparisons of
plethysmography with arterial cannulation, however, which demonstrate a close
correlation between the values obtained (Yamakoshi et al. 1979; Evans et al. 1994).
Rats were pre-warmed for 15 minutes in an incubator to 35°C, restrained in a drape,
and an appropriately sized cuffwas attached to each tail, as far proximal as possible.
Four cycles of inflation and deflation of the cuffwere performed, and the pulse wave
generated was followed on the computer screen. The pressure of the cuff at the
moment of the restoration of the pulse wave, on each deflation, is equivalent to the
systolic BP. This was automatically recorded, and the mean value was calculated for
each rat, excluding those cycles in which movement occurred. Each rat underwent
this procedure on three separate occasions. The results of all sets ofmeasurements
were averaged for each rat, as no effect of familiarisation with the technique was
observed over the course of these repetitions.
2.2.12 Extraction of total RNA from tissue
2.2.12.1 Muscle:
RNA was extracted with TRIzo1r, using a method derived from that of
(Chomczynski & Sacchi 1987). Portions ofmuscle were ground in a mortar and
pestle in liquid nitrogen and the powder emptied into 15ml Falcon tubes on dry ice.
10-15 volumes of TRIzolR were added and the mixture stood at room temperature for
five minutes to permit dissociation ofnucleoprotein complexes. It then was
vigorously agitated and vortexed ± auto-homogenised with the Ultra-Turrax,
involving an average of three 10 second bursts at the three-quarter speed setting. The
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tubes were centrifuged at 3000g for ten minutes at 4°C to remove insoluble material
and the supernatant aliquoted into 1.5ml Eppendorf tubes. One fifth volume of
chloroform was added and the tubes were vigorously shaken for fifteen seconds.
After centrifugation at 4°C for 15 minutes at 12000g, the upper aqueous phase, was
removed by pipette to fresh tubes. One half volume of propan-2-ol was added and the
agitated mixture stood at room temperature for a further 10 minutes to precipitate the
RNA. Centrifugation at 12000g for 20 minutes at 4°C pelleted the RNA, and the
supernatant was discarded. The pellet was washed by vortexing in > one volume of
75% ethanol, followed by centrifugation at 7500g for five minutes at 4°C. The wash
was removed by drawn-out pasteur pipette and the pellet dried, before resuspending
in DEPC-treated water. Resuspended RNA from the same tissue portion was
recombined in a single tube.
2.2.12.2 Adipose tissue:
As for muscle, except that tissue was first auto-homogenised in TRIzo1r in place of
grinding and then centrifuged at 600g for 10 minutes at 4°C. The upper lipid layer
was discarded, and the subnatant aliquoted into Eppendorf tubes for RNA extraction.
2.2.12.2 Liver:
As for muscle, except that tissue was first auto-homogenised in TRIzo1r filled
Eppendorfs in place of grinding.
2.2.13 Quantitation and agarose gel electrophoresis of extracted RNA
l-2pl of resuspended RNA from each tissue sample was diluted in lOOpl total
DEPC-water and its UV absorbance at 260 and 280nm measured on the GeneQuant.
The RNA concentration calculated was recorded and the original [RNA] in the
sample calculated. The ratio of Absorbance (260nm) / Absorbance (280nm) was also
recorded, which is indicative of the purity of the RNA. Values as near 2.0 as possible
are desirable.
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The intactness of extracted RNA was assessed by agarose gel electrophoresis:
2.2.13.1 Method 1:
A denaturing gel was made using 0.3g agarose (1%), mixed with 2ml formalin and
3ml 10 x MOPS, made up to 30ml with DEPC-water. This mixture was heated in a
microwave oven to melt the agarose and poured into a plastic mould, with a comb
placed to create loading wells upon its cooling back to solid form. l-2pg of the RNA
solution was mixed with 2.5pl formaldehyde, 2.5pl lOx MOPS and lOpl deionised
formamide and denatured at 65°C for 15 minutes or 95°C for five minutes. 2pl of a
mixture of 1 part ethidium bromide / 20 parts loading buffer type 3 was added and
the mixture loaded on to the gel. The gel was run at <70mA for approximately 30
minutes in lx MOPS prepared in baked glassware, and the results viewed on the
trans-illuminator at 240nm. The presence of intact 28S, 18S and 5S Ribosomal RNA
bands indicated that the preparation was undegraded.
2.2.13.2 Method 2:
A 30ml 1% agarose gel was made containing 3ml 10 x TBE and 0.5pl ethidium
bromide using RNase-free materials. 0.5-1.0pg ofRNA was loaded in 2.5pl loading
buffer per sample, and the electrophoresis performed in 0.5 x TBE. All other details
were as above.
2.2.14 Preparation of cDNA templates by PCR
cDNA templates were prepared by PCR for various genes of interest in fat and
muscle, to be used subsequently for synthesis of riboprobes for use in RPA.
Forward and reverse oligonucleotide primers were designed to target rat mRNA
sequences of interest of between 200 and 500bp, based upon published sequences,
usually available through the BLAST database (National Centre for Biotechnology
Information, National Library ofMedicine, Bethesda, MD, USA):
79
UCP-3 forward TTGGC CTCTA CGACT CTG
reverse GACAC CTTTC CCTGA ACC anneal: 57°C
ACTGC CACTT CAACC ACAG
CCCAA TACTT CGACC AGG 53°C
AGATT TGAAA GAAGC TGTGA ACC
TGTGA ACGGG ATGTC GTCTT CATAG 53°C
CCAAA ACCCT CATCA AGACC
GTCCA ACTGT TGAAG AATGT CCC 53°C
TGTGC CCTGC TGCTG AGCTC TC
GCTAG TGACG GTTGT GCCTT C 58°C
* Primers kindly provided by Dr. Nik Morton.
Total RNA was used to prepare cDNA populations, and oligonucleotides were used
to amplify the sequences of choice by PCR. 2-5pg ofRNA was diluted to 60pl
volume with ultra-pure water and denatured by heating at 65°C in a PCR block for
10 minutes, then transferred to ice. On occasion, RNA solutions were digested with
DNase prior to the denaturation to remove genomic contamination. RNA was mixed
with lpl 10 x DNase buffer, lpl RNase-free DNase I, and made up to lOpl total with
ultra-pure water, and left for 10 minutes at RTP; the digestion was terminated with
lpl of 25mM EDTA. Reverse transcription of the RNA was undertaken using RT
mixes containing multiples of 4pl first strand buffer, lpl of lOmM mixed dNTPs,
2pl 0.1M DTT, 1 pi random priming hexamers and 2pl superscript II enzyme. For the
positive RT reaction, multiples of lOpl ofRT mix were then added to lOpl of
denatured RNA and placed at 42°C for 90 minutes in a PCR block. A negative RT
reaction was usually set up in parallel, in which water was added to the mixture in
place of enzyme, to reveal any genomic contamination of the RNA.
In subsequent PCR reactions, multiples of 2pl cDNA (+RT product), 5pl 10 x PCR
buffer, 0.5pl lOmM mixed dNTPs, 2pl each of lOpg/ml forward and reverse primers






pure dH20 were mixed in 0.5ml Eppendorf tubes. For each reaction utilising a +RT
product, a parallel reaction was usually set up containing a -RT product in its place.
Tubes were placed in thermal cycler blocks under a heated lid and subjected to 37
cycles ofPCR amplification, consisting of lminute at each of 95°C (denaturation),
the specific annealing temperature for the primers used, and 72°C (polymerisation).
This was followed by a final extension period of 10 minutes at 72°C, and the tubes
were then held at 4°C until removed.
2.2.15 Checking and purification of DNA
The length and purity of the DNA was determined by agarose gel electrophoresis of
lpl of the solution in loading buffer against lOObp DNA ladder (PCR products) or
lkb DNA ladder and lpl of uncut plasmid (linearised plasmids). 1% gels were made,
containing 0.5pl of ethidium bromide, which were run at 130V for one hour in 0.5 x
TBE. Single bands were desired, and their lengths were estimated by comparison
with the appropriate ladder, and compared with that desired. DNA solutions showing
a single band of the appropriate length were either gel-purified or phenol /
chloroform-purified. The latter tended to be used for cleaning up linearised plasmids,
while the former method was preferred for PCR products, as it eliminated the
possibility of contamination with nucleotides or primer-dimers.
Gel purification involved similarly electrophoresing the entire volume on low
melting point gels, from which specific bands were cut under brief illumination at
365nm. DNA was extracted from excised gel pieces using phenol / chloroform
separation, sometimes followed by spin-column separation.
In the former case, gel blocks were melted in a hot-block at 68°C for 10 minutes,
then one volume of Tris-saturated phenol was added to each, and the mixture was
vortexed thoroughly, before centrifugation at 12000g for 15 minutes. The upper
aqueous layer was removed from each tube and this was vortexed with one volume
of phenol / chloroform / iso-amyl alcohol in fresh tubes. After five minutes'
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centrifugation at 12000g, the upper phase was again removed and the extraction
repeated. One tenth volume ofDEPC-treated 5M sodium chloride solution and 2.5
volumes of absolute alcohol were added to the final upper phases, and the mixtures
were vortexed and incubated at minus 80°C for 20 minutes to precipitate the DNA.
This was pelleted by 10 minutes' centrifugation, and the pellets were washed in 75%
ethanol, air-dried and resuspended in ultra-pure water. Where DNA solutions were
purified by phenol / chloroform extraction alone, only a one-stage phase separation
was employed, prior to DNA precipitation.
Where gel-separated DNA species were additionally column-purified, a silica gel
membrane-based spin preparation kit was used, according to the manufacturer's
instructions. This ensured the removal of any traces of extraneous organic
compounds remaining. 1 pi aliquots of the putative purified products were
electrophoresed as above to verify that the DNA was still present, and of the
expected length. The [DNA] present was determined in each case by dilution and
spectrophotometric assay on the GeneQuant.
PCR products were of the following lengths, corresponding to that predicted from
sequence information: 260bp (UCP-3), 469bp (LPL), 262bp (resistin) (Kim et al.
2001b), 394bp (leptin) and 239bp (PPARy).
2.2.16 Ligation of cDNA into vector
Purified PCR products were ligated into pGem-T Easy plasmid utilising -A/-T
overhangs generated by the Taq polymerase. The volume ofpurified PCR product
containing an amount ofDNA equal to three times the molar quantity of vector per
microlitre in the kit was calculated in each case. This volume was mixed with 5pi of
2 x Ligase buffer, lpl linear vector and lpl of T4 DNA Ligase and made up to lOpl
with ultra-pure water. Positive and negative control ligations were set up, containing
2pl of control DNA insert in place of PCR product, or no DNA respectively. The
mixtures were incubated at 4°C overnight.
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2.2.17 Cloning of plasmid DNA
Ligated plasmids containing the DNA fragment of interest were used to transform
competent Escherichia coli cells, in which large quantities of DNA could be
produced during microbial replication. All procedures were carried out using sterile
solutions, equipment and technique.
Competent cells (capable of readily taking up plasmids) were either bought-in
(JM109 - in vector kit) or made using cultures ofHB101 cells. In the latter case, a
single colony was inoculated into 5ml of L-Broth and grown overnight at 37°C in a
shaking incubator. The following morning, 1ml of this culture was pipetted into 50ml
of L-Broth in a conical flask, and this volume was incubated for a further 90 minutes,
at which time the bacteria would be in their log phase of growth. The broth
suspension was then centrifuged at 3500g for 5 minutes at 4°C, and the resulting cell
pellet was resuspended in 20 ml of ice-cold 0.1M calcium chloride solution. After at
least 10 minutes' incubation on ice, the suspension was re-centrifuged as above, and
the cells resuspended in 2ml 0.1M CaCb. The cells were ready for use after a further
2-24 hours on ice.
Petri dishes were prepared, containing LB-agar, which had been melted, cooled, and
lml per litre of lOOmg / ml ampicillin added (to a final concentration oflOOpg / ml).
Where colour-selection of colonies was desired, 200pl of 40mM IPTG and 20pl of
50 mg/ml X-Gal were spread across each plate just before use, and given 30 minutes
to dry in.
Competent cells were transformed as follows:
2.2.17.1 Method 1 (JM109s - ligation products):
2pl of each ligation reaction was pipetted into a 1.5ml Eppendorf on ice, to which
50pi of freshly thawed JM109s were added. After gentle mixing, the tubes were left
on ice for 20-30 minutes, then heat-shocked at 42°C for 50 seconds, and returned to
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ice for another 2-3 minutes. 950pl of L-broth was added to each tube of transformed
cells, and they were incubated at 37°C for 90 minutes. The cells were then pelleted
by centrifugation at lOOOg for 10 minutes, resuspended in 200pl of L-broth, and
lOOpl of this suspension distributed across each agar plate. Each culture was
incubated overnight (16-20h) at 37°C, and colonies inspected the following day, at
which stage the petri dishes were transferred for storage at 4°C. Colonies should
have only developed from bacteria which had taken up religated plasmids (and
contained an ampicillin-resistance cassette). If blue / white screening was
undertaken, white colonies were further utilised, as these bacteria should have taken
up an insert-containing plasmid, which could no longer express P-galactosidase
activity.
2.2.17.2 Method 2 (HBlOls - high concentration vectors):
The procedure was generally as above, except that 200pl of competent cells were
transformed per 2pl ofDNA, and typically, transformed cells were not initially
grown up in L-broth, but the whole volume was plated out directly on to LB-AMP
plates.
The presence of plasmids containing the insert of interest within a colony was
checked sometimes by a PCR technique, using primers for the T7 and SP6 RNA
polymerase sites flanking the insertion site.
Primers: (annealing temperature 54°C) (provided by Dr. David Brown)
T7 site TGTAATACGACTCACTATAG
SP6 site GATTTAGGTGACACTATAG
A small amount of each colony picked was taken on a pipette tip into 20pl of ultra-
pure water, boiled at 99°C for 10 minutes to destroy the cells, and centrifuged at
12000g for five minutes to pellet the disrupted cells. 2pl of each supernatant,
containing the plasmid DNA, was mixed with 2pl of 10 x PCR buffer, lpl of 5pg/ml
T7 primer, lpl of 5pg/ml SP6 primer, 0.4pl of lOmM dNTPs, 0.2pl of Taq DNA
polymerase and 13.4pl of ultra-pure water. The tubes were cycled as for the original
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cDNA synthesis, and aliquots of each mixture were examined by agarose gel
electrophoresis as also described above. Single bands of lengths corresponding to the
size of the insert ligated in, plus the portion of the vector (180bp) between the
polymerase sites were looked for.
2.2.18 Plasmid preparations
2.2.18.1 Maxipreps
This method was used when large quantities ofDNA were required for use in
multiple RPAs.
Single colonies identified as containing vector with the insert of interest were
inoculated into 2ml of LB and grown until appreciable turbidity was apparent. This
culture was then transferred into a conical flask containing 500ml LB, which was
incubated for 14-16 hours in the orbital incubator. Each culture was centrifuged in
two 250ml bottles at 3800g for five minutes at 4°C, and the cell pellet was
resuspended in 12ml ofGTE by pipetting. 24ml of fresh 0.2M NaOH / 1% SDS was
added, the suspension shaken vigorously, and left on ice for at least 10 minutes. 16ml
of cold pH 4.8 5M potassium acetate was then added, and the procedure repeated.
The resulting lysate was then centrifuged for at 3800g for 10 minutes at 4°C and the
supernatant filtered through Whatman number 4 filter paper into a fresh bottle, to
which 32ml of isopropanol was added. Thirty minutes later, this was spun at 1 lOOOg
for three minutes, and the resulting pellet was resuspended in 2.2ml TE by pipette.
2.95g of caesium chloride was dissolved in this suspension, and 100pl of ethidium
bromide was also added. Ultracentrifuge tubes were filled with this mixture,
balanced with 1% w/v caesium chloride in TE, sealed, and centrifuged for 17 hours
at 200000g. This yielded a red band across the middle of each tube, in which
ethidium-associated DNA was to be found. This layer was removed to a fresh tube
with a syringe and needle, and the centrifugation process repeated to re-band the
separated DNA, usually by spinning for four hours at 410000g. Each new band was
syringed into a test tube, and an equal volume of isopropanol added. Elaving mixed
this in, the upper layer was discarded and the process was repeated until all colour
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due to the presence of ethidium had vanished. The resulting product was dialysed
overnight at 4°C in three changes of fresh TE (2ml 0.5M EDTA and 10ml pH 8 1M
Tris in one litre ofwater) to remove salts, and the [DNA] quantified
spectrophotometrically.
2.2.18.2 Minipreps
Small-scale preparations ofDNA were undertaken using the Wizard PlusR kit to
identify cells transformed by specific plasmids. Single colonies identified as
containing vector with the insert of interest were inoculated into 2ml of LB and
grown until appreciable turbidity was apparent (between five and 15 hours). The
manufacturer's protocol was followed thereafter. DNA was purified from cells,
protein and RNA by lysis, RNase digestion and passage through mini-columns. The
products were eluted in ultra-pure water and the [DNA] quantified
spectrophotometrically.
2.2.19 Restriction enzyme digestion of DNA
Restriction enzyme digestion was used for the linearisation of insert-containing
vector in advance of riboprobe synthesis, the excision of inserts to verify their size
(LPL, leptin, resistin and PPARy), and to determine the orientation of inserts by
asymmetric digestion.
When preparing templates for use in RNase Protection Assay, clones were selected
from which antisense riboprobes could be transcribed using SP6 RNA polymerase,
as this enzyme was found to be more reliable in producing a single RNA species of
the predicted length. In the case of LPL, this orientation ofDNA insert could only be
achieved by excising the DNA insert from pGEM-T Easy using Sph I and Sac /, and
re-ligating into pGEM-3.
In general terms, l-2pl of enzyme was mixed with one tenth the total volume of the
supplied buffer (or the optimum buffer for two enzymes used simultaneously) and 1-
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5jLtg of DNA, ±BSA, and made up to between 20 and 60pl total volume with DEPC-
treated or ultra-pure water. This was incubated for 90 to 180 minutes at 37°C (or the
optimum temperature for the enzyme in use), and an aliquot electrophoresed on
agarose gels to verify linearisation or to examine the length of products with
reference to DNA ladder.
2.2.20 Sequencing of cDNA by dideoxy method
Chain termination sequencing involved the PCR synthesis ofDNA strands from the
cDNA template of interest, starting from a single primer-annealing site at the vector
T7 or SP6 RNA polymerase sites. 3' elongation occurs in the presence of dNTPs and
is terminated by the random incorporation of a dideoxyNTP, which is radiolabelled
and present in low concentration. Four reactions, each containing a different P-
labelled ddNTP, allow the production ofDNA chains of all lengths between two
nucleotides and the total number of nucleotides in the sequence. After
electrophoresis, the nucleotide sequence of the cDNA can then be read from bands
produced by autoradiography. This procedure was carried out to verify the identity of
the UCP-3 clone, with assistance from Val Lyons.
Termination mixes were prepared on ice. For each cDNA of interest, 2pl of the DNA
solution was mixed with 2pl of lpmol/pl T7 or SP6 primer (see above for sequence),
2pl of 10 x ThermoSequenase buffer, 2pl of ThermoSequenase DNA Polymerase
and 12pl ofwater. 4.5pl aliquots of this were pipetted into four 0.5ml Eppendorfs
and mixed with 2.5pl of one of the nucleotide mixtures. These were prepared from
2pl ofmixed dGTP, dATP, dTTP and dCTP, and 0.5pl of one of the 33P-labelled
ddNTPs each. 35 thermal cycles of 95°C for 60 seconds, 55°C for 60 seconds, and
72°C for 90 seconds were allowed, then 4pl of stop solution / loading buffer was
added to each tube. 3.5pi of each reaction was loaded on to a sequencing gel after
denaturing at 70°C for 10 minutes.
87
The 6% sequencing gel was made by dissolving 42g of urea in 4ml 20 x GTB, 15ml
40% acrylamide and 35 ml dEEO. After re-warming, the solution was made up to
100ml with dH^O, filtered, 600pl of ammonium persulphate and 40pi TEMED
added, and the gel poured. Electrophoresis occurred at <50mA for two hours, and the
gel was exposed against Kodak Biomax MR film until readable. The order of
occurrence ofbands in each of the nucleotide lanes was compared with the published
sequence for the gene of interest to verify its identity and orientation within the
vector.
2.2.21 Ribonuclease Protection Assay
This method was derived from that of (McCormick et al. 2000). RPAs were used to
determine the relative abundance ofmRNA transcribed from a gene of interest
between tissues of treated and control rats. Expression was compared to that of a so-
called "housekeeping" gene, p-actin, a cytoskeletal protein which is commonly used
for this purpose. 32P-labelled cRNA probes for P-actin and the gene of interest are
synthesised using linearised cDNA templates. These are hybridised in excess with
complementary sequences contained within total RNA extracted from tissue, and the
unprotected single-stranded RNA remaining is digested by ribonucleases.
Radiolabeled species are visualised then by electrophoresis and autoradiography.
The relative intensity of test versus P-actin bands can then be quantified, as the
intensity of each will be directly proportional to the amount of complementary RNA
in the mixture.
Riboprobes and RNA markers were synthesised in vitro transcription, ljul of
linearised template, 2pl of 1 OOmM DTT, 4pl of a 1:1:1:1 mixture of 1 OmM rATP,
rUTP, rCTP and DEPC-treated water, 4pl of 5x transcription buffer, 0.5pl of 40u/pl
RNase Inhibitor, 0.5pl of lOmg/ml BSA, 5pl of 32P-GTP, 2.5pl of cold GTP, and lpl
of 20u/pl RNA polymerase were mixed. This mixture was incubated for 90-120
minutes at 37°C (T7 polymerase) or 40°C (SP6 polymerase) to permit
polymerisation. The remaining DNA was removed by digesting with lpl of lu/pl
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RNase-free DNase for 15-20 minutes at 37°C. Labelled riboprobes and markers were
purified from unincorporated nucleotides by passage through sephadex G-50 DNA
columns, with elution in DEPC-treated water. 1ml of liquid scintillant was added to
lpl aliquots of each eluted fraction, vortexed, and counted on the P-counter. 1-
200000 cpm of each fraction was electrophoresed in type III loading buffer on a
denaturing 4% polyacrylamide gel for 15 minutes at 25mA to verify that single
labelled RNA species of the appropriate length were present. Gels consisted of 1ml
40% acrylamide, 1ml 10 x TBE, 3.6g urea, lOOpl ammonium persulphate, and lOpl
TEMED made up to 10ml with dHLO. Probes were either used immediately or frozen
at minus 20°C overnight.
The first phase of the RPA was the precipitation of each RNA sample and its re-
dissolution in hybridisation buffer. To a volume of solution containing the desired
quantity ofRNA, made up to 50pg with yeast t-RNA if required, an appropriate
number of cpm of both the test and P-actin riboprobes were added. Positive controls
consisted of 50pg of yeast t-RNA to which only one probe was added, and negative
controls contained 50pg of yeast t-RNA and both probes. If the total volume was
below 20pl, DEPC-water was used to make it up to this total. One tenth volume of
ammonium acetate and 2.5 volumes of ethanol were then added, the mixture was
vortexed, and incubated at minus 20°C for 20 minutes. The precipitated RNA was
pelleted by centrifugation at 12000g for 15 minutes and air-dried.
Pellets were re-suspended in 20pl of hybridisation buffer by heating to 95 °C for 15
minutes, with vortexing every five. Tubes were swiftly transferred to a second hot-
block at 68°C for 10 minutes' hybridisation, before being allowed to cool. lOOpl of
digestion buffer was added to the positive control tubes, and lOOpl of a 1:10 dilution
ofRNase A/Ti mixture in digestion buffer to the samples and negative control tubes.
Incubation for two 15 minute spells at 37°C with an intervening vortex permitted
digestion of non-hybridised RNA in sample tubes and therefore all RNA in the
negative control tube.
89
After this time was up, the reaction was stopped, and the remaining intact RNA was
re-precipitated by the addition of 150pl ofprecipitation / inactivation buffer to each
tube, and incubation at minus 20°C for 15 minutes. Hybridised RNA was pelleted by
centrifugation as before, and pellets re-dissolved in 8pl each of loading buffer by
heating to 95°C and vortexing. The denatured RNA solutions were loaded on to 5%
polyacrylamide gels alongside controls and markers. 100-150000 cpm ofmarkers
were heat-denatured prior to parallel loading, and positive controls were diluted in
loading buffer to a number of cpm similar to the sample lanes.
The gel mixture consisted of 5ml 40% acrylamide, 5ml 10 x TBE, 21 g urea, lOOpl
fresh ammonium persulphate and 40pl ofTEMED, made up to 50ml with water.
Electrophoresis took place at 30mA for 50-60 minutes, and gels were subsequently
dried for c. 75 minutes, before placing them against phosphorimager screens and
Kodak X-AR5 film at minus 80°C sequentially to develop images.
No bands appeared in the negative control lanes, while bands corresponding to the
full-length probe (from vector RNA polymerase site to utilised restriction site) could
be seen in the positive control lanes. Sample RNA lanes contained bands of lengths
equal to the specific cDNA insert only. Band intensity was determined from
phosphorimager-generated images using Fluorescent image analyser and Auto-image
data analyser software, and mean values of test band divided by P-actin band
intensity were calculated for each treatment group, and the results compared. For
quantitation between gels and sets of probes, comparison between band intensities
produced by bulk standard RNA preparations on each gel were made.
2.2.22 Protein concentration by the Bradford method
The concentration of total protein in a solution was determined using the method of
Bradford (Bradford 1976). The assay is based upon the binding ofCoomassie
brilliant blue G-250 to basic and aromatic amino acid residues, and consequent
colour change in proportion to the amount of protein of > 3000kDa present.
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Samples were diluted with buffer to give solutions in the linear range of 0.05 -
0.5mg protein/ml, and BSA standards were prepared in the same buffer to 0.05, 0.1,
0.2, 0.3, 0.4 and 0.5 mg/ml. To duplicate lOpl aliquots of samples and standards in a
96 well plate, 200pl of a 1:4 dilution ofBio-Rad Protein Assay reagent were added.
After agitation and five minutes' incubation at RTP, the absorbances in each well
were measured in a microplate reader at 570nm. The [protein] in each sample was
calculated from the mean absorbance, the dilution factor, and a graph of [protein
standard] versus mean absorbance at 570nm.
2.2.23 Competitive receptor-binding assay
The quantity of functional receptor protein in a tissue can be measured using an
assay in which various concentrations of "cold", unlabelled ligand are incubated with
a defined concentration of tracer ligand, labelled with tritium. Bound and unbound
ligand are separated, and the amount of label retained with the receptor in each
incubate is measured by p-emission. From this information, the amount of receptor
present per unit mass of tissue can be determined. The method described by
(Panarelli et al. 1995) was utilised for the quantitation of GR binding in tissue.
Portions of liver were harvested from freshly killed rats and placed immediately into
ice-cold Molybdate buffer, which stabilises GR-hsp complexes. On return to the
laboratory, tissue was rinsed of blood and the buffer replaced, and it was
subsequently minced with scissors. Auto-homogenisation in approximately three
volumes ofbuffer followed, with care taken not to warm the buffer above 4°C.
Homogenates were centrifuged at 20000g for 20 minutes at 4°C to generate crude
cytosol preparations. Further centrifugation of supernatants at 105000g for 60
minutes at 4°C yielded refined supernatants. The [protein] within was measured as
described above, and supernatants were diluted subsequently to 4mg/ml and used
immediately, or frozen at minus 80°C.
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96 well microtitre plates were prepared containing duplicate mixtures of lOOpl
cytosol, 50pl ~H dexamethasone (diluted in Molybdate buffer to 6nM) and 50pl of
"cold" dexamethasone dilutions (0, 0.632nM, 2nM, 6.32nM, 20nM, 63.2nM, 200nM,
632nM, 2pM, 6.32pM, 20pM and 200pM). These were incubated overnight at
between zero and 4°C.
The following day, the contents of each well were vacuum-aspirated through glass
microfibre filters on a cell harvester. This separates steroids bound to receptor from
unbound steroid, as the latter is free to pass through the filter, while the former is
retained. The filters were dried, and scintillator sheets melted on to their surfaces.
The p-emission from each incubate was assessed by five minutes' counting per
corresponding area of the filters, indicative of the amount of radioactive steroid
bound to GR in each.
Plots ofmean cpm versus [Dex standard] were constructed to verify that a typical
sigmoid dissociation curve was described by the data. Kd and Bmax for the tissue were
calculated from Scatchard analysis of the data, using the Radlig package: on a plot of
Ratio [Bound receptor] / [Free Receptor] versus [Bound receptor], the intercept on
the abscissa is equal to Bmax, and Kj is equal to the negative reciprocal of the
gradient.
2.2.24Western Blotting
The quantity of a specific protein present in a tissue was determined by western
blotting. Total protein from lysed cells or a subcellular fraction of homogenate was
prepared as detailed below. The protein content of each protein preparation was
measured as described above, and diluted 1:1 with 2 x Laemmli buffer.
For determination of GR protein content, muscle lysates were prepared. l-200mg of
each muscle was minced in ice-cold 1.05ml LSM buffer, containing 20mM HEPES,
lOmM KC1, 20mM sodium molybdate, ImM EDTA, ImM EGTA, O.lmM sodium
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orthovanadate, pH 7.9, 0.2% Nonidet P-40, and 10% glycerol (Eickelberg et al.
1999), to which 2pg/ml each of pepstatin A, leupeptin, aprotinin, soybean trypsin
inhibitor (STI), and antipain, had been added immediately before use, to inhibit
intracellular proteases. 400pM PMSF then was added, and the mixture auto-
homogenised using the Ultra-TurraxR. Homogenates were centrifuged at 400g for 15
minutes, to remove insoluble matter, and the supernatant frozen at minus 20°C over¬
night.
Low density microsomes (LDM) (consisting ofmembranes and vesicles) were
prepared for measurement of total GLUT-4 in muscle, using a method derived from
those of (Kim et al. 2000a) and (Castello et al. 1994). Less than 24 hours before
electrophoresis, 3-400pg ofmuscle was minced and auto-homogenised in ice-cold
buffer B (30mM HEPES, 600mM KC1, pH 7.4), containing 5pg/ml pepstatin A,
4pg/ml leupeptin, 3pg/ml aprotinin, 2pg/ml aprotinin and STI, and 400pM PMSF,
prepared as above for the LSM buffer. Homogenates were centrifuged at 1 l,400g for
10 minutes, and the supernatants at 356,000g for 60 minutes. The resulting LDM
pellets were resuspended in 100-250pl of ice-cold buffer C (20mM Tris, 255mM
Sucrose, ImM EDTA, pH 7.4).
1mm thick SDS-PAGE gels were prepared in the vertical electrophoresis system as
follows. An 8% resolving gel containing 5.3ml dH20, 2.0ml 40% acrylamide, 2.5ml
1.5M tris.HCl pH 8.8, 0.1ml 10% SDS, 75pl 10% ammonium persulphate and lOpl
TEMED was poured between the glass plates to two-thirds of their height. Its surface
was covered with water-saturated butanol while the gel set, which was then washed
out and a 4% stacking gel poured on top, and a comb added. This consisted of
7.565ml dH20, 1.0ml 40% acrylamide, 1.25ml 1M tris.HCl pH 6.8, 0.1ml 10% SDS,
75pi 10% ammonium persulphate and lOpl TEMED.
A pre-determined quantity ofprotein in Laemmli buffer was denatured for four
minutes by heating to 95°C and immediately loaded into each well. Samples were
electrophoresed in Running buffer at 40mA versus molecular weight colour markers
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until the dye front reached the base of the resolving gel. Protein species are separated
according to their mass, with smaller species migrating further over the same period.
The resolving gel was subsequently removed from the assembly and pre-soaked in
cold Transfer buffer, along with ECL blotting membrane, for 20 minutes. Proteins
were transferred to the membrane by electroblotting in cold Transfer buffer at
250mA for 2.5-3 hours. Complete transfer was verified by the loss ofmarker dyes
from the gel, or occasional staining of the gel with coomassie blue, which revealed
any remaining protein.
Membranes were transferred to trays containing 5% milk powder and 0.1% Tween-
20 in 2.5 x TBS and left overnight at 4°C on an orbital shaker, to minimise the
availability of non-specific antibody-binding sites. The following day, dilutions of
primary antibody in the same solution were applied to membranes for two hours,
followed by three five-minute washes on the orbital shaker. Dilutions of the
appropriate secondary antibody (directed against rabbit or mouse IgG) were then
applied to the membranes for one hour. Three further five-minute washes in 0.1%
Tween-20 in 2.5 x TBS and a final wash in 2.5 x TBS followed to remove any
unbound antibody.
Antibody complex bound to the protein of interest was visualised using the ECL
chemoluminescence method. Secondary antibodies are attached to a horseradish-
peroxidase molecule, which catalyses the oxidation of luminol in the presence of
hydrogen peroxide. The light produced exposes chemoluminescence-sensitive film in
areas corresponding to the specific protein bands on the membrane. 1:1 mixtures of
ECL reagents 1 and 2 were made and applied to membranes for one minute, and then
ECL film placed against the wrapped membranes. The film was left in place for a
period sufficient to give a suitable exposure, after which it was developed and fixed.
Based upon the intensity of the visible bands, further exposures were made until
clear specific bands were visible. Film images were captured on the MCID software
via an imaging camera and illuminator, and band intensity on the resulting files
analysed using AIDA.
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A second antibody application could be made to membranes using the same protocol
after existing bound antibody had been stripped. Blots were incubated for one hour
on the orbital shaker with 0.2M glycine 0.1% SDS 0.1% Tween-20 pH 2, washed
three times in 0.1% Tween-20 2.5 x TBS, and blocked as above for one hour at RTP
or overnight at 4°C.
2.2.25 PEPCK assay
PEPCK catalyses the decarboxylation and phosphorylation of oxaloacetate to form
phosphoenolpyruvate during gluconeogenesis, as well as the reverse reaction
(incorporation of carbon dioxide and dephosphorylation, with dGDP as phosphate
acceptor). The assay measures PEPCK activity by coupling oxaloacetate formation
with its reduction by excess malate dehydrogenase to yield malate, with the
equimolar consumption ofNADH. The rate of decrease of [NADE1], measured
spectrophotometrically, is proportional to the activity ofPEPCK (Petrescu et al.
1979).
Portions of liver from freshly killed rats were taken into ice-cold 250mM Sucrose /
5mM HEPES buffer pH 7.4 and minced with scissors. They were homogenised with
the Ultra-Turrax in two 2ml Eppendorfs per sample, and centrifuged at 8000g for 10
minutes at 4°C. The crude cytosolic supernatants from each pair ofEppendorfs were
then combined and re-centrifuged at 105000g for 60 minutes. The supernatants
(refined cytosol) were then frozen at minus 70°C, apart from an aliquot of each
which was used for determination of protein concentration by the Bradford method.
Sample mixtures were pre-incubated in duplicate at 30°C for > three minutes. Each
lml reaction mixture contained 50mM HEPES pH 6.5, 50mM sodium bicarbonate,
ImM manganese (II) chloride, 0.25mM NADH, ImM phosphoenolpyruvate, 1.5 i.u.
malate dehydrogenase and 50-150pl cytosol preparation. The reactions were initiated
in a spectrophotometer, set to "Kinetic" mode, using 0.15mM dGDP, and the drop in
absorbance at 340nm followed for four to seven minutes. Reaction mixtures lacking
bicarbonate were introduced periodically as negative controls. PEPCK activity was
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calculated from the rate of decrease in absorbance during the linear phase of the
curve, and the molar absorptivity ofNADH.
2.2.26 Assay of 2-deoxy-D-glucose uptake by adipocytes
The rate of glucose uptake by adipocytes can be estimated by assaying the uptake of
2-deoxy-D-glucose, which is a close structural analogue of glucose. This compound
is transported into cells by glucose transporters with equal efficiency to glucose and
is phosphorylated by hexokinase, but it is not further metabolised. Since the activity
of hexokinase is not rate-limiting, the rate of accumulation of 2-deoxy-D-glucose in
cells is equivalent to the rate of glucose uptake by glucose transporters (Jenkins et al.
1986).
Cytochalasin B inhibits glucose transporter activity, and hence assays in its presence
show the uptake of glucose into cells by simple diffusion. 2-deoxy-D-glucose uptake
was measured in the presence of insulin (GLUT-4 mediated) and without insulin
(basal uptake, predominantly GLUT-1 mediated), and the non-specific uptake,
measured in the presence of cytochalasin B, deducted in each case (Gibbs et al.
1988).
Buffers to be used were freshly prepared each day, and warmed to 37°C in a water
bath. 1 litre ofKRH buffer was prepared, containing 118mM NaCl, 5mM NaHC03,
4.7mM KC1, 1.2mM KH2P04, 1.2 mM MgS04.7H20, 25mM HEPES, 2.5mM CaCl2
and 0.2pM adenosine, pH 7.4. 500ml of KRH/BSA buffer was made by dissolving
1% Fraction V BSA in KRH and re-setting to pH 7.4. 100ml ofKRH/BSA/glucose
was made by dissolving 3.0mM glucose in KRH/BSA and re-setting to pH 7.4.
15-20ml ofKRH/BSA/glucose was warmed to 37°C in a 50ml Falcon tube and
placed in a thermos flask in water of between 37 and 40°C for transport to the
Animal Unit. Both epididymal fat pads were dissected out from a freshly killed rat,
weighed, and placed into the warm buffer for immediate return to the laboratory.
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A suitable piece of fat was weighed and quickly placed in 4ml / g fat of
KRH/BSA/glucose in a Falcon tube at 37°C. To this, 2mg / ml collagenase was
added and the fat was minced with scissors. The tube was then shaken in the water
bath for 30 minutes and the resulting digest filtered through a tea strainer into
another tube in the water bath. The collected adipocytes were allowed to float to the
top of the liquid, and the buffer below was removed with a syringe and needle, prior
to the addition of 20ml KRH/BSA. This flotation and washing step was repeated
three times over a 20 minute period. The cells were then stored at 40% cytocrit until
use (within 20 minutes).
Solutions for the glucose transport assay were prepared during the collagenase
digestion. The sugar cocktail solution contained 400pM cold 2-deoxy-D-glucose and
16.7pM 2-[3H(G)]-Deoxy-D-Glucose (3.7MBq / ml). The lOmM stock of
cytochalasin B was diluted 1 in 10 with KRH for use, and the insulin was prepared in
KRH to concentrations of InM and 25nM. These concentrations were chosen based
upon preliminary experiments indicating that 1 OpM insulin would induce an
approximately half-maximal, and 25OpM insulin a maximal glucose uptake.
Six 50ml tubes were set up in the shaking water bath for each assay, containing
900pl KRH/BSA (glucose-free buffer) and lOOpl of cells. lOpl of insulin dilution (0,
1 or 25nM) were added to two tubes each and incubated for 15 minutes. One minute
prior to the end of this period, lOpl cytochalasin B was added to one tube containing
each of the insulin concentrations. Afterwards, 25pl of sugar cocktail was added to
each tube, and the mixture incubated for a further three minutes. Three 200pl
aliquots of incubate were removed from each tube at the end of this period and added
to 0.5ml Eppendorfs containing 200pl Dow Corning oil each, to terminate the
reaction. Eppendorfs were centrifuged at 12000g for 30 seconds to collect the cells in
pellets at the top of the oil. The adipocytes were transferred by Pasteur pipette to
scintillation vials, and c. 1ml of 1% Triton-X-100 used to remove the remaining cells
and solubilise them for at least 30 minutes. After vortexing in a large excess of
scintillation fluid, dpm per vial were measured in the (3-counter. Basal and insulin-
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stimulated 2-deoxy-D-glucose transport rates into 1 OOpl of adipocytes from the
chosen rat were then calculated.
2.2.27 Assay of glycogen content by the Anthrone method
The method used was derived from that of (Van Handel 1965), with tissue
preparation adapted from (Azpiazu et al. 2000). Portions of each muscle were
powdered under liquid nitrogen and 12-22pg scraped into Eppendorfs, which were
weighed before and after the addition. The powder was homogenised in 400pl 30%
potassium hydroxide by syringe and needle, having been weighed again after each
step to allow for variable pipetting and losses in the syringe. After heating in a hot-
block at 100°C for 30 minutes to solubilise the tissue, 1,05ml absolute alcohol was
added to each tube to precipitate the glycogen. After pelleting the glycogen by
centrifugation at 6000g for 10 minutes, the pellets were washed with 1ml 70%
ethanol. The tubes were re-centrifuged for five minutes and then the washing and
centrifugation were repeated twice. The final pellets were dried and resuspended in
150-200pl ofwater by vortexing and heating to 70°C for 20 minutes. These were
stored at minus 20°C overnight.
In duplicate or triplicate, 50pl of glycogen solution or glucose standard (0, 5, 10, 15,
20, 25, 30, 35 or 40pg glucose in d^O) was pipetted into pyrex tubes and placed
into a 90°C water bath. 950pl of Anthrone reagent was added to each tube and
marbles placed on top to minimise evaporation. After 20 minutes' incubation, the
tubes were agitated and the absorbance of each incubate was measured at 620nm in a
spectrophotometer blanked with dH20. The quantity of glucose and therefore
glycogen per sample aliquot was estimated using a standard curve of [glucose]




All data are quoted as the mean ± standard error of the mean. Results were taken to
be significant with p<0.05. Statistical analyses were undertaken using either
SigmaStat or Statistica programmes.
The difference between the mean values ofmeasurements made on two comparable
treatment groups was tested by Student's t-test, and between multiple groups by One-
Way ANOVA. Where multiple separate treatment types were involved, Two or
Three-Way ANOVA was performed, with post-hoc testing using Tukey's Honest
Significant Difference test, or Student's t-test. Ifmeasures were repeated, this was
also taken into account. Analyses were made using equivalent non-parametric tests if
data were not normally distributed, according to the statistics package used.
Linear regression analysis was used to examine the relationship between two
continuous variables.
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3 Chapter Three - Programming of Skeletal Muscle
and Adipose Tissue Metabolism by
Glucocorticoids
3.1 Introduction
Low birth weight and thinness at birth has been associated with increased incidence
ofhypertriglyceridaemia, hyperglycaemia, hyperinsulinaemia, and type two diabetes
in later life (Hales et al. 1991; Phillips et al. 1994; Curhan et al. 1996; Fall et al.
1995a; Phillips et al. 1998), implying a pathophysiological link between in utero
growth retardation and the development of insulin resistance. Hyperglycaemia and
hyperinsulinaemia have been induced in the adult offspring of rats that were
prenatally malnourished (Ozanne & Hales 1999; Holness & Sugden 1999), or over¬
exposed to glucocorticoids in utero (Nyirenda et al. 1998; Lindsay et al. 1996b),
providing models with which to dissect this phenomenon.
Insulin resistance causes hyperglycaemia through the failure of inhibition of hepatic
glucose output by insulin (Boden et al. 2001) and the attenuation of glucose uptake
by GLUT-4 in skeletal muscle and adipose tissue (Bonadonna et al. 1996; Kelley et
al. 1996). Similarly, fatty acid uptake by adipose tissue is attenuated, due to reduced
LPL activity (Maheux et al. 1997; Reynisdottir et al. 1997), resulting in increased
plasma triglycerides and LDL, at the expense of atheroprotective HDL (Daae et al.
1993). Multiple gene expression changes in muscle and fat have been associated with
insulin resistance. For example, fat mass signalling is interrupted by insulin
resistance, as the secretory response of leptin to insulin is subnormal (Liu et al. 1999;
Hardie et al. 1996), muscular UCP-3 has been found to be differentially expressed in
states of insulin resistance (Kageyama et al. 1998; Krook et al. 1998), while PPARy,
which is a transcriptional regulator ofmultiple genes in multiple insulin sensitive
tissues (Way et al. 2001b), including UCPs (Sears et al. 1996), resistin (Way et al.
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2001a) and leptin (Hollenberg et al. 1997), is itself up-regulated in muscle of obese
subjects (Way et al. 2001a).
In the adult offspring of rats that were protein-restricted or given dex during
pregnancy, permanently elevated expression and activity of hepatic PEPCK has been
identified (Nyirenda et al. 1998; Desai et al. 1997). This implies increased
gluconeogenesis in the liver, and therefore, increased hepatic glucose output. Insulin-
stimulated glucose transport and insulin signalling mechanisms have been shown to
be programmed in muscle (Ozanne et al. 1996) and fat (Ozanne et al. 1999) by a low
protein diet, and these animals are also resistant to ketosis, in a similar manner to
some type two diabetic patients (Ozanne et al. 1998b). Evidence also exists for
dysregulation of the adipoinsular axis in malnutrition models (Vickers et al. 2001;
Holness & Sugden 2001a). However, the effect ofprenatal glucocorticoid over¬
exposure on glucose uptake and metabolism in muscle and adipose have not been
investigated to date.
Changes in glucocorticoid activity in these tissues may mediate the observed
metabolic changes in programmed offspring at a molecular level, through altered
level of GR expression (Schmidt & Meyer 1994). Supporting evidence for this
contention comes from findings that improved insulin sensitivity is associated with
lower GR expression in muscle (Vestergaard et al. 2001), and the association of
receptor polymorphisms with both insulin resistance and obesity (Weaver et al.
1992; Rosmond et al. 2000). Accordingly, differences in GR expression have been
noted in both models ofprenatal programming. In the dex rat, GR is elevated in
periportal zones of the liver, which may mediate the increased PEPCK (Nyirenda et
al. 1998), while GR is down-regulated in the hippocampus of adult dex offspring
(Welberg et al. 2001). Moreover, widespread permanent GR up-regulation has been
reported in the offspring of undernourished sheep and rats: in kidney, liver, lung and
brain (Bertram et al. 2001; Whorwood et al. 2001), but the expression ofmuscle and
fat GR in programmed offspring has not been reported.
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Both white adipose tissue and skeletal muscle can be subdivided on a functional and
anatomical basis. Muscle fibres are the functional units of skeletal muscle, and are
subdivided firstly into type I and II fibres, which occur in different proportions in
muscles with differing primary functions. For example, the rat soleus is composed of
87% slow twitch, type I, predominantly oxidative muscle fibres, while the EDL
contains 98% fast twitch, type II, mainly glycolytic fibres (Armstrong & Phelps
1984). Muscle fibres types differ with respect to absolute levels of GR expression
(Claus et al. 1996; DuBois & Almon 1984), the effects of glucocorticoids on them
(Polla et al. 1994), and their metabolic function (Rivero et al. 1998). Intra-abdominal
or visceral fat is less responsive to the anti-lipolytic effects of insulin than
subcutaneous fat, and lipid accumulation in this depot is specifically associated with
other features of the metabolic syndrome (Bjorntorp 1991). Visceral fat metabolism
is particularly sensitive to glucocorticoids, since both GR (Pedersen et al. 1994;
Montague & O'Rahilly 2000) and 11P-HSD type I (Bujalska et al. 1997) are highly
expressed here. Additionally, the increased quantity of fatty acids released into the
portal circulation from this depot in obesity may be responsible for induction of
insulin resistance elsewhere (Benthem et al. 2000; Rebrin et al. 1996).
In this chapter, I present data to show that adult muscle and fat metabolism is
programmed by in utero over-exposure to glucocorticoids. I have examined the
expression of key metabolic genes in these tissues, and assayed various associated
biochemical parameters. I have also further characterised the expression of GR in
insulin target tissues of the model, as alterations in local glucocorticoid sensitivity
may be important in the development of insulin resistance.
3.2 Methods
3.2.1 Animals
Female rats and their litters were maintained, bred, and administered with
dexamethasone or vehicle during their third week of pregnancy as described in
Chapter 2. Male offspring were killed at 6-8 months of age, and tissues and trunk
plasma frozen as described in Chapter 2.
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Tissues were obtained from animals used in other experiments (Welberg et al. 2001;
Nyirenda et al. 1998), in which in utero dexamethasone administration had been
shown to reduce birth weight and cause subsequent glucose intolerance,
hyperinsulinaemia, hypercorticosteronaemia, and elevated hepatic PEPCK activity in
adulthood.
3.2.2 Muscle Glycogen Assay
The glycogen content of portions of quadriceps muscle was assayed using the
Anthrone method, as described in Chapter 2.
3.2.3 Measurement of plasma leptin, p-Hydroxybutyrate and lipids
These measurements were undertaken using thawed trunk plasma as described in
Chapter 2. Measurements ofplasma TAG, NEFAs, cholesterol, and HDL-cholesterol
were made by Dr. Philip Wenham, Department ofMedical Biochemistry, Western
General Hospital, Edinburgh.
3.2.4 Cloning of DNA sequences
DNA templates were prepared to target each gene of interest, purchased (p-TRI-B-
Actin-125-Rat plasmid) or obtained courtesy of Val Lyons and Dr. Karen Chapman
(PVL167: pGEM-T Easy vector, containing 186bp GR exon 2, derived by 5'-RACE
PCR from rat thymus RNA). Oligonucleotide primers were designed to amplify
sequences from cDNA populations derived from rat quadriceps muscle (UCP-3) and
retroperitoneal fat (all others). PPARy primers were designed such both mRNA
splice variants would be identifiable as separate bands on a RPA gel.
These methods are all described in detail in Chapter 2. A summary of the restriction
enzymes used for insert excision, for determination of insert orientation, and for
plasmid linearisation, and the predicted lengths of the DNA fragments, is shown
below, in Table 3.1.
103
Table 3-1 Summary of DNA templates used in RNase Protection Assays
For each DNA template used in RNAse protection assays, the method of insert length and orientation
determination within the vector are listed. Restriction enzymes used for this, and for linearisation of
templates are detailed, along with the insert sizes produced, and the consequent length of protected
RNA fragments on RNAse protection gels.
Key: Full: full length riboprobe; Prot: protected fragment on RPA gel; PCR: determined by PCR;








Enzyme Length Enzyme Length Enzyme Full Prot
GR N/A N/A N/A N/A Ncol 383 186
P-actin N/A N/A N/A N/A BamHI 218 108
UCP-3 PCR 440 SEQ N/A Ncol 236 163
Leptin Not I 437 BstXI 110 Ncol 511 394
LPL Not I 505 Ncol 449 Apa I 361 315
PPARy Not I 282 Ncol 101 SphI 347 171*
239
Resistin Not I 305 Apa I 149 Sac II 360 262
3.2.5 RNase Protection Assay
The relative quantity of specific mRNAs was assessed in insulin target tissues using
RNase Protection Assay (RPA). Total RNA was extracted from frozen tissues using
the TriZolR method, quantified, and verified as intact as described in Chapter 2.
Complementary 32P-GTP-labelled riboprobes and CenturyR markers were
synthesised by in vitro transcription, using linearised DNA insert-containing
plasmids, broadly as described in Chapter 2. The concentration of "cold" rGTP in the
transcription mixture was varied according to the desired specific activity of the
riboprobes. RPAs were undertaken as described, using appropriate quantities of total
RNA , test and actin riboprobes. A summary of probe specific activities and RPA
reaction constituents in each of the assays performed is shown below in Table 3-2.
Typical riboprobe and polyacrylamide RPA gels are displayed as Figure 3-1.
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Table 3-2 Summary of riboprobe properties and reaction mixtures used in
RNAse protection assays
For each target gene in each tissue examined, the final concentrations of unlabelled GTP used in the
synthesis of test and actin probes (volumes and components as detailed on page 89) are shown. These
were chosen based upon preliminary experiments to determine the optimum specific activity of each
for quantitation of the relative abundance of the test probe. The quantity of labelled probe per
microlitre was assessed by scintillation counting, and excess cpm of each probe, as determined in
preliminary experiments, along with a sufficient quantity of total RNA to produce a signal, was mixed



























12.5 100,000 12.5 250,000 50
GR EDL 12.5 100,000 12.5 250,000 30
GR Soleus 6.25 100,000 12.5 250,000 30
GR Retroperitoneal,
subcutaneous fat
4.17 150,000 62.5 150,000 25
UCP-3 Quadriceps 12.5 120,000 12.5 150,000 30
Leptin Retroperitoneal
fat
25 100,000 12.5 150,000 5
LPL RP Fat 62.5 100,000 12.5 150,000 7.5
PPARy RP Fat 4.17 75,000 25 175,000 15
Resistin RP Fat 25 100,000 12.5 250,000 7.5
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Figure 3-1 Typical examples of riboprobe and RPA polyacrylamide gels
a Leptin and actin riboprobes and century markers, synthesised from DNA templates
as detailed on page 89 and in table 3-2. Aliquots of each probe and markers were
electrophoresed on urea-PAGE gels and film autoradiographs obtained, such as that shown,









b Sample RPA gel for PPARy mRNA quantitation in retroperitoneal fat, generated as
described on page 90, and in table 3-2, visualised by autoradiography. Positive control,
marker, 3 repeat standard and sample lanes (each from a different individual) are shown, with
bands labelled according to length and identity. Key: *: protected RNA band; bp: base pairs
ofRNA; Standards: standard preparation of total RNA from adipose tissue; Saline: RPAs
utilising RNA from control offspring; Dex: RPAs utilising RNA from dexamethasone-treated
offspring
PPARy: 347 bp
* Total PPARy: 239 bp
Actin: 218 bp
* PPARy2: 171 bp

















In order to determine whether differences in GR mRNA correlated with function, the
development of a ligand-binding assay was attempted for skeletal muscle. A number
of variations based upon the method of (Panarelli et al. 1995), and incorporating a
scintillation proximity assay (Bosworth & Towers 1989) were attempted. Although
the method could be successfully reproduced using liver cytosol, the amount of non¬
specific binding of dex by skeletal muscle was too great to permit quantification of
GR binding. See Figure 3-2. Western blotting was utilised, therefore, as an
alternative method of semi-quantifying GR protein in muscle homogenates, and was
also used for assay of GLUT-4 protein. The biological relevance of results for GR
protein was improved by standardising between blots using a bulk preparation of
liver cytosol of known dex-binding capacity, which was stored at minus 80°C, and
electrophoresed alongside muscle protein samples. The ligand-binding capacity of
this standard preparation was determined as described in Chapter 2.
Figure 3-2 Specific binding of dexamethasone by liver and skeletal muscle
cytosol of an adrenalectomised rat
Fraction of specific binding versus [Dexamethasone] in a preliminary ligand-binding experiment for
GR in liver and quadriceps cytosol. Even in an acutely adrenalectomised rat, whereas liver GR
binding follows a typical sigmoid dissociation curve, muscle GR binding is a minority of the total,
making quantitation in this tissue unreliable.
Concentration of cold Dexamethasone/ |iM
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In the case ofGR, measurement ofprotein content, SDS-PAGE and western blotting
undertaken as described in chapter 2. On each gel, 5x 60pg muscle protein samples
were electrophoresed alongside a lane containing colour protein markers, and lanes
containing 4, 14, 26, and 40pg liver cytosol protein. Specific GR bands were
identified according to the method detailed in Chapter 2. Blots were exposed to
1:500 dilutions of anti-GR Ab, followed by 1:5000 dilutions of anti-rabbit 2° Ab.
After exposure to ECLR reagents, blots were typically exposed to film for 1-2.5
minutes. Single bands at approximately 95kDa were typically produced using this
method, as can be seen in the typical blot displayed as Figure 3-5d, later in this
chapter. Plots of pg protein loaded versus GR band intensity for the liver cytosol
were used to estimate the amount ofGR protein present in each muscle homogenate.
Three blots were generated for each muscle sample, and the mean Bmax used to
calculate overall mean binding capacity for the treatment group.
Total GLUT-4 content of quadriceps muscle was measured using a method derived
from those ofKim (Kim et al. 2000a) and Castello (Castello et al. 1994). Quadriceps
low density microsome (LDM) preparations were made as described in Chapter 2,
including a bulk preparation of standard quadriceps LDM, which was
electrophoresed alongside LDM samples to control for inter-gel variation in GLUT-4
protein band intensity. 25pg ofLDM protein per sample were used in SDS-PAGE
and western blotting, which were conducted as detailed in Chapter 2. 1° and 2° Abs
were applied to blots at dilutions of 1:750 and 1:7500 respectively, and after ECL
reagent application, blots were placed against fdm for 80s each. Triplicate blots were
used to calculate the mean band intensity at 43kDa for quadriceps of each treatment
group. See Figure 3-3.
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Figure 3-3 Western blots for GLUT-4 in quadriceps muscle: specificity.
Although multiple bands appeared on each film using anti-GLUT-4 antibodies, bands corresponding
to protein species of sizes other than 43kDa were also present either when 2° Ab was applied alone, or
when both Abs were applied to brain lysates in preliminary experiments. Conversely, these lanes did
not display the main 43kDa band, hence the 43kDa band could be regarded as the only specific
GLUT-4 band. Gels containing muscle and brain protein lanes exposed to both antibodies or to
secondary antibody alone are shown together below.
2° Ab only, muscle 1° and 2° Ab, muscle 1° + 2°, brain
3.3 Results
3.3.1 Glucocorticoid Receptor in insulin target tissues
The effect ofprenatal dex on GR expression was tissue-specific. In liver (Figure 3-4
a), it caused a 38% increase in GR mRNA, and in RP fat (3-4 b), a 50% increase.
Conversely, in soleus (3-4 d), GR mRNA was reduced by prenatal dex (by 23%),
while no difference in expression was seen in EDL muscle (3-4 e) or SC fat (3-4 c).
In quadriceps muscle, GR mRNA and protein were not different between treatment
groups (Figure 3-5 a and 3-5 b). The trends displayed in Figure 3-5 are similar for
message and protein (p = 0.12 for protein, Student's t-test), and the results are
weakly correlated (r = 0.32, p = 0.17)(3-5 c), implying that the abundance of GR
protein follows that ofmRNA. The Scatchard plot for the standard liver cytosol
preparation used in western blotting is shown in 3-5 d (IQ = 3.5 x 10~9M, Bmax = 6.3
x 10"9M). An example of a western blot film is displayed in 3-5 e.
109
Figure 3-4 GR mRNA expression in insulin target tissues of dexamethasone
and saline-treated offspring.
GR mRNA measured by RNAse Protection in A liver, B retroperitoneal fat, C subcutaneous fat, D
soleus muscle and E EDL muscle of 6 month old male rat offspring, and expressed as a ratio versus P-
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Figure 3-5 GR expression in Quadriceps muscle
A GR mRNA, quantified by RNAse protection analysis versus P-actin, and B GR protein, quantified
by western blotting in triplicate, standardised using a bulk preparation of liver cytosol of known
binding capacity, for 6 month old male offspring of dexamethasone and vehicle-treated rats. N=10 per
group. C Scatter diagram showing estimated Bmax for GR protein versus relative GR mRNA
expression for all rats investigated. D Scatchard plot for bulk liver cytosol preparation used to
quantify/ standardise between muscle GR western blots. From this, Kd = 3.5 x 10"9M (-1/gradient) and
B„iax = 6.3 x 10~9M (x intercept). E Typical western blot for GR protein in quadriceps. Total GR
protein was detected as a single band at 95kDa in muscle lanes, with an additional non-specific band
at c.35kDa in liver lanes, which was not used in quantitation. The quantity of total protein loaded into
each lane is shown, with 4 different amounts of standard liver cytosol protein, and 5 lanes containing
protein samples from vehicle (2, left) and dex-treated (3, right) quadriceps on each gel.
B
1




Standard liver Muscle homogenates
4 14 26 40pg 60pg
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3.3.2 Biochemistry: Quadriceps glycogen and GLUT-4 content
The glycogen content of quadriceps muscle from adult dex offspring was 26% lower
than that of control quadriceps (Figure 3-6 a). There was no significant difference in
LDM GLUT-4 protein between groups, but there was a trend towards a lower level
in muscle from dex rats (p = 0.14, Student's t-test) (Figure 3-6 b).
3.3.3 mRNA expression of muscle and adipose metabolic genes
There was no difference between groups in the relative abundance ofmRNAs for
UCP-3 in quadriceps (Figure 3-7), or for leptin or resistin in RP adipose tissue
(Figure 3-8 a and 3-8 b), as measured by RPA. There was, however, a 28%
reduction in LPL mRNA in retroperitoneal fat of dex-treated rats (3-8 c). Whereas no
significant difference was seen in total PPARy expression (Figure 3-9), there was a
trend towards increased PPARy2 mRNA in dex-treated retroperitoneal fat (p=0.09,
Student's t-test), and a small, but significant, shift from the PPARyl isoform to y2.
3.3.4 Plasma parameters
In aliquots of freshly thawed plasma, there were no differences seen in the plasma
levels of leptin, P-Hydroxybutyrate, triglycerides, non-esterified fatty acids,
cholesterol, or HDL-cholesterol between treatment groups. See Figure 3-10.
Figure 3-6 Quadriceps glycogen and GLUT-4 content
Glycogen storage and GLUT-4 content of quadriceps muscle of 6 month old dex and saline-treated
rats. A Glycogen content (pig per mg muscle), measured by the Anthrone method; n = 20 and 18
respectively. By Student's t-test, * p = 0.01 versus control. B GLUT-4 protein in low density
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Figure 3-7 Quadriceps Uncoupling Protein-3 mRNA content
UCP-3 mRNA, measured using RNAse protection assay, normalised to p-actin, in 6 month old male




Figure 3-8 mRNA expression of key metabolic genes in retroperitoneal fat
mRNA levels quantified in retroperitoneal fat taken from 6 month old male offspring of dex and
vehicle-treated rats using RNAse protection assays, normalised to P-actin. N=9-10 per group; by
Student's t-test, * p=0.013 versus saline control. A Leptin B Resistin C Lipoprotein lipase.
B
SALINE DEX SALINE DEX
13
SALINE DEX
Figure 3-9 Expression of PPARy isoforms in retroperitoneal fat
Level of expression ofmRNA of PPARy isoforms in retroperitoneal fat of 6 month old male dex and
saline-treated offspring, measured by RNAse protection. A PPARy 1 (calculated from total PPARy
minus PPARy2 band intensity), PPARy2 and total PPARy mRNA, normalised to P-actin mRNA
expression. B Ratio of PPARy 1 to total PPARy mRNA expression. N = 10 per group. By Student's t-
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Figure 3-10 Plasma concentrations of substances related to lipid metabolism
Concentrations of substances related to lipid metabolism in trunk plasma of ad lib fed 6 month old
male offspring of dex and vehicle-treated rats, measured using commercial kits. N=7 (saline group)
and 12 (dex group). A Leptin B P-Hydroxybutyrate C Triglycerides D Non-esterified fatty acids E
Total cholesterol F High density lipoprotein cholesterol.
A B
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3.4 Discussion
In line with the hypothesis, the results indicate that the effects of prenatal dex do
indeed extend to skeletal muscle and white adipose tissue glucocorticoid sensitivity
and metabolism. A programmed up-regulation ofGR in retroperitoneal fat, similar to
that previously observed in the liver, was accompanied by a reduction in LPL
mRNA, and a small shift from PPARyl to PPARy2 expression in this tissue. Despite
this, no difference between groups was observed in plasma lipid composition, and
the expression of leptin and resistin in RP fat of dex offspring was similar to
controls. In contrast, there was a dex-programmed reduction in GR in soleus muscle,
while GR mRNA was unchanged in two other muscles, in spite of elevated plasma
corticosterone. Nevertheless, glycogen storage was reduced in the quadriceps,
accompanied by a downward trend in total GLUT-4 protein, suggesting that glucose
disposal into muscle may be attenuated.
Up-regulation of liver GR as a result of prenatal dex treatment is consistent with
previously reported in situ hybridisation data (Nyirenda et al. 1998). This finding
validates the RPA method used, in which quantification of GR was undertaken
versus (1-actin, to compensate for the variable gel loading seen using this technique.
This finding is important, as the method assumes that the latter can be regarded as a
"housekeeping" gene, a supposition which is hard to judge from RPA gels, due to
inherent variation in gel loading. In practice, because of the extremely widespread
transcriptional effects of insulin, a genuine "housekeeping" gene is hard to come by.
Indeed, cytoskeletal actin is involved in the intracellular trafficking of GLUT-4
(Omata et al. 2000), and is probably transcriptionally regulated by insulin (Knight et
al. 1995).
The hypothesis that increased GR expression in fat and muscle might mediate
peripheral insulin resistance was partially confirmed, as GR programming was found
to be specific to depot and fibre type, respectively. Whereas in EDL muscle, there
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was no difference in GR between groups, GR mRNA was decreased by prenatal dex
in soleus muscle, while an intermediate trend was apparent in quadriceps, consistent
with its mixture of type I and II muscle fibres (Armstrong & Phelps 1984). A similar
trend was identified in GR protein in quadriceps, with a weak correlation between
individual protein and mRNA measurements. This is in line with expectation, in
view of the predominantly transcriptional level of control of GR expression (Okret et
al. 1986; Dong et al. 1988). The antibody used shows total GR content of the tissue,
through direction against an epitope common to both human GRa and |3 at the amino
terminus. The latter isoform does not bind ligand, and has been hypothesised to
inhibit transactivation of glucocorticoid target genes by competition with active GRa
for glucocorticoid response elements, thereby modulating tissue sensitivity to
glucocorticoids (Bamberger et al 1995; Oakley et al 1999). However, GRP is not
present in the mouse (Otto et al 1997), and has not been reported in the rat,
questioning its physiological significance, and implying that the assays used herein
do not conceal a potential confounder ofGR activity as part of their detection of
"total" GR.
The reduced glucocorticoid sensitivity in soleus muscle, and therefore presumably in
type I fibres, would be expected to ameliorate insulin resistance locally (Kusunoki et
al. 1995; Dimitriadis et al. 1997), so this may be a protective adaptation of type I
fibres against the prevalent hypercorticosteronaemia, as these fibres normally over-
express GR relative to type II fibres (DuBois & Almon 1984). A lack of GR down-
regulation in the face of hyper-corticosteronaemia, however, suggests that type II
fibres may still be relatively susceptible to glucocorticoid-mediated effects.
Despite the lack of difference in quadriceps GR, the amount of glycogen stored by
this muscle was reduced in dex offspring, implying either that glucose uptake is
attenuated, or that the general level ofmuscular activity is increased in dex-
programmed rats. The latter possibility is less likely, however, as empirical
observation of rats in cages, and behavioural testing, for example using an "open
field" (Welberg et al. 2000) do not support this contention. The downward trend in
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GLUT-4 protein in the LDM fraction of quadriceps is also consistent with a
reduction in glucose uptake by this muscle.
Glucose transport, and the phosphorylation and glycogen synthase-catalysed steps
have all been suggested as rate-limiting in glycogen accumulation (Azpiazu et al.
2000; Cline et al. 1999), but glucose transport seems to be most significant (Cline et
al. 1999). However, the primary control of glucose transport is at the level of
intracellular trafficking of glucose transporters (Gibbs et al. 1988), so membrane
fractionation, showing altered distribution of transporter molecules, might support
the hypothesis more convincingly. In other models of insulin resistance, an altered
ratio of plasma membrane GLUT-4: intracellular vesicular GLUT-4 has been
recorded, as a result of defective translocation (Coderre et al. 1996; Weinstein et al.
1998). In support of this idea, young protein-restricted rats show increased glucose
uptake, associated with unchanged total GLUT-4, but increased plasma membrane
transporter. More may have been learned from assay of adipose GLUT-4, as
hyperinsulinaemia has been shown to increase adipose, but not muscle GLUT-4
expression (Cusin et al. 1990), and adipose-selective reduction in GLUT-4 results in
muscle and hepatic insulin resistance (Abel et al. 2001). The preservation ofGR
levels in this muscle suggests that the attenuated glucose uptake could occur as a
result of the prevalent hypercorticosteronaemia, or could be programmed through an
independent mechanism.
There is no evidence that mitochondrial uncoupling is programmed in quadriceps
muscle, however, as no difference in UCP-3 expression was recorded, despite this
being both glucocorticoid-regulated (Silva & Rabelo 1997), and altered in other
models of insulin resistance (Kageyama et al. 1998; Krook et al. 1998). Down-
regulation ofUCP-2 and -3 has been noted in cardiac muscle of rats given dex
continuously during their third week ofpregnancy (Langdown et al. 2001b),
however, implying that altered oxidative efficiency could be important in other
tissues.
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The pronounced increase in GR in retroperitoneal fat implies an increase in
glucocorticoid sensitivity in this depot, in contrast to the lack of effect of prenatal
treatment on subcutaneous fat. The combination of increased GR and plasma
corticosterone would be expected to greatly amplify glucocorticoid-mediated effects
in the former depot. Although measurement was also made ofmesenteric GR, no
difference in mRNA was found in this depot (data not shown). However, the freezing
of this depot precluded assay of GR in adipocytes only, and the yield of RNA from
this tissue suggested that there was a large degree of contamination with vascular or
other GR, which probably masked the genuine result. For the purposes of
interpretation, therefore, intra-abdominal retroperitoneal fat is used as a proxy for
visceral adipose tissue.
A fuller consideration of local glucocorticoid sensitivity would incorporate
measurement of 11 |3-HSD type I in these tissues, which re-constitutes active
glucocorticoid (Chapman et al. 1997). This enzyme is expressed at high levels by
visceral fat (Bujalska et al. 1997), and its activity is increased in this depot in a
model of obesity and insulin resistance (Livingstone et al. 2000a). Moreover, over-
expression of this enzyme in visceral fat ofmice has recently been shown to cause an
increase in [corticosterone] in the portal circulation, which may adversely affect
hepatic insulin sensitivity (Masuzaki et al. 2001). Nevertheless, 1 lp-HSD type I was
found not to be programmed by prenatal dex in the liver (Nyirenda et al. 1998).
The expression of several genes which are differentially regulated in insulin
resistance was also examined in retroperitoneal fat, to determine whether there was a
down-stream metabolic effect of this locally increased sensitivity to glucocorticoid
action. Leptin (ob) mRNA and plasma leptin were unaltered by prenatal dex,
probably implying a lack of obesity in adult offspring (Pelleymounter et al. 1995;
Lonnqvist et al. 1995). However, leptin was increased in one year old rats given dex
continuously during their third week of gestation (Sugden et al. 2001), and in others
malnourished prepartum (Vickers et al. 2000), and it has been suggested that
programmed rats have a sensitised leptin response to insulin (Holness & Sugden
2001a), so it is possible that there is an altered set point of leptin secretion relative to
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fat mass in these rats. The lack of differential expression of resistin mRNA observed
in RP fat is not surprising, however, if no difference in fat mass develops as a result
ofprenatal dex, as this adipose product is theorised to induce insulin resistance
secondary to obesity (Steppan et al. 2001). However, increased expression might
have been expected as a result of hypercorticosteronaemia, since dex has a direct
effect upon adipocytes (Haugen et al. 2001).
Down-regulation ofLPL mRNA in retroperitoneal fat is consistent with reduced
import of fatty acids into this fat depot. LPL is down-regulated by glucocorticoids
alone in isolated adipocytes (Ong et al. 1992), but up-regulated if insulin is also
present (Ottosson et al. 1994; Fried et al. 1993), suggesting that this is not a direct
effect of elevated plasma corticosterone. Furthermore, mutations at the LPL locus
have been associated with insulin resistance (Zhang et al. 1997), and reduced activity
is present in insulin resistant patients (Reynisdottir et al. 1997), so this change could
be very significant in the development of the insulin resistant phenotype, through
alteration of overall lipid status and distribution.
Since lipolysis of chylomicrons and VLDL by LPL liberates NEFAs, and this is a
pre-requisite for the disposal of fatty acids to adipose tissue (Eckel 1989), it might be
expected that measured plasma lipid parameters might also be different. However,
plasma TAG, NEFAs, HDL-cholesterol and total cholesterol (and by extrapolation,
LDL / VLDL) were unchanged by prenatal dex. However, these measurements were
made on plasma from rats killed without a prior period of food withdrawal, so they
bear repeating in fasted animals. Alternative explanations for this apparent
dichotomy might be parallel reductions in the activity ofHSL, which is rate-limiting
in the re-mobilisation of fatty acids from adipose, or in lipoprotein synthesis. Finally,
up-regulation ofLPL activity in other tissues could be responsible, since up-
regulation ofLPL in muscle or liver results in increased triglyceride storage in these
tissues, which is causatively associated with local insulin resistance (Kim et al.
2001a; Pan et al. 1997; Simoneau et al. 1999). Measurement of the LPL activity and
triglyceride levels in muscle of dex-programmed rats would be interesting from this
respect. Although the anti-lipolytic activity of insulin is impaired in low protein
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offspring (Holness et al. 1998), no detailed molecular investigations have addressed
these issues in other models of programming. Additionally, there was no difference
in BHB, the principal ketone body in the plasma of dex rats, in contrast to in utero
protein-malnourished rats (Ozanne et al. 1998b). This measurement also bears
repeating when starved plasma is available.
Finally, a change in PPARy expression may also mediate adipose insulin sensitivity
in dex-treated offspring, and fatty acid uptake specifically. Although no overall
change was observed in PPARy mRNA in retroperitoneal fat, there was a trend
towards up-regulation of the PPARy2 isoform, and a small but significant shift from
PPARyl to y2. PPARy has great importance in differentiation of and metabolic gene
regulation in adipose tissue (Wahli et al. 1995; Way et al. 2001b). Thus, altered
expression ofPPARy isoforms, alongside changes in GR, could be involved in
mediating expression ofmetabolic genes in fat, and inducing local insulin resistance.
PPARy activation certainly affects LPL activity, although its effect is usually positive
(Lapsys et al. 2000; Lefebvre et al. 1997). Interestingly, whereas PPARyl expression
has not been found not to vary in obesity or insulin resistance in other studies
(Kruszynska et al. 1998; Vidal-Puig et al. 1997b), the PPARy2 isoform was
increased in human obese subcutaneous fat, and y2 / yl ratio correlated with body
mass index (Vidal-Puig et al. 1997b). Furthermore, glucocorticoids predominantly
increase the yl isoform (Vidal-Puig et al. 1997b), suggesting that this finding is not
purely a result of hypercorticosteronaemia. The differential expression ofPPARy
isoforms therefore may be of significance in the phenotype of the dex-programmed
rat.
In summary, GR expression is programmed in the prenatally glucocorticoid over¬
exposed rat in a tissue-specific fashion. It is down-regulated in soleus muscle, but
unchanged in two other muscles, possibly implying a protective mechanism against
excessive effects of glucocorticoid in type I muscle fibres. However, visceral fat of
dex-programmed rats has increased GR, and by analogy with liver (Nyirenda et al.
1998) may be hyper-sensitive to glucocorticoids. Elevated GR in liver and fat,
121
combined with elevated plasma corticosterone, is likely to result in a significant
reduction in insulin sensitivity these tissues. Glycogen storage is reduced in muscle,
suggesting attenuated glucose uptake, presumably programmed through a
glucocorticoid-independent mechanism. GR up-regulation, alongside altered
expression of PPARy isoforms, is associated with reduced LPL expression in visceral
fat, consistent with a programmed attenuation of fatty acid uptake by this tissue. All
of these molecular changes could be involved in the development or phenotype of
insulin resistance in rats over-exposed to glucocorticoids in utero.
The hypothesis that metabolic changes in liver and fat occur secondary to
programmed increases in GR requires testing, perhaps through specific
pharmacological inhibition of receptor activity in adulthood, or assessment of the
sequence with which gene expression and metabolic changes develop. Furthermore,
the mechanisms involved in the tissue-specific programming ofGR require
elucidation. The question ofwhether GR programming is important in determining
insulin resistance in dex-programmed offspring, or whether it is merely a secondary
feature of the adult syndrome is addressed in Chapter 4.
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4 Chapter Four - Effect of corticosterone and
insulin-sensitising drugs on dysregulation of GR in
adulthood
4.1 Introduction
Tissue-specific differences in expression of glucocorticoid receptors seem to be
important in determining key alterations in the physiology of adult dex-treated
offspring. In the hippocampus, which is key in modulating feedback sensitivity of the
HPA axis (Sapolsky et al. 1985), down-regulation of GR is apparent in dex-treated
offspring (Levitt et al. 1996; Welberg et al. 2001), while in liver, GR is up-regulated
(Nyirenda et al. 1998), specifically in the peri-portal zones in which gluconeogenesis
is under positive regulation by glucocorticoids (Friedman et al. 1993). Increased
hepatic glucose output is the likely result .Plasma glucose levels are also determined
by peripheral disposal to skeletal muscle and adipose tissue, and in Chapter 3,1
showed that GR is also selectively increased in visceral adipose tissue, but not in
either subcutaneous adipose tissue or in skeletal muscle; indeed in the soleus muscle
GR mRNA levels are reduced. Although GR in visceral adipose is important for
glucose uptake and metabolic homeostasis, which may be pertinent to the insulin-
resistant hyperglycaemic phenotype (Carter-Su & Okamoto 1987), the mechanism(s)
underlying these tissue-selective changes in GR density in key metabolic tissues
remain unclear.
GR expression determines tissue sensitivity to glucocorticoids (Schmidt & Meyer
1994), and its activity is regulated through control over transcription, through
binding of transcription factors, including GR itself, and post-translationally.
Previous in vivo studies have shown that short term increases in glucocorticoid levels
down-regulate GR mRNA in liver (DuBois et al. 1995; Kalinyak et al. 1987) and
skeletal muscle (McKay et al. 1997), while adrenalectomy up-regulates GR mRNA
in muscle (DuBois et al 1984), but not in liver (Kalinyak et al. 1987), but there is
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very little published information documenting GR auto-regulation in adipose tissue,
in muscles of differing fibre type composition, or the effects of chronically altered
glucocorticoid levels on GR. A key question then, is whether the observed changes in
GR are important in determining the adult phenotype of dex-programmed rats, or
whether altered GR expression is secondary to their hypercorticosteronaemia.
Glucocorticoids are known to attenuate insulin-stimulated glucose uptake and usage
in muscle and fat (Dimitriadis et al. 1997; Sakoda et al. 2000), and excess
glucocorticoid activity has been associated with the development of insulin
resistance and syndrome X (Brindley 1995; Reynolds et al. 2001). It is also possible
that hyperinsulinaemia could also affect GR expression, however, since insulin
sensitivity has been inversely correlated with GR expression in diabetes (Vestergaard
et al. 2001), hyperinsulinaemia has been associated with a GR polymorphism in
obese women (Weaver et al. 1992), and cAMP levels are known to affect GR mRNA
stability (Dong et al. 1989). A second key question, then, is whether changes in GR
expression in dex offspring are secondary to their insulin resistant phenotype.
Thiazolidinediones, such as rosiglitazone, are pharmacological ligands for the
peroxisome proliferator-activated receptor y (PPARy) (Guerre-Millo et al. 2000),
which lower blood glucose, and have been shown to attenuate glucocorticoid-
induced changes in insulin sensitivity (Anil & Marita 2000; Okumura et al. 1998).
Metformin has been used for decades in the management of non insulin-dependent
diabetes, and has insulin-sensitising, anti-hypertriglyceridaemic, and anti-
hyperglycaemic effects (Wiernsperger & Bailey 1999). These are mediated
particularly through improved cellular glucose uptake (Anil & Marita 2000; Thomas
et al. 1998), as well as increased glycogen storage and suppression of hepatic
gluconeogenesis and fatty acid oxidation (Wiernsperger & Bailey 1999). However, a
molecular mechanism for these effects has yet to be identified.
In this chapter I examine whether the observed tissue-specific changes in GR
expression in adult offspring of dams administered dex prenatally are permanent, or
can be attenuated by manipulation of the HPA axis or insulin sensitivity. To these
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ends, I chronically altered the concentration of circulating corticosterone (cort) in
adult offspring, and in a separate experiment, administered insulin-sensitising drugs
(metformin or rosiglitazone), and examined the resulting level of GR expression in
primary insulin target tissues.
4.2 Methods
4.2.1 Animals
Rats were maintained and offspring generated as detailed in Chapter 2. Killing and
harvesting of tissues from rats used in the drug treatment experiment was performed
by Dr. Moffat Nyirenda.
4.2.2 Manipulation of plasma [corticosterone]
Only dex-treated offspring produced during the course of the investigations detailed
in Chapter 5 were used in this experiment, as the evidence suggested that the
phenotype of saline-treated animals was specifically compromised.
Dex offspring underwent bilateral surgical adrenalectomy (ADX), adrenalectomy
plus corticosterone pellet implantation (CORT), or sham surgery (SHAM group), at 8
months. Adrenalectomy or sham surgery was performed through paralumbar
incisions under halothane anaesthesia, and 5 corticosterone pellets were
subcutaneously implanted through the same incisions, where appropriate.
Adrenalectomised rats were maintained subsequently on 0.9% saline. After 3 weeks,
animals were killed by decapitation between 9:00 and 11:00am. Organs were
weighed, and trunk plasma and tissues frozen at -80°C.
Corticosterone 21-acetate pellets consisting of a 2:1 mixture of corticosterone 21-
acetate with elastomer (SilasticR medical grade, Dow Corning Corp, Midland,
Michigan, USA) were prepared as previously described (Nyirenda et al. 1998). In
preliminary experiments, pellets were incubated in 0.9% saline, and the quantity of
hormone released was estimated by measurement of the spectrophotometric
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absorption of the solution at 240nm. 5 pellets were calculated to release 0.6-0.7mg
corticosterone over 24 hours.
4.2.3 Administration of insulin-sensitising drugs
Offspring of dex and saline-treated dams were given insulin-sensitising drugs
dissolved in water, or water alone, by gavage from 5 months of age, by Dr. Dawn
Livingstone. Each received lmg/kg rosiglitazone (ROS group), 43mg/kg metformin
(MET group), or lml/kg water (VEH group) daily, at 9:00am (Livingstone et al.
2000b). During this period, animals were weighed on alternate days, and food intake
per cage was measured daily. Animals were killed after 3 weeks' treatment, as
described above.
4.2.4 Plasma [Corticosterone]
[Corticosterone] in trunk plasma of nine month old offspring was measured using the
method outlined in Chapter 2.
4.2.5 RNase Protection assay
RNA was extracted from tissues as described in Chapter 2. GR and P-actin templates
were linearised and used to synthesise riboprobes as described in Chapter 3. The
concentration of "cold" rGTP in the transcription mixture was varied according to
the desired specific activity of the riboprobes. RPAs were undertaken as described,
using appropriate quantities of total RNA , GR and actin riboprobes. A summary of
probe specific activities and RPA reaction constituents in each of the assays
performed is shown in Table 3-2. A typical polyacrylamide RPA gel is displayed as
Figure 4-1.
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Figure 4-1 Sample RNase Protection gel for glucocorticoid receptor mRNA
quantitation
Typical gel yielded during an assay of GR mRNA in quadriceps muscle of 6 month old male dex- and
saline-treated offspring, subsequently given one of two insulin-sensitising drugs or vehicle as adults
for three weeks, normalised using (3-actin mRNA expression. Positive control lanes, containing
undigested full length probes, century marker lane, repeated inter-gel control lanes, and sample lanes
(n=2 per sub-group per gel) are labelled. Key: * protected band- showing size of digested riboprobe-
mRNA hybrid; Saline: prenatal vehicle treatment; Dex: prenatal dexamethasone treatment; VEH:
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Analysis of the birth cohort used in the Cort experiment showed that prenatal dex
treatment reduced birth weight by an average of 15.2% (6.04±0.05g versus
5.12±0.04g; n=83 and 162; p<0.001 by Student's t-test). There was no effect of dex
on either litter size (9.2±0.7 versus 10.1±1.0; n=16 and 9; p=0.43 by Student's t-test)
or sex distribution (47 male, 36 female versus 72 male, 90 female; x =3.46).
4.3.2 Effect of modifying plasma [corticosterone] in adulthood
To determine whether chronic alterations in glucocorticoid levels may explain the
tissue-specific differences in GR gene expression seen in dex offspring, adults were
adrenalectomised ± cort replacement.
4.3.2.1 Plasma [corticosterone]
Trunk plasma [cort] was undetectable (<50nM) in ADX rats, and similar in SHAM
and CORT rats (see Figure 4-2).
Figure 4-2 Plasma corticosterone concentration 3 weeks after surgery
Plasma [corticosterone], measured by radioimmunoassay ofmorning trunk plasma taken from
8-9 month old male dex-treated offspring, which had been adrenalectomised, sham-operated,
or adrenalectomised and implanted with subcutaneous corticosterone pellets 3 weeks
previously. N=6-7 per group. By 1-Way ANOVA, p<0.001 for effect of surgery. Post-hoc:


















4.3.2.2 Body and Organ weight
There was no difference in the body weight between groups at the end of the
experiment (ADX 470±14g, SHAM 513±35g, CORT 492±31g; n=7 or 8 per group;
p=0.29 by 1-Way ANOVA). Thymus mass decreased as the chronic plasma [cort]
increased (expressed as a fraction of body mass: n=7 per group) (see Figure 4-3).
Figure 4-3 Thymus weight after 3 weeks' manipulation of plasma corticosterone
Thymus weight as a percentage of body weight at death, 3 weeks after surgery (adrenalectomy, sham
surgery or adrenalectomy / corticosterone pellet implantation). N = 7 per group, effect of surgery by
ANOVA, p<0.001, post hoc * p<0.05 versus SHAM group using Tukey's HSD test.
4.3.2.3 GR mRNA in tissues
In the liver, both ADX and CORT rats showed an approximate two-fold increase in
GR mRNA expression relative to SHAM controls in rats prenatally over-exposed to
glucocorticoids (see Figure 4-4 a). In contrast, these manipulations had no effect on
GR mRNA in skeletal muscle (either EDL or soleus, 4-4 b and 4-4 c) or adipose






Figure 4-4 Glucocorticoid Receptor mRNA expression in insulin target tissues of
dex-programmed rats after 3 weeks' manipulation of plasma corticosterone level
GR mRNA expression in tissues of 8-9 month old male dex offspring, measured by RNAse protection
analysis, normalised to P-actin mRNA, 3 weeks after surgery (adrenalectomy or sham surgery or
adrenalectomy / corticosterone pellet implantation.. A Liver B EDL muscle C Soleus muscle; D
Subcutaneous fat E Retroperitoneal fat. N=6-7 per group. By 1-way ANOVA, groups were different in liver
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4.3.3 Effect of treatment of adults with insulin-sensitising drugs
To examine the possible role of the documented insulin resistance in this model in
producing the changes in GR expression, two classes of insulin-sensitising drugs
were exploited.
4.3.3.1 Body Weight /Appetite
Examining all 24 rats utilised from each of the two prenatal treatment groups
revealed that dex offspring were heavier at the start (Saline 296.5±3.3g, Dex
322.5±6.4g; p=0.003) and end of the experiment. The administration of insulin-
sensitising drugs did not alter body weight gain (see Table 4-1). Dex offspring
consumed more chow compared to controls, while treatment with both metformin
and rosiglitazone resulted in a further increase, which was most pronounced in dex
rats given rosiglitazone as adults.
Table 4-1 Effects of insulin sensitising drugs on food intake and body weight
Body weight was monitored during the 3 week period of treatment of 5-6 month old male dex and
saline-treated offspring with either metformin (43 mg/kg), rosiglitazone (lmg/kg) or vehicle by
gavage. Appetite was quantified on a daily basis by division of total food eaten per cage by number of
rats in the cage. By 2-Way ANOVA, both prenatal (p<0.001) and adult treatment (p<0.001) had
effects on appetite. Both metformin (p<0.05) and rosiglitazone (p<0.05) increased appetite,
independent of prenatal treatment. Post-hoc * p<0.05 versus prenatal control by Tukey's HSD test.
Drug treatment had no effect on body weight at the end of the experiment, but a difference due to
prenatal treatment was maintained (2-Way ANOVA, p<0.001 overall).
Treatment group
Prenatal Adult
Mean Food intake per
cage (g/day)
Body weight at end
of experiment (g)
Saline VEH 157 ± 4 318 + 9
Saline MET 172 ±3 327 + 6
Saline ROS 168 ±3 320 ± 7
Dex VEH 162 ±2 335 ± 13
Dex MET 175 ±2 350 ±11
Dex ROS 187 ± 2 371±10 *
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4.3.3.2 GR mRNA in tissues
There were independent effects of both prenatal dex and treatment with insulin-
sensitising drugs on GR expression in liver (see Figure 4-5a). Prenatal exposure to
Dex during the third week ofpregnancy resulted in a 38% increase in liver GR
expression in adulthood. Rosiglitazone reduced GR mRNA expression in liver
independently of prenatal treatment. In striking contrast, metformin reduced GR
mRNA levels preferentially in liver of dex-programmed animals, and thus abolished
the difference in liver GR levels between offspring exposed to dex and vehicle
prenatally.
In quadriceps muscle, no significant effect of prenatal treatment was seen (4-5b).
There was no effect of rosiglitazone administration on GR mRNA, but in contrast,
metformin reduced GR mRNA levels in skeletal muscle. Once again, this was
predominantly an effect in prenatally dex-programmed animals: there was a
significant 29% reduction in GR mRNA in Dex-MET versus Dex-VEH rats, while
the reduction in Saline-MET versus Saline-VEH rats was not significant.
In subcutaneous fat, no effect of either prenatal treatment or administration of
insulin-sensitising drugs on adult GR mRNA was observed. (4-5c).
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Figure 4-5 Glucocorticoid receptor mRNA expression in tissues of prenatally treated
rats, given insulin sensitising drugs as adults
GR mRNA quantified by RNAse protection assay versus P-actin mRNA, in tissues removed from male 6 month old
dex and saline-treated offspring, given metformin (43mg/kg), rosiglitazone (lmg/kg) or vehicle by gavage for 3
weeks previously. N = 7-8 per group. A Liver. By 2-Way ANOVA, effects of prenatal (p=0.043) and adult
(p=0.018) treatment were significant. Rosiglitazone reduced GR compared to vehicle (p<0.05). Post-hoc $ p<0.04
versus prenatal control, by Student's t-test. B Quadriceps muscle. By 2-Way ANOVA, there was an effect of adult
treatment (p=0.037), with metformin reducing GR relative to vehicle (p<0.05). Post-hoc $ p<0.03 versus Saline-
VEHICLE by Student's t-test. C Subcutaneous fat. Key: Black bars = saline, white bars = dex-treated offspring.




































The results show that in adult rats prenatally exposed to dex, GR mRNA expression
in skeletal muscle and adipose tissue is unaffected by chronic manipulation of
plasma cort. In liver, GR mRNA appeared to be down-regulated in sham-operated
animals, but was unaffected by chronic manipulation of plasma cort. In contrast,
treatment of dex-treated offspring with metformin in adulthood normalised GR
expression in liver and muscle. These effects were not seen with another insulin-
sensitising drug, rosiglitazone, which reduces liver but not muscle GR irrespective of
prenatal treatment. This suggests that hyperinsulinaemia is not of itself responsible
for up-regulation of GR expression in programmed animals. Further investigation of
the action ofmetformin on GR regulation may, however, provide key insights into its
mechanism of action and the determinants ofprogramming of adult GR expression
by prenatal dex.
Consistent with prior observations, dex treatment of rats in week three ofpregnancy
resulted in a significant reduction in birth weight of the offspring, with no alteration
in either litter size or sex distribution ofpups (Levitt et al. 1996; Nyirenda et al.
1998). By five months of age, however, dex treated offspring were 9% heavier than
controls, which differs from previous results, where offspring prenatally over¬
exposed to glucocorticoids were of the same weight (Lindsay et al. 1996b; Nyirenda
et al. 1998), or lighter in adulthood (Welberg et al. 2000). During the three week
period that food intake was monitored, dex offspring showed a marginal, but
significant hyperphagia. This may be the cause of the weight gain, as hyperphagia
was found to mediate obesity in the offspring of undernourished dams (Vickers et al.
2000). Further analysis of growth trajectory and body composition ofprogrammed
offspring would be interesting in the light of the association between low birth
weight and later obesity in other animal models (Vickers et al. 2000; Jackson et al.
1996) and human populations (Ong et al. 2000).
Plasma [cort] was chronically manipulated by adrenalectomy ± supraphysiological
cort replacement to determine whether dysregulation of GR mRNA in the tissues of
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adult dex offspring is determined by hypercorticosteronaemia. Preliminary
investigations, and data from a previous experiment (Nyirenda et al. 1998) suggested
that implantation of five cort pellets subcutaneously would achieve
hypercorticosteronaemia over the course of the experiment. The inverse relationship
between expected three week [cort] and thymus mass confirmed that adrenalectomy
and cort pellet implantation had their desired effects (Akana et al. 1985). Plasma
[cort] was minimal in ADX animals, and highly elevated relative to the circadian
mean in the CORT rats (Dallman et al. 1993; Welberg et al. 2001). [Cort] was
similarly elevated at the time of sampling in SHAM rats, probably as a result of acute
stress, which could not be reflected by the adrenalectomised CORT rats.
No effect of chronic cort manipulation was seen in either of two different skeletal
muscles, the soleus (87% slow twitch, type I, predominantly oxidative muscle fibres)
and EDL (98% fast twitch, type II, mainly glycolytic fibres) (Armstrong & Phelps
1984). Similarly, no effect of altering circulating glucocorticoid was found in either
of the white adipose tissue depots tested. The similarity ofGR mRNA levels in liver
of the CORT and ADX groups suggests that there is, also no effect of chronic
alterations in plasma cort on liver GR mRNA. However, lower GR mRNA was
observed in SHAM operated animals. This may have been an effect of acute hyper¬
corticosteronaemia, resulting from stress immediately prior to killing, to which
adrenalectomised animals would not respond. In support of this contention, liver GR
mRNA down-regulation has been recorded previously within 30 minutes of
administration of dex in vivo (DuBois et al. 1995). Furthermore, an effect of sham
surgery per se has been previously identified on the expression in liver of 1113-
Hydroxysteroid dehydrogenase type I, the enzyme responsible for re-activation of
endogenous glucocorticoid (Jamieson et al. 1999).
Previous studies have not considered the effect of altered [cort] on GR mRNA in
muscles of varying fibre type composition (DuBois et al 1984; McKay et al 1997) or
adipose depots, or the effect of such chronic manipulations on liver (DuBois et al.
1995; Kalinyak et al. 1987). However, down-regulation of GR provoked by addition
of dex to hepatoma cells reverses within a few days (Okret et al. 1986), while the
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effect of adrenalectomy on hippocampal GR is abolished within 2 weeks (Holmes et
al. 1995), supporting the implication of this study that GR auto-regulation is a
relatively acute phenomenon. These findings indicate that chronic
hypercorticosteronaemia is not responsible for tissue-specific dysregulation ofGR
mRNA levels in dex-programmed rats. Control of glucocorticoid sensitivity is also
exerted post-translationally, through phosphorylation (Webster et al. 1997) and
proteasomal degradation (Wallace & Cidlowski 2001), however, thus examination of
GR binding or protein abundance would be required for completeness.
In a separate series of experiments, insulin-sensitising drugs were administered to
adult dex-treated and control rats, to evaluate whether normalisation of
hyperinsulinaemia would affect programmed GR expression. Metformin and
rosiglitazone, two drugs used widely in the clinical treatment of type two diabetes,
were given using the same protocol as has been successfully applied previously to
reduce the glucose intolerance and insulin resistance ofZucker obese rats, as
assessed by oral glucose tolerance tests (Livingstone et al. 2000b).
The appetite of rats on both of these treatments was stimulated, independent of any
programmed effect, but this did not affect weight gain during the course of the
experiment. This effect is in contrast to that seen in Zucker obese rats, where appetite
was depressed by metformin in one study (Rouru et al. 1992), and unaffected in
another (Livingstone et al. 2000b). Indeed, reduction of appetite and therefore
obesity has been suggested to play a role in the clinical effect ofmetformin (Lee &
Morley 1998). In this study and those of Livingstone (Livingstone et al. 2000b) and
Wang (Wang et al. 1997), rosiglitazone caused an increase in appetite, but the
increased weight gain of the obese Zuckers was not replicated during this study.
These effects may be due to down-regulation of leptin expression by
thiazolidinediones (Hollenberg et al. 1997).
Liver GR mRNA was up-regulated in adult rats given dex prenatally in this study, as
previously demonstrated, using an in situ hybridisation technique (Nyirenda et al.
1998). The effects of insulin-sensitising drugs differed between tissues and between
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classes of drug. In liver, whereas rosiglitazone reduced GR expression irrespective of
prenatal treatment, metformin normalised the programmed over-expression of GR. In
skeletal muscle, metformin but not rosiglitazone reduced GR mRNA, again having a
greater effect in dex-treated offspring. In adipose tissue, however, neither
rosiglitazone nor metformin affected GR mRNA expression, which perhaps reflects
the use of SC rather than RP fat, in which GR up-regulation was recorded, in the
assay. It would be instructive to examine the effect of these drugs on the up-
regulation ofGR in RP fat. Thus, the effect ofmetformin in reducing GR in both
tissues is specific to programmed animals, whereas that of rosiglitazone in the liver is
non-specific. As both drugs have similar effects to normalise hyperinsulinaemia
(Livingstone et al. 2000b), yet they do not both normalise GR, we can conclude that
GR gene expression in dex-programmed rats is not determined simply by
hyperinsulinaemia. However, programming ofGR gene expression in this model
does appear susceptible to a specific, and novel, action ofmetformin. Moreover, the
effect of rosiglitazone on liver GR mRNA was unexpected and may be important.
Thiazolidinediones, such as rosiglitazone have anti-hyperglycaemic effects (Anil &
Marita 2000; Thomas et al. 1998), mediated through binding to PPARy,
predominantly in adipose tissue (Guerre-Millo et al. 2000). However, PPARy
activation also suppresses hepatic glucose output, despite low levels of expression in
the liver (Kimura et al. 2000). It is possible that rosiglitazone has direct effects on the
liver, since thiazolidinediones have been shown to modify GR-mediated effects in
cell culture (Johnson et al. 1999). However, it is widely supposed that effects on
hepatic metabolism are mediated by factors released from adipose tissue which are
altered by thiazolidinediones, such as resistin (Steppan et al. 2001), free fatty acids
(Rebrin et al. 1996) or glucocorticoids (Masuzaki et al. 2001). Which of these might
influence GR expression in liver has not been tested, but this is an important question
for further study.
Metformin has well-recorded physiological effects in reducing hyperglycaemia,
through insulin-sensitising and non-insulin dependent means (Wiernsperger & Bailey
1999). The specific site of action has not been identified, but possibilities have been
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suggested, such as potentiation of pyruvate kinase (McCarty 1999), vasodilatory
effect in skeletal muscle (Katakam et al. 2000), and enhanced translocation of
glucose transporter proteins (Rouru et al. 1995). This study shows effects of
metformin in reducing GR expression in two insulin-sensitive tissues, most potently
in insulin-resistant dex-programmed animals.
The mechanism of programming ofGR mRNA remains obscure, but it has been
proposed that its tissue-specificity is explained by differential regulation of alternate
promoters influencing transcription at alternate exon 1 start sites (McCormick et al.
2000). The specific effect ofmetformin on GR mRNA in programmed animals offers
a tool to dissect pathways which influence these tissue-specific promoters, which
may respond directly or indirectly to metformin, and thereby unravel the molecular
mechanism of programming. Equally importantly, down-regulation ofGR may be a
component of the poorly understood insulin-sensitising effect ofmetformin
(Vestergaard et al. 2001). Moreover, this effect may recommend metformin as an
appropriate therapeutic agent for amelioration of the metabolic syndrome in
individuals of low birth weight. Further work is required to determine whether the
effect ofmetformin on GR is direct or indirect, in order to assess its significance in
the treatment of diabetes.
In summary, these studies provide evidence that neither hypercorticosteronaemia nor
insulin resistance is sufficient to explain all the tissue-specific changes in GR gene
expression observed in rats prenatally over-exposed to glucocorticoids, implying that
GR expression is permanently programmed and may be a primary mechanism of
insulin resistance. In addition, it has been shown that rosiglitazone lowers hepatic
GR mRNA independently ofprogramming, which may be important in the hepatic
insulin sensitising effect of thiazolidinediones. Finally, metformin reduces GR
expression specifically in insulin resistant liver and muscle, which may offer insights
into the molecular determinants of programming ofGR and the mechanism of action
of this drug.
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5 Chapter Five - Effect of perinatal stress upon
programming by glucocorticoids
5.1 Introduction
The HPA axis is strongly activated by stressful stimuli, which come in many forms,
including both psychological and physical varieties. Increased secretion ofCRH and
AVP is initiated through neuronal inputs from poorly identified higher brain centres,
which also receive ascending inputs from other tissues. Acute stress results in the
secretion of adrenaline additionally, which potentiates the effects ofCRH and AVP
in the pituitary. The corticosterone / Cortisol secreted aids the individual in coping
with stressors through adaptations including increased availability ofmetabolic
substrates, anti-inflammatory and vascular effects. Chronic or repeated stress is
detrimental to health, however, through persistence of these adaptive responses.
Loud noise is a stressful stimulus for rodents and humans (Armario et al. 1984;
Andren et al. 1982), and rodents possess a hearing range that incorporates both ultra-
and subsonic frequencies. Acute or chronic, intermittent noise causes hyperactivation
of the HPA axis (Armario et al. 1984; Vogel & Jensh 1988), and demonstrable
physiological effects, such as increased mean arterial pressure (Andren et al. 1982).
Prenatal stress has been shown to programme subsequent physiology and behaviour
in a number of rodent studies. Exposures to stressful stimuli during pregnancy results
in HPA axis activation in both mother and foetuses before birth (Williams et al.
1999), that persists until weaning (Takahashi et al. 1992). There are long term
implications, however, as anxious behaviour and increased stress responsiveness are
manifested into adulthood (Takahashi et al. 1992; Vallee et al. 1997). These
behavioural effects are associated with altered GR expression in brain regions (Koehl
et al. 1999; McCormick et al. 1995) and alterations in the circadian rhythm of
corticosterone secretion (Koehl et al. 1999), suggesting ongoing involvement of
HPA-axis dysregulation. Further evidence that the in utero effects of stress are
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induced through excessive foetal glucocorticoid comes from observations that the
long term effects of prenatal stress are analagous to those induced by prenatal dex
treatment. Specifically, prenatal dex treatment results in life-long hyperactivation of
the HPA axis (Levitt et al. 1996) and altered GR expression in various brain regions,
associated with increased anxiety-related behaviour (Welberg et al. 2001). Alteration
in stress-susceptibility can also be induced by early post-natal manipulation, such as
handling of pups, which reduces anxiety through altered HPA feedback sensitivity
and hippocampal GR expression (Meaney et al. 1989; O'Donnell et al. 1994).
This chapter relates investigations into the phenotype of offspring of rats that were
dex- or vehicle-treated during their third week of pregnancy, but which were
subsequently discovered to have been exposed to ultrasonic and / or subsonic
frequencies prenatally and / or postnatally, as a result of emission from strip lights
and / or adjacent building work, respectively. This affected cohorts of rats housed in
the Biological Research Facility at the Western General Hospital between late 1999
and early 2001. This unit was refitted, with the installation of a new lighting system
in early 1999, and is situated next to the new Anne Ferguson building, on which
building work was completed in summer 2000.
5.2 Methods
5.2.1 Animals
Female rats and their litters were maintained, bred, and administered with
dexamethasone or vehicle during their third week of pregnancy as described in
Chapter 2. Male offspring were weighed at days 25, 40, 60, 80, 100 etc. Some
animals were killed at approximately two, six and nine months.
8-9 month old rats underwent triplicate measurements of systolic blood pressure on
consecutive days by tail cuff plethysmography, as described in Chapter 2. After a
further week, oral glucose tolerance tests (OGTT) were performed on each animal, as
described, and after three weeks total, animals were killed by decapitation between
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9:00 and 11:00am. Muscles were weighed, and trunk plasma and tissues frozen at -
80°C.
5.2.2 Plasma [corticosterone]
[Corticosterone] in trunk plasma of nine month old offspring was measured using the
method outlined in Chapter 2.
5.2.3 RNase Protection Assay for GR
The relative abundance ofGR mRNA was assayed in the liver of nine month old
rats, as described in Chapters 2 and 3.
5.2.4 Muscle Glycogen Assay
The glycogen content of portions of quadriceps muscle taken from nine month old
rats was assayed using the Anthrone method, as described in Chapter 2.
5.2.5 PEPCK Activity Assay
Measurement ofPEPCK activity was made in cytosol derived from homogenates of
liver obtained from offspring killed at two months of age, according to the method
described in Chapter 2. This assay was undertaken with the assistance ofDr. Moffat
Nyirenda.
5.2.6 Measurement of plasma parameters
Measurement of plasma TAG, NEFAs, cholesterol, and HDL-cholesterol were made
on aliquots of thawed trunk plasma from nine month old rats by Dr. Philip Wenham,
Department of Clinical Biochemistry, Western General Hospital, Edinburgh, as
described in Chapter 2. Measurement of plasma leptin was undertaken on the same
material using the method described previously. Glucose, insulin and BHB were
assayed in plasma samples collected during the OGTT, using the methods described
in Chapter 2.
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5.2.7 Deoxyglucose uptake by adipocytes
Preparations of isolated adipocytes were made from the pre-weighed epididymal fat
pads of dex- and vehicle-treated offspring killed at six months. The basal and insulin-
stimulated uptake of 2-[3H(G)]-Deoxy-D-Glucose by aliquots of cells from each
animal was measured, in order to compare the ability of adipocytes from rats in each
treatment group to import glucose from the circulation. The methods are described in
detail in Chapter 2.
5.2.8 Assessment of ultrasonic noise pollution
A "bat detector", set at 80kHz, was used to periodically sweep the animal unit for




Birth weights for control and dex-treated rats subsequently killed at two months were
6.26 ± 0.07g and 5.21 ± 0.05g (n = 102 and 104 respectively, p<0.001 by Student's t-
test), representing a mean 16.8% reduction in birth weight as a result of prenatal dex
treatment. There was no difference in either litter size or sex ratio between dex and
saline-treated rats (results not shown).
5.3.2 Growth trajectory
Figure 5-1 shows that rats in both treatment groups gained weight throughout the
course ofmeasurement. Catch-up growth by dex-treated rats occurred until
approximately three months of age, when this ceased, and the mean weight of dex-
treated offspring remained thereafter approximately 7% less than that controls. At
240 days of age, mean body masses were 589 ± 7.9g and 545 ± 12.0g for vehicle and
dex-treated offspring (n = 25 and 21 respectively, p = 0.003 by Student's t-test).
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Figure 5-1 Growth of offspring to 8 months of age
Dex and saline-treated offspring were weighed every 20 days from birth until euthanasia. A Growth
trajectory of each cohort. B Catch-up growth of dex-treated rats: ratio ofmean body weights of dex versus
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There was no effect ofprenatal treatment on blood pressure (see Figure 5-2).
Figure 5-2 Systolic Blood Pressure of rats at 8 months of age
Systolic blood pressure ofmale dex and vehicle-treated offspring at 8 months, measured in







5.3.4 Oral glucose tolerance test
No difference was observed between prenatal treatment groups in either plasma
glucose (Figure 5-3 a) or insulin (5-3 b) during the OGTT.
5.3.5 Plasma [corticosterone]
There was a trend towards increased plasma corticosterone in dex-treated offspring
(Saline 178 ± 29nM versus Dex 264 ± 38nM, n = 7-8 per group, p = 0.079 by
Student's t-test).
5.3.6 Organ masses
At six months, the epididymal fat pad of dex-treated offspring was on average 20.9%
lighter than that of controls, relative to total body weight (2.78 ± 0.10% versus 2.20 ±
0.10%; n= 6 / 7, p = 0.002 by Student's t-test). The weights ofmuscles taken from
nine month old rats are shown below, in Table 1. There were no significant effects of
prenatal treatment.
Figure 5-3 Plasma glucose and insulin during an oral glucose tolerance test
Plasma [glucose] and [insulin] quantified in blood taken from 9am from the tail-tip of rats starved
overnight. N = 7-8 per group A Plasma Glucose before, and at 20 and 120 minutes after an oral glucose













Table 5-1 Weight of muscles from 9 month old offspring
Weights of soleus, EDL and quadriceps muscles removed from male dex and saline-treated offspring,
expressed as a percentage of body weight at death, n = 8 per group.
Muscle Saline Dex
Soleus 0.035 ± 0.002 0.036 ± 0.003
Quadriceps 0.760 ± 0.020 0.694 ± 0.025
EDL 0.040 ± 0.001 0.040 ± 0.001
5.3.7 Liver GR
As can be seen in Figure 5-4, there was no difference in GR expression between
treatment groups at nine months of age.
Figure 5-4 Glucocorticoid receptor mRNA expression in liver
GR mRNA expression in liver of 8-9 month old male dex and vehicle-treated offspring, quantified by




Figure 5-5 shows that glycogen storage by the quadriceps muscle of dex-treated
offspring was no different from controls.
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Figure 5-5 Quadriceps Glycogen content
Micrograms glycogen per mg quadriceps muscle removed from 8-9 month old dex and saline-




5.3.9 Liver PEPCK activity
By inspection of Figure 5-6, it is clear that at two months of age, no difference in
PEPCK activity of offspring livers was apparent.
Figure 5-6 Hepatic Phosphoenolpyruvate carboxykinase activity
PEPCK activity measured in microsomal extracts from livers of 2 month old male dex and saline-







5.3.10 Deoxyglucose uptake by adipocytes
Figure 5-7 shows the deoxyglucose uptake by epididymal adipocytes from six month
old offspring. Although uptake was different at each time point (p < 0.05 by 2-Way
ANOVA), there was no significant difference in deoxyglucose import between
treatment groups (p=0.12).
Figure 5-7 2-Deoxyglucose uptake by epididymal adipocytes
Net 2-DOG uptake by glucose transporters (total uptake minus that in the presence of
cytochalasin B) measured in isolated epididymal adipocytes from 6 month old male dex and
saline-treated offspring, at 3 different insulin concentrations. N = 6-7 per group.
0 5 10 15 20 25 30
[Insulin] / nM
5.3.11 Plasma parameters
There were no differences between prenatal treatment groups in plasma leptin
(Figure 5-8 a), BHB (5-8b), NEFA (5-8d), cholesterol (5-8e) and HDL-cholesterol
(8f) as a result of prenatal dex, but there was a slight trend towards lower TAG in
dex-treated offspring (p = 0.16 by Student's t-test) (5-8c).
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Figure 5-8 Plasma concentrations of substances related to lipid metabolism
Concentrations of substances related to lipid metabolism in trunk plasma of ad lib fed or in tail-tip plasma of
starved ((3-Hydroxybutyrate only) 8-9 month old male offspring of dex and vehicle-treated rats, measured
using commercial kits. N=7-8 per group. A Leptin B p-Hydroxybutyrate C Triglycerides D Non-esterified fatty
acids E Total cholesterol F High density lipoprotein cholesterol.
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5.3.12 Detection of noise pollution
Substantial emission of ultrasound at 80kHz was detected close to the fluorescent
lighting fitted in the animal rooms of the Biological Research Facility, in close
proximity to caged rats.
The frequent but irregular passage by the building of lorries heading to the adjacent
building site was noted.
5.3.13 Comparison of offspring phenotypes
Many of the results generated from these cohorts of offspring contrasted with those
reported in Chapter 3, and previously. A summary of the results demonstrating
discrepancies between offspring cohorts generated for this study, and those before
and afterwards, is shown in Table 5-2.
Offspring cohorts generated simultaneously in another animal unit showed the
expected phenotypic differences. These are also being re-established in the
Biological Research Facility, after the cessation of building work, and modification
of the lighting system.
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Table 5-2 Comparison between results confounded by perinatal stress, and
those obtained using unaffected cohorts of rat offspring
Measurements of Systolic BP, Plasma glucose, insulin and leptin, hepatic PEPCK activity and liver
GR expression in adult male offspring of dex and saline-treated mothers are compared before, during
and after the period between late 1999 and early 2001, when ultrasound-emitting lights were installed,
and when building work adjacent to the animal house was in progress. All statistical testing utilises
Student's t-test.


























































Increased by 60% by
dex; p<0.01
(Nyirenda et al. 1998)





This chapter relates data accumulated during the course of investigations intended to
further define the insulin resistant phenotype of the dex-programmed rat. What it
shows, however, is that the phenotype can probably be confounded in certain cohorts
of offspring by perinatal stress, induced by noise. During the period following the
refurbishment of the Biological Research Facility, it was discovered that strip-
lighting had been altered to a type that emitted ultrasonic noise locally, as
demonstrated with a "bat detector". Furthermore, there was a period ofmonths
during which the animal unit was frequently and irregularly passed by lorries
accessing an adjacent building site, which would have involved emission of
infrasound. Either of these frequencies are audible to rodents, and may have caused
stress, either pre- or early postnatally (Armario et al. 1984; Andren et al. 1982;
Vogel & Jensh 1988), to both dex and saline-treated rat cohorts, either through the
maternal HPA axis, or potentially through the placental CRH-ACTH axis (Challis et
al. 1995).
Many previously described characteristics of the adult phenotype of rats over¬
exposed to glucocorticoids were not apparent in these cohorts of animals, despite
comparable in utero growth retardation. However, Table 5-2 suggests that this might
be because vehicle-treated offspring have developed phenotypic characteristics
similar to those of dex offspring, without any appreciable change in the phenotype of
the latter. The lack of any further effect of stress upon the insulin resistant phenotype
of dex-treated offspring implies that there may be a "ceiling" for the effects of
perinatal glucocorticoids. In the complex milieu of endocrine and other influences
upon development, it is possible that a factor exists which is capable of antagonising
the effects of glucocorticoids, such that their long term effects can be limited.
Birth weights were of the same order of magnitude, and dex offspring showed a
similar reduction in weight to that previously reported (Levitt et al. 1996; Nyirenda
et al. 1998), implying that noise stress may have occurred only after birth, or only
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have had an impact post-natally. Alternatively, it may be that perinatal stress did not
influence the growth of the foetus, but did have an effect on later insulin sensitivity.
The implication of this is that prenatal stress might programme later insulin
resistance but not growth in utero, implying that separate mechanisms might exist for
the development of each, rather than insulin resistance being the consequence ofpoor
prenatal growth. Reports documenting altered adult insulin sensitivity as a result of
in utero malnutrition, in the absence of an effect on birth weight, lend weight to this
theory (Roseboom et al. 2001a). This is an important possibility that requires further
dissection in models ofprenatal programming.
Catch-up growth of dex-treated offspring occurred subsequently, but this was
incomplete, since between three and eight months of age, dex offspring remained on
average 7% lighter than controls. It is not possible to say with certainty whether this
growth pattern differs from the norm, however, as previously reported dex-treated
cohorts were lighter (Welberg et al. 2000), or there was no difference between
groups (Nyirenda et al. 1998; Lindsay et al. 1996b), whereas in Chapter 4, dex
programmed animals were heavier at six months of age. Perhaps group sizes did not
permit statistical analysis to detect a difference in the case of the quoted studies, but,
in any case, larger scale investigation of catch-up growth in this model is warranted.
A variety of effects has also been seen in other programming models, including
complete catch-up (Desai et al. 1995; Woodall et al. 1996) or lack of catch-up
(Langley & Jackson 1994) a few months after prenatal malnutrition, and induction of
obesity in adult rats as a result of severe malnutrition in utero (Vickers et al. 2001),
or prenatal treatment with cytokines (Dahlgren et al. 2001). This is an important
issue in the context of the association between catch-up growth and later obesity
(Ong et al. 2000), and presumably therefore, other features of the metabolic
syndrome, in later life.
At nine months, there was no difference in systolic blood pressure detectable using
tail cuff plethysmography (Evans et al. 1994). This contrasts with previous reports
that prenatal over-exposure to glucocorticoids results in adult rats with a relative
hypertension of approximately lOmmHg (Levitt et al. 1996; Lindsay et al. 1996a).
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The lack of difference seems to reflect an increase in systolic BP in vehicle-treated
rats to the previously documented level of glucocorticoid over-exposed offspring
(Lindsay et al. 1996a), an effect which is not additive to that of prenatal dex. This
may reflect perinatal programming of increased blood pressure by noise stress.
Although this phenomenon has not been identified per se, it would most likely be
mediated through elevated glucocorticoids in utero, or in later life, both ofwhich are
features of the dex model (Levitt et al. 1996). Although the tail cuff technique has
been widely used in investigations of this type, the stress of the procedure could
affect the results generated, and it is unlikely to detect differences in BP of
<10mmHg in treatment groups of this size. If smaller differences were present, they
would be better detected using arterial cannulation or radiotelemetry methods of BP
measurement. However, the technique was able to detect reduced BP as a result of
adrenalectomy in contemporaneous measurements, consistent with previous reports
(van den Berg et al. 1990), and the known effect of corticosterone upon BP (data not
shown).
Similarly, no difference was observed as a result of prenatal dex on either plasma
glucose or insulin measured at three time points during an OGTT, in contrast to the
previously reported effect (Lindsay et al. 1996b; Nyirenda et al. 1998). However,
glucose administration resulted in an increase in plasma glucose and insulin after 20
minutes, as expected (Nyirenda et al. 1998), suggesting that there was no problem
with the procedure. Consistent with BP findings, the plasma [glucose] measured in
vehicle-treated offspring was elevated relative to expected values, such that it was
similar to that of dex offspring.
There was a trend for dex offspring to have higher plasma corticosterone than
controls, consistent with previous findings (Welberg et al. 2001; Levitt et al. 1996).
A significant difference may not have been generated because of stress at the time of
euthanasia (both mean values are high), or because of the confounding effect of
perinatal stress. There were no differences between cohorts in the weight of any of
three muscles containing different proportions of muscle fibre types at euthanasia
(Armstrong & Phelps 1984), relative to body weight. Storage of glycogen by
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quadriceps, expression ofGR in liver, and hepatic PEPCK activity in dex rats were
no different to controls in these cohorts. These findings are in contrast to the reduced
storage of glycogen, reported in Chapter 3, and the previously documented up-
regulation ofGR and PEPCK in liver of dex-treated offspring (Nyirenda et al. 1998).
The implied lack of difference in both glucose uptake by muscle and hepatic
gluconeogenesis are consistent with the similar insulin-glucose status of these
offspring cohorts.
Despite the presence of stressful stimuli around birth, differences between groups
were identified in fat. Epididymal fat pads were reduced in size by prenatal dex, but
this was not associated with a difference in plasma leptin, although values were
higher than those measured in treated and control offspring in Chapter 3. This result
is in stark contrast to the increased fat mass associated with programming by both
cytokines and prenatal malnutrition (Dahlgren et al. 2001; Vickers et al. 2001).
Although the dominant effect of increased circulating glucocorticoid would be to
induce plasma leptin (De Vos et al. 1995), this response is attenuated in diabetes (Liu
et al. 1999), which probably explains the lack of effect of hypercorticosteronaemia in
these, and standard dex-programmed offspring. There were no changes in plasma
BHB, NEFA, cholesterol, or HDL-cholesterol associated with the reduced fat mass,
but there were trends toward lower plasma TAG and increased deoxyglucose uptake
by adipocytes. These differences are consistent with improved insulin sensitivity in
dex rats under these circumstances, which is consistent with the increased glucose
uptake in young adult offspring of protein-restricted dams (Ozanne et al. 1997),
although these rats later become insulin resistant, with reduced glucose uptake
(Holness & Sugden 1999). Increased lipolytic activity is also a feature of in utero
protein-restricted offspring in later life (Ozanne et al. 1999; Holness et al. 1998),
which would normally be associated with increased plasma TAG and NEFA. It
seems in general that, with respect to adipose tissue, dex-treated rats are relatively
resistant to the development of obesity and consequent adipose insulin resistance,
when compared with perinatally stressed vehicle-treated animals. The explanation
for this phenotype is likely to be obscure, and it could be that both cohorts of animals
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are relatively more obese than unstressed control offspring, since plasma leptin in
both groups is higher than previously measured.
In summary, it is clear that perinatal stress induced by environmental noise, is
sufficient to confound dex-programming experiments. Insulin resistance and
hypertension were induced in vehicle-treated animals such that a similar phenotypes
were apparent in both treatment groups. No additional effect on insulin-glucose
status or BP were noted in dex-treated offspring, suggesting that there may be a
ceiling effect ofperinatal stress / glucocorticoids. This would not be surprising, in
view of the importance of glucocorticoids in mediating stress-induced changes in
physiology. Despite these effects on metabolism, in ntero growth differences were
preserved, suggesting that effects on growth may be programmed separately. Given
time, of course, repetition ofmany of these measurements would be instructive in
further elucidating the phenotype of the dex-programmed rat. The re-establishment
ofprogrammed differences in metabolism should permit this.
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6 Chapter Six - Discussion
6.1 Background and Aims
This thesis concerns a potential mechanism explaining the "Foetal origins of adult
disease" hypothesis (Barker 1995), which was put forward following the
the repeated identification of epidemiological links between low birth weight and
increased incidence of disease in later life; most notably insulin resistance and non
insulin-dependent diabetes mellitus (Hales et al. 1991). Edwards et al proposed that
over-exposure of the foetus to glucocorticoids could explain both the reduced birth
weight and later insulin resistance (Edwards et al. 1993). This hypothesis was
supported by experiments in rat models in which dexamethasone was given daily
during the third week of pregnancy (Nyirenda et al. 1998), or in which the placental
barrier to glucocorticoids, 11P-HSD type II, was inhibited using liquorice derivatives
(Lindsay et al. 1996b): treated offspring showed both reduced birth weight, and
hyper-insulinaemia and hyperglycaemia in adulthood.
Further work demonstrated that dex-programmed offspring were
hypercorticosteronaemic, resulting from an overactive HPA axis (Levitt et al. 1996),
associated with reduced GR mRNA in hippocampus (Welberg et al. 2001). Up-
regulation ofPEPCK in the liver, the rate-limiting enzyme of gluconeogenesis,
implied that increased hepatic glucose output contributed to the observed
hyperglycaemia, and this was also associated with an increase in expression ofGR in
liver (Nyirenda et al. 1998).
The aims of the thesis were to determine firstly whether metabolism in skeletal
muscle and white adipose tissue was also programmed by prenatal dex, especially
with regard to glucose disposal. Secondly, glucocorticoid sensitivity, as indicated by
GR expression, was assessed in these tissues; and thirdly, it was asked whether
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dysregulation of GR was important in determining the insulin resistant phenotype, or
whether it was secondary to hyperinsulinaemia or hyper-corticosteronaemia.
6.2 Programming of insulin resistance
The results presented in this thesis add further weight to the hypothesis that in utero
over-exposure to glucocorticoids can programme insulin resistance in later life.
Evidence is presented that glucose uptake into skeletal muscle of rats is attenuated by
prenatal dex treatment, implying that increased hepatic glucose output is not the sole
cause of hyperglycaemia in this model. This effect exists despite concurrent
hyperinsulinaemia, so resistance to the action of insulin in skeletal muscle can be
inferred. Furthermore, visceral fat ofprogrammed rats has a reduced lipolytic
capacity, suggesting that there is also attenuated insulin-stimulated fatty acid uptake
into adipose tissue. This change may be mediated by increased glucocorticoid
sensitivity, and a shift in the expression ofPPARy isoforms.
Analogous findings have been made in alternative models of programmed insulin
resistance: a single prenatal glucocorticoid injection is sufficient to programme
glucose metabolism in lambs (Moss et al. 2001), while various forms of prenatal
malnutrition have also been demonstrated to induce insulin resistance in adult rats
(Ozanne & Hales 1999; Vickers et al. 2000). These collective findings reinforce the
foetal origins hypothesis, by providing a further line of evidence for the
programming of insulin resistance in addition to that derived from epidemiological
associations.
Furthermore, genes identified as being differentially expressed between prenatally
manipulated and control animals become potential targets for investigation of the
mechanisms linking poor growth in utero with later insulin resistance in human
clinical studies. In the longer term, therapeutic interventions targeting genes
underpinning this association could be used in those individuals deemed at risk
because of low birth weight, to ameliorate or prevent the development of the insulin
resistance syndrome.
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The degree and significance for glycaemic control of variation in supply of
endogenous glucocorticoids to the human foetus remains to be established. However,
one study has shown that Cortisol supply is increased to growth retarded foetuses
(Goland et al. 1993). Administration of exogenous glucocorticoids to pregnant
mothers is a practice which has long been pursued to prevent respiratory distress
syndrome in cases of threatened premature delivery (Liggins & Howie 1972). It is
now also becoming increasingly common to administer glucocorticoids for longer
periods pre-partum to prevent the development of virilising congenital adrenal
hyperplasia, due to foetal 21-hydroxylase deficiency (Mercado et al. 1995). It has
been known for some time that large doses of glucocorticoids can result in low birth
weight babies (Reinisch et al. 1978), and although rare, reports ofmaternal side-
effects (Pang et al. 1992) and deleterious long term consequences for the offspring
(Trautman et al. 1995; Doyle et al. 2000) are starting to appear. The direct relevance
of examination of the long term effects of prenatal dex on insulin sensitivity in
animal models, in order to assess the potential consequences of this practice, is clear.
In the light of the further evidence presented in this thesis, however, caution is
required in the use of these interventions.
Data presented in this thesis reinforces previous results suggesting that the third
week of pregnancy is the crucial "developmental window" in the rat, during which
insulin resistance can be programmed (Nyirenda et al. 1998). There is scope for this
window to be further defined, however, as administration of dex during the last two
days of pregnancy alone did not result in adult hyperglycaemia (Nyirenda et al.
2001). The window for programming by dex is species-specific, as insulin resistance
is caused by a relatively earlier treatment in sheep (Moss et al. 2001), which may
reflect differences in the relative timing of differentiation of pancreatic or insulin-
sensitive tissues. Epidemiological studies have suggested that infant size and
proportion, and the nature of subsequent metabolic derangement varies according to
the trimester during which malnutrition occurred (Osmond & Barker 2000;
Roseboom et al. 2001a). The precise nature of the systems susceptible to dex
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treatment during particular windows will be defined by consideration of foetal gene
expression and biochemistry throughout gestation.
6.3 Programming of glucocorticoid sensitivity
Results presented in this thesis have extended our knowledge of the tissue-specific
nature ofprogramming of GR by glucocorticoids. Programmed up-regulation of GR
occurs in visceral but not subcutaneous fat, in addition to the liver. No change in
expression was recorded in muscle ofmixed fibre type, however, or in muscle
composed predominantly of type II fibres. In contrast, down-regulation occurred in
type I fibre-rich muscle, in common with the situation in hippocampus. It has been
hypothesised that increased sensitivity to glucocorticoids may be responsible for
resistance to the actions of insulin to inhibit gluconeogenesis in the liver (Nyirenda et
al. 1998), and it indeed may mediate the observed reduction in lipolytic capacity in
visceral fat.
The significance of increased GR in these tissues as a potential primary determinant
of the programmed insulin resistance has been reinforced by the demonstration
herein that neither hyperinsulinaemia nor hypercorticosteronaemia are sufficient to
explain it. Furthermore, observations of specific effects of both metformin and
rosiglitazone in reducing or attenuating GR over-expression suggest interesting
avenues for further investigation of their respective modes of action.
The mechanism whereby GR expression can be determined through programming,
auto-regulation, and drug administration in a tissue-specific fashion has yet to be
established. However, a candidate mechanism that might permit such exquisite
control over GR expression is the regulation of transcription from multiple alternate
promoters. Tissue specific patterns of transcription have been identified already,
which are modified by two different programming paradigms (McCormick et al.
2000). Metformin in particular could prove a useful tool to dissect the pathways
influencing the expression of specific GR transcripts.
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6.4 Effect of perinatal stress on programming
I have inferred from the data in Chapter 5 that the imposition of noise stress on dex-
treated and control offspring perinatally altered the published rat phenotype
(Benediktsson et al. 1993; Nyirenda et al. 1998). The programming effects of stress
alone upon insulin-glucose metabolism have not been established, but since any
effects are likely to be at least partially mediated through increased glucocorticoid
secretion, the results of perinatal stress may be directly superimposed upon those of
the intended prenatal treatments with dex or saline.
Dex-treated and control birth phenotypes normally observed in this paradigm were
preserved, but the previously identified differences in adult phenotype were
abolished in these experiments. Consideration of the absolute results for glucose
tolerance and blood pressure suggested that the phenotype of the control offspring
had been shifted towards that of the dex-treated animals, supporting the above
contention, but also implying that there might be a "ceiling" for the programming
effects of stress and glucocorticoids. The preservation of the birth phenotypes may
imply that stress was only present post-natally, and "hard-wired" the metabolism of
control offspring at this stage, as has been previously observed with respect to the
HPA axis (Meaney et al. 1996).
Alternatively, and more intriguingly, it could be that perinatal stress exerts a
programming effect on insulin-glucose metabolism but not on birth weight, implying
a mechanistic separation between the two phenomena. Insulin resistance has been
previously recorded as a result ofprenatal manipulation in the absence of reduced
birth weight (Roseboom et al. 2001a; Gatford et al. 2000), hence this is a possibility.
Birth weight is at best an approximate surrogate for foetal growth, as it fails to reflect
differences in body proportions and underlying differences in development of
particular organs or tissues. Indeed, thinness at birth in particular has been associated
with later insulin resistance (Phillips et al. 1994), presumably reflecting under¬
development of abdominal organs, most crucially the pancreas and / or liver. It is
possible that the development of insulin-sensitive tissues is specifically affected by
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perinatal stress, but not prenatal growth overall. Reduced fat mass in later life may
reflect this.
6.5 Further work indicated
There is a great deal of scope for further characterisation of the insulin resistant
phenotype of the dex model. Clearly, elements of the work presented in Chapter 5
bear repeating in the absence of the confounding effect of perinatal stress, in
particular basic measurements such as muscle and fat depot size. Measurement of
glucose uptake by adipocytes and muscle strips could confirm the attenuation of
peripheral glucose uptake, but a particularly elegant method of elucidating the
relative contributions of hepatic glucose output and peripheral glucose uptake to the
hyperglycaemia would be to utilise hyperinsulinaemic-euglycaemic clamp methods,
incorporating multiple radiolabelled tracers (Kraegen et al. 1990).
Further analysis of the role ofGR in the model is also indicated. As insulin resistance
does not arise in prenatally treated rats until well into adulthood, it would be
interesting to establish at what age elevated GR expression develops, as this may
chronologically precede the development of insulin resistance, if it is a causative
influence. Treatment with metformin prior to the development of insulin resistance
could help explore this possibility. Extension of the insulin-sensitising drug treatment
experiment to examine effects on GR in visceral fat, and on the HPA axis could
further strengthen the arguments made herein. The importance of these findings
would also be emphasised if the expression of down-stream metabolic targets were
also found to be altered. An obvious first gene to consider would be hepatic PEPCK.
There is clearly a need for corroboration of the novel effects ofmetformin and
rosiglitazone on GR expression described, as these could be of great potential interest
to clinicians involved in diabetes management. Examination of the effect of these
drugs in other models of insulin resistance, in which elevated GR has been observed,
would be worthwhile, in order to establish whether the effects are applicable to
syndromes with different aetiology. The specific mechanism through which each
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drug acts also requires elucidation, however. Tissue culture techniques might be
suitable to determine whether direct or indirect effects are involved.
There are a number of further issues that have not been addressed in the
glucocorticoid over-exposure model. No-one has yet examined whether glucose-
sensing or insulin-secretory mechanisms are intact in the pancreas of these rats. This
is important in establishing the relative importance of insulin secretion and resistance
in this model. Epidemiological studies have also associated low birth weight with
altered immune function (Beasley et al. 1999; McDade et al. 2001a; McDade et al.
2001b), osteoporosis (Dennison et al. 2001), and renal impairment (Hinchliffe et al.
1992) in later life. Whether glucocorticoid over-exposure in utero might be
responsible for these abnormalities could also be addressed.
The potential significance of early life events is reinforced strikingly by recent work
which has also identified effects on the health of the subsequent generation. Barker
found a clear inverse correlation between maternal birth weight and offspring blood
pressure, independent of offspring birth weight (Barker et al. 2000), and a study in
rats (Martin et al. 2000) showed that maternal malnutrition in utero resulted in F2
offspring with pronounced insulin resistance. Work investigating the potential for
prenatal dex to influence glycaemic control in the subsequent generation is underway
in the laboratory.
6.6 Summary
In summary, this thesis adds weight to the hypothesis that in utero over-exposure to
glucocorticoids can programme insulin resistance in later life, and supports a role for
both skeletal muscle and adipose tissue metabolism in mediating this. Moreover, it
seems that programmed dysregulation ofGR in insulin target tissues plays a
significant role in determining the offspring phenotype. These findings may be
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